

Myalgic encephalomyelitis (or encephalopathy) / chronic fatigue syndrome: diagnosis and management

[E] Management strategies before diagnosis

NICE guideline NG206

*Evidence reviews underpinning recommendations and research
recommendations in the NICE guideline*

October 2021

Final

*These evidence reviews were developed
by the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2021. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-4221-3

Contents

1	Management strategies before diagnosis.....	5
1.1	Review question.....	5
1.1.1	Introduction.....	5
1.1.2	Summary of the protocol.....	5
1.1.3	Methods and process.....	6
1.1.4	Effectiveness evidence.....	6
1.1.5	Summary of the study included in the effectiveness evidence.....	6
1.1.6	Quality assessment of clinical studies included in the evidence review.....	8
1.1.7	Economic evidence.....	10
1.2	The committee's discussion and interpretation of the evidence.....	11
1.2.1	The outcomes that matter most.....	11
1.2.2	The quality of the evidence.....	11
1.2.3	Benefits and harms.....	12
1.2.4	Cost effectiveness and resource use.....	14
	Appendices.....	15
Appendix A	Review protocols.....	15
Appendix B	Literature search strategies.....	27
Appendix C	Effectiveness evidence study selection.....	36
Appendix D	Effectiveness evidence.....	37
Appendix E	Forest plots.....	42
Appendix F	GRADE tables.....	44
Appendix G	Economic evidence study selection.....	46
Appendix H	Economic evidence tables.....	47
Appendix I	Health economic model.....	48
Appendix J	Excluded studies.....	49
	References.....	69

1 Management strategies before diagnosis

1.1 Review question

- 1 What is the clinical and cost effectiveness of pre diagnosis management strategies for people with symptoms consistent with ME/CFS but are not clinically diagnosed?

1.1.1 Introduction

A diagnosis of ME/CFS is based on clinical history and the criteria for a diagnosis of ME/CFS include a minimum time period during which symptoms are present and persistent. Some people may present to healthcare professionals with symptoms consistent with ME/CFS but do not yet meet the criteria for diagnosis of ME/CFS. The need to consider alternate diagnoses and await investigation or specialist opinion may all contribute to delay in diagnosis. The committee were interested in management strategies during this period that might improve outcomes for people with suspected ME/CFS.

This review aims to determine the effectiveness of pre diagnosis management strategies for people experiencing symptoms suggestive of ME/CFS.

1.1.2 Summary of the protocol

For full details see the review protocol in Appendix A.

Table 1: PICO characteristics of pre-diagnosis management strategies review question

Population	Adults, children and young people who are experiencing symptoms consistent with ME/CFS, but are not clinically diagnosed.
Interventions	<ul style="list-style-type: none"> • Pharmacological interventions/management • Non-pharmacological interventions/management • Combinations of pharmacological and non pharmacological management
Comparisons	<ul style="list-style-type: none"> • No treatment • Each other (both within and between pharmacological and non pharmacological management strategies) • Placebo/control/usual care
Outcomes	<p>CRITICAL OUTCOMES (at longest follow up available)</p> <ul style="list-style-type: none"> • Quality of life (any validated scales) • Fatigue/fatiguability (any validated scales) • Patient satisfaction • Physical/cognitive functioning • Psychological status (may be separated into more specific outcomes, such as depression) • Pain (VAS) • Sleep quality (any validated scales) • Any treatment-related adverse effects <p>IMPORTANT OUTCOMES (at longest follow up available)</p> <ul style="list-style-type: none"> • Care needs • Impact on families and carers • Ability to resume occupation/school/study
Study design	<ul style="list-style-type: none"> • Systematic reviews • RCTs

- If no RCT evidence is available, search for non-randomised comparative studies will be considered. Non-randomised comparative studies will only include non-randomised trials and prospective/retrospective cohort studies.

1.1.3 Methods and process

This evidence review was developed using the methods and process described in [Developing NICE guidelines: the manual](#). Methods specific to this review question are described in the review protocol in appendix A and the methods document.

Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

1.1.4 Effectiveness evidence

1.1.4.1 Included studies

A search was conducted for randomised controlled trials and non-randomised comparative studies comparing the effectiveness of pharmacological and non-pharmacological interventions versus each other, placebo or usual care/no treatment implemented as management strategies in people experiencing symptoms consistent with ME/CFS, but who are yet to be clinically diagnosed. No relevant randomised trials were identified. One relevant retrospective cohort study in young people was identified and included in the review¹⁹⁵ and is summarised in Table 2 below. Evidence from this study is summarised in the clinical evidence summary below (Table 3). See also the study selection flow chart in Appendix C, study evidence tables in Appendix D, forest plots in Appendix E, and GRADE tables in Appendix F.

1.1.4.2 Excluded studies

See the excluded studies list in Appendix J.

1.1.4.3 Call for evidence

See the methods document for detail on the process and methods for the call for evidence.

The committee identified management strategies before diagnosis as an area of the scope with a lack of published evidence and proposed a call for evidence to identify any relevant literature not identified in the searches. Submissions were received from 42 separate organisations or individuals, consisting of 508 reports or references to publications (after removal of duplicates). All the 508 reports or references were checked for relevance to the review question according to the review protocol, all were excluded. For details why submitted evidence was not relevant see call for evidence excluded studies list in Appendix J.

1.1.5 Summary of the study included in the effectiveness evidence

Table 2: Summary of study included in the evidence review

Study	Intervention and comparison	Population	Outcomes	Comments
Gill 2004 ¹⁹⁵	<p>Inpatient management (n=5): Admission to the hospital involved 1 to 4 weeks on the adolescent ward, daily physiotherapy to institute a graded exercise regime, attendance at the hospital school, and involvement of the adolescent counsellors of the psychiatry team. The subjects' agreement to return to their own school at discharge was a condition of entering the program.</p> <p>Versus</p> <p>Outpatient management (n=3): Subjects managed as outpatients were educated about the course and management of CFS and encouraged to return to school and engage in a graded exercise program.</p>	<p>N=8 people with symptoms consistent with CFS, yet to be clinically diagnosed. These participants had been referred to a specialist service with prominent fatigue and symptoms consistent with CFS but failed to meet the definition (1994 CDC criteria) as symptom duration was less than 6 months.</p> <p>Strata details: young people, severity mixed or unclear (adolescents, mean age 13.84 years (SD 2.07).</p>	<p>CRITICAL OUTCOMES: Quality of life (dichotomous outcomes – near or complete improvement in symptoms; no improvement or worsening and meet CFS definition)</p> <p>IMPORTANT OUTCOMES: Ability to resume occupation/school/study (dichotomous outcomes – number who attended school or work part-time for more than 2 years from diagnosis; number who have resumed normal activities)</p>	<p>Conducted in Australia.</p> <p>Retrospective cohort study.</p> <p>A questionnaire administered by telephone was used to collect outcome data.</p> <p>Participants were divided into 3 groups: 1) those with CFS, 2) those with idiopathic chronic fatigue (according to 1994 CDC criteria), and 3) those with prominent fatigue/symptoms consistent with CFS but failed to meet the definition as symptom duration was less than 6 months. Only data from the third group is relevant to this protocol. No participants in this group were eventually diagnosed with CFS.</p> <p>Very serious population indirectness: unclear if participants would have gone on to develop ME/CFS without intervention and study used 1994 CDC criteria which does not include PEM as a compulsory feature.</p> <p>Other outcomes were reported but results were not separated by intervention: Dichotomous: number with current fatigue, number with fatigue when enjoying an activity, number exercising regularly, number receiving counselling;</p>

Study	Intervention and comparison	Population	Outcomes	Comments
				Continuous: estimate of current best level of activity (1-10 scale), days tired per week, symptoms over the last month, time from diagnosis to return to school, days of school missed in the past year.

See Appendix D for full evidence tables.

1.1.6 Quality assessment of clinical studies included in the evidence review

Table 3: Clinical evidence summary: inpatient versus outpatient management

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with inpatient versus outpatient management (95% CI)
Quality of life: near or complete improvement	8 (1 study) 5.84 years	⊕⊕⊕⊕ VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1 (0.64 to 1.56)	Moderate 1000 per 1000	0 fewer per 1000 (from 360 fewer to 560 more)
Quality of life: no improvement or worsening and meet CFS definition	8 (1 study) 5.84 years	⊕⊕⊕⊕ VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision	RD 0 (-0.39 to 0.39)	Moderate 0 per 1000	0 fewer per 1000 (from 390 fewer to 390 more)
Ability to resume occupation/school/study: number who have resumed normal activities	8 (1 study) 5.84 years	⊕⊕⊕⊕ VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	RR 1 (0.64 to 1.56)	Moderate 1000 per 1000	0 fewer per 1000 (from 360 fewer to 560 more)
Ability to resume occupation/school/study: number who attended school or work part time for more than 2 years from diagnosis	8 (1 study) 5.84 years	⊕⊕⊕⊕ VERY LOW ^{1,2,4} due to risk of bias, indirectness, imprecision	RD 0 (-0.39 to 0.39)	Moderate 0 per 1000	0 fewer per 1000 (from 390 fewer to 390 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with inpatient versus outpatient management (95% CI)
<p>1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>2 Downgraded by 1 increment if the majority of the evidence included an indirect population or by 2 increments if the majority of the evidence included a very indirect population. Downgraded by 2: 1) unclear if participants would have gone on to develop ME/CFS without intervention; 2) study used 1994 CDC criteria which does not include PEM as a compulsory feature.</p> <p>3 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs (MID = minimally important difference, see Methods Chapter of guideline for more information)</p> <p>4 Zero events in both arms - downgraded by 1 increment if the sample size is between 70 and 350, and downgraded by 2 increments if the sample size is less than 70</p>					

See Appendix F for full GRADE tables.

1.1.7 Economic evidence

1.1.7.1 Included studies

No health economic studies were included.

1.1.7.2 Excluded studies

No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.

See also the health economic study selection flow chart in Appendix G.

1.2 The committee's discussion and interpretation of the evidence

The committee discussed this evidence with the findings from the reviews on Information for people with ME/CFS and their families and carers (report A), Information and Support for health and social care professionals (report B), access to care (report C), Diagnosis (D) non pharmacological management (report G) and the report on Children and Young people (Appendix 1). Where relevant this is noted.

1.2.1 The outcomes that matter most

Quality of life, fatigue/fatigability, patient satisfaction, physical function, cognitive function, psychological status, pain, sleep quality, treatment-related adverse events were agreed by the committee to be critical outcomes for decision making.

The committee was aware of concerns from the ME/CFS community that delays in diagnosis and the potential for inappropriate advice on activity and rest could result in deterioration of symptoms and poorer prognosis for people who are later diagnosed with ME/CFS. Fatigue/fatigability, unrefreshing sleep and physical and cognitive dysfunction are recognised as key symptoms of ME/CFS. The worsening or improvement of these symptoms reflect the impact of an intervention or strategy. The committee agreed that pain though not key to the diagnosis of ME/CFS, is a common symptom in people with ME/CFS and should be considered by the committee in their decision making. The committee agreed that any decisions on interventions and strategies should be informed by treatment related adverse events as a possible indicator of harm.

Care needs, impact on families and carers and ability to resume occupation, school or study were considered important outcomes for decision making. Management interventions and strategies implemented before diagnosis are intended for short term support to prevent deterioration of symptoms. The committee was also interested in any potential benefit in the longer term. The diagnosis of ME/CFS can be delayed and any intervention that would impact longer term outcomes may be important.

The committee acknowledged the lack of existing objective outcome measures of effectiveness of interventions for ME/CFS and the limitations of subjective measures (see Professor Edwards expert testimony – Appendix 3: Expert testimonies). Only validated outcome measurement scales were included in the evidence review.

1.2.2 The quality of the evidence

Several RCTs were identified that included populations with fatigue, including some with additional symptoms consistent with ME/CFS. These populations included people diagnosed with post viral fatigue syndrome, idiopathic chronic fatigue and CFS-like illness. The studies did not report whether these people were subsequently diagnosed with ME/CFS. It was therefore not possible to know whether the symptoms were related to ME/CFS or some other cause or whether any of the participants would have gone on to develop ME/CFS without the interventions. These studies were therefore excluded from the review.

One non-randomised study was included in the review as the participants at the time of intervention (people referred with a possible diagnosis of CFS, described as having symptoms consistent with CFS but failing to meet the definition, as symptom duration was less than 6 months) met the population criteria in the review protocol and diagnosis at follow up was reported. However, the committee noted several important limitations of the evidence.

Evidence was only identified for quality of life and ability to resume school in young people with a mean age of 13.84 years. All the evidence was very low quality. The evidence was

downgraded for study design, and very serious risk of bias, indirectness and imprecision. The committee noted all the evidence came from 1 small non-randomised study with 8 participants, with allocation to groups based on consecutive patients in a clinic. The study only included subjective outcomes with data collection by telephone questionnaire up to 5 years after the intervention. No evidence was identified for children or adults.

In particular, the committee noted that although the participants at the time of intervention met the population criteria in the review protocol (adults, children and young people who are experiencing symptoms consistent with ME/CFS, but who are yet to be clinically diagnosed) at follow up none of them met the CDC 1994 criteria for a diagnosis of ME/CFS. This is problematic as it is not clear if the participants ever had ME/CFS and if their symptoms at the time of the study enrolment were a result of another condition. If this is the case the participants are not the population set out in the review protocol. Another explanation could be that the participants in both groups did not develop ME/CFS as a result of the interventions.

The committee agreed it was not possible to make any conclusions based on the evidence. In one interpretation the study has an indirect population (they do not have ME/CFS) and in the other the assumption that these interventions result in young people not developing ME/CFS is potentially a harmful generalisation of the very low quality evidence.

After reviewing the evidence, the committee agreed it was not useful in supporting their decision making on pre diagnosis interventions and strategies.

1.2.3 Benefits and harms

The committee acknowledged there is a lack of evidence on management strategies and interventions before a diagnosis of ME/CFS. The committee considered that the time period between suspicion of ME/CFS and diagnosis can be an anxious time for people with these symptoms and agreed to make consensus recommendations based on their own experience and taking into account the evidence from findings from the reviews on Information for people with ME/CFS and their families and carers (report A), Information and Support for health and social care professionals (report B), access to care (report C), Diagnosis (D) non pharmacological management (report G) and the report on Children and Young people (Appendix 1).

The committee noted that people with ME/CFS report delays in diagnosis. The reasons for delays in diagnosis are explored further in the evidence reports (see Evidence review A: Information for health and social care professionals, Evidence review C: Access to care, and Evidence review D: Diagnosis). The committee agreed that in their experience delays in diagnosis can have a negative impact on a person's physical and emotional health, with the potential worsening of symptoms and deterioration in health. People waiting for a diagnosis have reported receiving little or no support and inappropriate information on managing the symptoms they are experiencing (see Evidence review C: Access to care). This reinforced the committee's opinion that it was important to make consensus recommendations for people when ME/CFS is suspected to ensure they receive advice without having to wait for a diagnosis to be confirmed by a ME/CFS specialist service. This was also seen as important to the person, validating the symptoms they are experiencing and that they are believed.

The key features of ME/CFS are debilitating fatigue, post exertional malaise, unrefreshing sleep and cognitive difficulties (see Evidence review D: Diagnosis). When these symptoms are present for a minimum of 6 weeks in adults and 4 weeks in children and young people ME/CFS is suspected. The committee agreed it was important to give prompt advice on how to manage and reduce the impact of symptoms. The committee stated this advice should be given while waiting for a diagnosis to potentially avoid worsening symptoms.

The committee noted there is NICE guidance on how to manage some of the symptoms that are commonly reported by people with ME/CFS and this guidance is referenced in the

recommendations (for example, Neuropathic pain in adults). In addition, the committee have made recommendations on other symptoms commonly experienced by people with ME/CFS (see Evidence G: Non pharmacological management).

Based on their experience and the evidence the committee advised people with suspected ME/CFS to manage their energy levels by resting as needed, not pushing themselves by managing their daily activity and not pushing through their symptoms and maintaining a healthy balanced diet with adequate fluid intake.

The committee recognised this was different to the advice some people with suspected ME/CFS have been given about managing fatigue. For example, people have been told to push through pre-illness levels of activity or to exercise more despite experiencing debilitating fatigue as a result.

The committee did not make a recommendation on daytime sleep or naps due to a lack of evidence and a lack of agreement in the committee on a strategy that was suitable for all people with suspected ME/CFS. The committee are aware that in the early stages or acute phase of the illness some people find daytime sleep or naps beneficial, allowing for more meaningful activities to be achieved during the day; while other people have found daytime sleep or naps to be unrefreshing, potentially affecting the quality of sleep at night and contributing to sleep-wake reversal which can be difficult to regulate in the future.

The committee acknowledged there is a lack of evidence to support that advice to rest prevents deterioration and improves prognosis in people with suspected ME/CFS, but they agreed the advice would not be harmful in the short term. This was also an important consideration when the committee recognised that some people with suspected ME/CFS may have a different condition or co-existing conditions and it was crucial that this recommendation would not result in harm to anyone.

The committee noted that throughout the evidence in the guideline (Evidence review C: Access to care) people with ME/CFS describe long waits for diagnosis and uncertainty about the pathway for diagnosis. The committee agreed it was important that people with suspected ME/CFS are kept informed about the process for diagnosis and the time they can expect to wait. The committee made a consensus recommendation to advise people with suspected ME/CFS that their diagnosis can only be confirmed after 3 months of persistent symptoms.

The committee discussed the importance of people with suspected ME/CFS being aware of changes in their symptoms. The committee noted there is a lack of awareness that ME/CFS is a fluctuating condition in which a person's symptoms can change unpredictably in nature and severity over days, weeks and made recommendations to raise awareness about this in the principles of care for people with ME/CFS and Information and support sections of the guideline. This is important for people with suspected ME/CFS to be aware of and to know that if they develop new or worsening symptoms they can return to their GP for advice. The committee made a consensus recommendation to reinforce this in the guideline section on advice for people with suspected ME/CFS.

This discussion has focused on advice being given to people with a short duration of symptoms. The committee were aware that clinicians do encounter people who have not been diagnosed with ME/CFS but have had symptoms consistent with ME/CFS and been unwell for many months and in some cases years. These people would benefit from the same advice but should be diagnosed and referred to specialist services without delay.

Children and young people with suspected ME/CFS

The committee noted the identified evidence was conducted on young people but as detailed above they were not confident using the evidence to make any recommendations. The committee used their own experience and evidence from the Children and young people report (Appendix 1) to inform their decision making for children and young people.

The journey to diagnosis for children and young people was identified as one of the key themes in the report findings. The participants describe their symptoms initially as a resolvable short-term illness but it soon became apparent they were experiencing something that was unknown and different. The symptoms lasted longer, were more debilitating and felt like a more serious illness. The understanding of their experiences, the process and how to manage their illness was difficult initially for all the participants. This was compounded by a lack of knowledge the healthcare professionals they met had about ME/CFS. Some of the participants expressed anger at the lack of support and advice they received before a diagnosis relying on research they or family members had done. The participants identified the need for an earlier diagnosis to reduce the extreme experience of symptoms.

This resonated with the committee's experiences, and they agreed that the recommendations on management strategies before diagnosis equally applied to children and young people.

In addition, the committee noted the participants highlighted increased periods of time away from school and the negative impact this had on their education and not being able to see friends. The committee reflected that when children and young people have symptoms that are consistent with ME/CFS the impact on their education or training can be immediate and can result in them being disadvantaged and missing out on education. To address this the committee agreed it was important that the child or young person's place of education or training was contacted as soon as possible once ME/CFS is suspected. This contact was important to provide education about ME/CFS (for example, the impact of schools being high stimulus environments) and to advise about any flexible adjustments or adaptations. In the committee's experience this helps to minimise the disruption to the child or young person's education or training. Some of the committee members recalled experiences where classmates as well as the teacher had received information about ME/CFS and this had had a positive impact in increasing the understanding and support the child or young person received. The adjustments and adaptations are discussed by the committee in the report on information and support for people with ME/CFS (Evidence report A).

Taking this into account the committee recommended that when ME/CFS is suspected in a child or young person the GP should work with the child or young person's place of education or training to advise about flexible adjustments or adaptations.

1.2.4 Cost effectiveness and resource use

There were no published economic evaluations for managing people suspected of having unconfirmed ME/CFS.

Since there was not good quality evidence of clinical effectiveness, the cost effectiveness of specific interventions remains unproven.

Given the lack of evidence the committee decided to primarily recommend the management of symptoms, using treatments that have been shown to be cost effective in other NICE guidelines.

Based on their experience, the committee also recommended advising these people to stay within their energy limits and maintain healthy eating and sleeping habits. This advice would not impose a significant cost on the NHS and if it leads to fewer patients deteriorating then it would be highly cost effective.

Appendices

Appendix A Review protocols

ID	Field	Content
0.	PROSPERO registration number	1. Not registered
1.	Review title	What is the clinical and cost effectiveness of pre diagnosis management strategies for people experiencing symptoms consistent with ME/CFS but are not clinically diagnosed?
2.	Review question	What is the clinical and cost effectiveness of pre diagnosis management strategies for people experiencing symptoms consistent with ME/CFS?
3.	Objective	As there is no diagnostic test for ME/CFS, diagnosis is based on assessment of signs and symptoms and clinical history. Several different definitions and diagnostic criteria are used in clinical practice, and symptoms can take time to develop, meaning some people do not meet the criteria for diagnosis of ME/CFS immediately. However, these people still need support in managing their symptoms. In addition, exclusion of differential diagnoses may delay formal diagnosis as well, even in the absence of a mandatory diagnostic delay period. Therefore, this review aims to determine the clinical and cost effectiveness of pre-diagnosis management strategies for people experiencing symptoms consistent with ME/CFS.
4.	Searches	The following databases will be searched: <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR)

		<ul style="list-style-type: none"> • Embase • MEDLINE • Cinahl <p>Searches will be restricted by:</p> <ul style="list-style-type: none"> • English language • Human studies • Letters and comments are excluded. <p>Other searches:</p> <ul style="list-style-type: none"> • Inclusion lists of relevant systematic reviews will be checked by the reviewer. <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review</p>
5.	Condition or domain being studied	ME/CFS
6.	Population	Adults, children and young people who are experiencing symptoms suggestive of ME/CFS, but who are yet to be clinically diagnosed.
7.	Intervention/Exposure/Test	<ul style="list-style-type: none"> • Pharmacological management • Non-pharmacological management, for example: <ul style="list-style-type: none"> ○ Self-management strategies (Diaries) ○ Occupational/school advice ○ Psychological interventions/support

		<ul style="list-style-type: none"> ○ Exercise interventions ○ Activity management (includes rest/convalescence) ○ Lifestyle advice ○ Dietary advice ○ Sleep interventions ○ Complementary therapies ● Combinations of pharmacological and non- pharmacological management
8.	Comparator/Reference standard/Confounding factors	<ul style="list-style-type: none"> ● No treatment ● Each other (both within and between pharmacological and non pharmacological management strategies) ● Placebo/control/usual care
9.	Types of study to be included	<ul style="list-style-type: none"> ● Systematic reviews ● RCTs <p>If no RCT evidence is available, search for non-randomised comparative studies will be considered. Non-randomised comparative studies will only include non-randomised trials and prospective/retrospective cohort studies.</p>
10.	Other exclusion criteria	Non-English language studies.

11.	Context	N/A
12.	Primary outcomes (critical outcomes)	<p>CRITICAL OUTCOMES (at longest follow up available)</p> <ul style="list-style-type: none"> • Quality of life (any validated scales) • Fatigue/fatiguability (any validated scales) • Patient satisfaction • Physical/cognitive functioning • Psychological status (may be separated into more specific outcomes, such as depression or anxiety) • Pain (VAS) • Sleep quality (any validated scales) • Any treatment-related adverse effects
13.	Secondary outcomes (important outcomes)	<p>IMPORTANT OUTCOMES (at longest follow up available)</p> <ul style="list-style-type: none"> • Care needs • Impact on families and carers • Ability to resume occupation/school/study
14.	Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. Titles and/or abstracts of studies retrieved using the search strategy and those from additional sources will be screened for inclusion.</p> <p>The full text of potentially eligible studies will be retrieved and will be assessed for eligibility in line with the criteria outlined above.</p>

		<p>10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</p> <p>An in-house developed database; EviBase, will be used for data extraction. A standardised form is followed to extract data from studies (see <u>Developing NICE guidelines: the manual</u> section 6.4) and for undertaking assessment of study quality. Summary evidence tables will be produced including information on: study setting; study population and participant demographics and baseline characteristics; details of the intervention and control interventions; study methodology' recruitment and missing data rates; outcomes and times of measurement; critical appraisal ratings.</p> <p>A second reviewer will quality-assure the extracted data. Discrepancies will be identified and resolved through discussion (with a third reviewer where necessary).</p>
15.	Risk of bias (quality) assessment	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <p>For intervention reviews the following checklist will be used according to study design being assessed:</p> <ul style="list-style-type: none"> • Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS) • Randomised Controlled Trial: Cochrane RoB (2.0) • Non randomised study: including cohort studies: Cochrane ROBINS-I <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>

16.	Strategy for data synthesis	<p>Where possible, data will be meta-analysed. Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5) to combine the data given in all studies for each of the outcomes stated above. A fixed effect meta-analysis, with weighted mean differences for continuous outcomes and risk ratios for binary outcomes will be used, and 95% confidence intervals will be calculated for each outcome.</p> <p>Heterogeneity between the studies in effect measures will be assessed using the I^2 statistic and visually inspected. We will consider an I^2 value greater than 50% indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented using random-effects.</p> <p>GRADE pro will be used to assess the quality of each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome.</p> <p>If the population included in an individual study includes children aged under 12, it will be included if the majority of the population is aged over 12, and downgraded for indirectness if the overlap into those aged less than 12 is greater than 20%.</p> <p>Publication bias is tested for when there are more than 5 studies for an outcome. Other bias will only be taken into consideration in the quality assessment if it is apparent.</p> <p>Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</p> <p>If sufficient data is available to make a network of treatments, WinBUGS will be used for network meta-analysis.</p>
-----	-----------------------------	--

17.	Analysis of sub-groups	<ul style="list-style-type: none"> • <u>Stratification:</u> • Age: children vs young people vs adults • Severity of presenting symptoms: severe vs not severe <p><u>Subgroups to investigate if heterogeneity is present</u></p> <ul style="list-style-type: none"> • Diagnostic criteria used in study (each set of criteria is a separate sub-group) • Type of onset (gradual/sudden [in less than 1 week]) • Earlier [within 1 month of presentation] vs later [>1 month after presentation] pre-diagnosis management (outcomes for later management may be worse) • Studies where analysis restricted to randomised participants who were later diagnosed with ME/CFS vs studies where all (regardless of final diagnosis) are kept together
18.	Type and method of review	<ul style="list-style-type: none"> <input checked="" type="checkbox"/> Intervention <input type="checkbox"/> Diagnostic <input type="checkbox"/> Prognostic <input type="checkbox"/> Qualitative <input type="checkbox"/> Epidemiologic <input type="checkbox"/> Service Delivery <input type="checkbox"/> Other (please specify)

19.	Language	English		
20.	Country	England		
21.	Anticipated or actual start date	01/01/20		
22.	Anticipated completion date	01/01/21		
23.	Stage of review at time of this submission	Review stage	Started	Completed
		Preliminary searches	<input checked="" type="checkbox"/>	<input type="checkbox"/>
		Piloting of the study selection process	<input checked="" type="checkbox"/>	<input type="checkbox"/>
		Formal screening of search results against eligibility criteria	<input type="checkbox"/>	<input type="checkbox"/>
		Data extraction	<input type="checkbox"/>	<input type="checkbox"/>

		Risk of bias (quality) assessment	<input type="checkbox"/>	<input type="checkbox"/>
		Data analysis	<input type="checkbox"/>	<input type="checkbox"/>
24.	Named contact	<p>5a. Named contact National Guideline Centre</p> <p>5b Named contact e-mail</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>		
25.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.		
26.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.		
27.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with		

		section 3 of <u>Developing NICE guidelines: the manual</u> . Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ng10091
28.	Other registration details	
29.	Reference/URL for published protocol	
30.	Dissemination plans	<p>NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as:</p> <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
31.	Keywords	
32.	Details of existing review of same topic by same authors	N/A
33.	Additional information	N/A
34.	Details of final publication	www.nice.org.uk

Table 4: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2004, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).³⁶⁷</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and</p>

methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2004 or later but that depend on unit costs and resource data entirely or predominantly from before 2004 will be rated as ‘Not applicable’.
- Studies published before 2004 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B Literature search strategies

This literature search strategy was used for the following review question:

- What is the clinical and cost effectiveness of pre diagnosis management strategies for people with symptoms consistent with ME/CFS?

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.³⁶⁷

For more information, please see the Methodology review published as part of the accompanying documents for this guideline.

B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve.

Searches for patient views were run in Medline (OVID), Embase (OVID), CINAHL, and PsycINFO (ProQuest).

Table 5: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 23 June 2020	Exclusions
Embase (OVID)	1974 – 23 June 2020	Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 6 of 12 CENTRAL to 2020 Issue 6 of 12	None
CINAHL, Current Nursing and Allied Health Literature (EBSCO)	Inception – 23 June 2020	None
PsycINFO (ProQuest)	Inception – 23 June 2020	Exclusions
Epistemonikos (The Epistemonikos Foundation)	Inception - 23 June 2020	None

Medline (Ovid) search terms

1.	Fatigue Syndrome, Chronic/
2.	chronic* fatigue*.ti,ab.
3.	(fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.

9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.
10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.
11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter/
18.	editorial/
19.	news/
20.	exp historical article/
21.	Anecdotes as Topic/
22.	comment/
23.	case report/
24.	(letter or comment*).ti.
25.	or/17-24
26.	randomized controlled trial/ or random*.ti,ab.
27.	25 not 26
28.	animals/ not humans/
29.	exp Animals, Laboratory/
30.	exp Animal Experimentation/
31.	exp Models, Animal/
32.	exp Rodentia/
33.	(rat or rats or mouse or mice).ti.
34.	or/27-33
35.	16 not 34
36.	limit 35 to English language

Embase (Ovid) search terms

1.	chronic fatigue syndrome/
2.	chronic* fatigue*.ti,ab.
3.	(fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.
9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.

10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.
11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter.pt. or letter/
18.	note.pt.
19.	editorial.pt.
20.	case report/ or case study/
21.	(letter or comment*).ti.
22.	or/17-21
23.	randomized controlled trial/ or random*.ti,ab.
24.	22 not 23
25.	animal/ not human/
26.	nonhuman/
27.	exp Animal Experiment/
28.	exp Experimental Animal/
29.	animal model/
30.	exp Rodent/
31.	(rat or rats or mouse or mice).ti.
32.	or/24-31
33.	16 not 32
34.	limit 33 to English language

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Fatigue Syndrome, Chronic] this term only
#2.	chronic* fatigue*.ti,ab
#3.	(fatigue* near/2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)):ti,ab
#4.	((myalgic or post infection* or postinfection*) near/1 (encephalomyelitis or encephalopathy)):ti,ab
#5.	((ME near/1 CFS) or (CFS near/1 ME) or CFIDS or PVFS):ti,ab
#6.	(Systemic Exertion Intolerance Disease or SEID):ti,ab
#7.	((CFS near/1 SEID) or (SEID near/1 CFS) or (ME near/1 CFS near/1 SEID) or (ME near/1 SEID) or (SEID near/1 ME)):ti,ab
#8.	(Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS)
#9.	((Post-exertional or postexertional) near/2 malaise):ti,ab
#10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia):ti,ab
#11.	((atypical or simulating or resembling) near/1 poliomyelitis):ti,ab
#12.	((chronic epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis):ti,ab
#13.	xenotropic murine leukemia virus-related virus:ti,ab
#14.	effort syndrome*.ti,ab

#15.	((akureyri or iceland or tapanui or "royal free" or "royal free hospital") near/1 disease*):ti,ab
#16.	((yuppie or yuppy or tapanui) near flu):ti,ab
#17.	(or #1-#16)

CINAHL (EBSCO) search terms

S1.	(MH "Fatigue Syndrome, Chronic")
S2.	chronic* fatigue*
S3.	(fatigue* n2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*))
S4.	((myalgic or post infection* or postinfection*) and (encephalomyelitis or encephalopathy))
S5.	((ME and CFS) or (CFS and ME) or CFIDS or PVFS)
S6.	(Systemic Exertion Intolerance Disease or SEID)
S7.	((CFS and SEID) or (SEID and CFS) or (ME and CFS and SEID) or (CFS and ME and SEID) or (ME and SEID) or (SEID and ME))
S8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome) and (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion))
S9.	((Post-exertional or postexertional) n2 malaise)
S10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia)
S11.	((atypical or simulating or resembling) and poliomyelitis)
S12.	(chronic epstein Barr virus or chronic mononucleosis)
S13.	xenotropic murine leukemia virus-related virus
S14.	effort syndrome*
S15.	((akureyri or iceland or tapanui or royal free or royal free hospital) and disease*) or ((yuppie or yuppy or tapanui) and flu))
S16.	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15

PsycINFO (ProQuest) search terms

1.	(((((chronic* fatigue*) OR (fatigue* NEAR2 (disorder* OR syndrome* OR post viral OR postviral OR immune dysfunction* OR post infection* OR postinfection*)) OR ((myalgic OR post infection* OR postinfection*) NEAR1 (encephalomyelitis OR encephalopathy)) OR ((ME NEAR1 CFS) OR (CFS NEAR1 ME) OR CFIDS OR PVFS) OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS NEAR1 SEID) OR (SEID NEAR1 CFS)) OR ((ME NEAR1 CFS NEAR1 SEID) OR (ME NEAR1 SEID) OR (SEID NEAR1 ME)) OR ((Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) NEAR6 (CFS OR chronic* fatigue* OR ME OR myalgic OR SEID OR systemic exertion)) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR ((atypical OR simulating OR resembling) NEAR1 poliomyelitis)) OR (((chronic NEAR2 epstein Barr virus) OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*)) OR ((akureyri OR iceland OR tapanui OR royal free OR royal free hospital) NEAR1 disease*) OR ((yuppie OR yuppy OR tapanui) NEAR1 flu) OR MAINSUBJECT.EXACT.EXPLODE("Chronic Fatigue Syndrome")))) AND (styp.e.exact("Scholarly Journals") AND la.exact("ENG") AND po.exact("Human") NOT (me.exact("Empirical Study" OR "Quantitative Study" OR "Longitudinal Study" OR "Clinical Trial" OR "Qualitative Study" OR "Prospective Study" OR "Followup Study" OR "Literature Review" OR "Retrospective Study" OR "Systematic Review" OR "Meta Analysis") AND po.exact("Human"))
----	---

Epistemonikos search terms

1.	(advanced_title_en:((advanced_title_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR
----	--

<p>fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu)) OR advanced_abstract_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu)))) OR advanced_abstract_en:((advanced_title_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu)) OR advanced_abstract_en:((chronic* fatigue* syndrome*) OR (fatigue* syndrome* OR fatigue* disorder* OR postviral fatigue* OR post viral fatigue* OR fatigue* immune dysfunction OR post infection fatigue* OR postinfection fatigue*) OR (encephalomyelitis OR encephalopathy) OR ("ME/CFS" OR "CFS/ME" OR "CFIDS" OR "PVFS") OR (Systemic Exertion Intolerance Disease OR SEID) OR ((CFS AND SEID) OR (SEID AND CFS) OR (ME AND CFS AND SEID) OR (ME AND SEID) OR (SEID AND ME)) OR (Orthostatic intolerance OR postural orthostatic tachycardia syndrome OR postural tachycardia syndrome OR POTS) OR ((Post-exertional OR postexertional) AND malaise) OR (neurasthenic neuroses OR epidemic neuromyasthenia OR neurataxia OR neuroasthenia OR neurasthenia) OR (atypical poliomyelitis OR simulating poliomyelitis OR resembling poliomyelitis) OR (chronic epstein Barr virus OR CEBV OR CAEBV OR chronic mononucleosis) OR (xenotropic murine leukemia virus-related virus) OR (effort syndrome*) OR (akureyri OR iceland disease OR tapanui OR royal free disease) OR (yuppie flu OR yuppy flu OR tapanui flu))))))</p>
--

B.2 Health economics literature search strategy

Health economic evidence was identified by conducting a broad search relating to ME/CFS population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated

after March 2015) and the Health Technology Assessment database (HTA – this ceased to be updated after March 2018), with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics.

Table 6: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2014 – 30 June 2020	Exclusions Health economics studies
Embase	2014 –30 June 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - 2003 – 31 March 2018 NHSEED - 2003 to 31 March 2015	None

Medline (Ovid) search terms

1.	Fatigue Syndrome, Chronic/
2.	chronic* fatigue*.ti,ab.
3.	(fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.
9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.
10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.
11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter/
18.	editorial/
19.	news/
20.	exp historical article/
21.	Anecdotes as Topic/
22.	comment/
23.	case report/
24.	(letter or comment*).ti.
25.	or/17-24

26.	randomized controlled trial/ or random*.ti,ab.
27.	25 not 26
28.	animals/ not humans/
29.	exp Animals, Laboratory/
30.	exp Animal Experimentation/
31.	exp Models, Animal/
32.	exp Rodentia/
33.	(rat or rats or mouse or mice).ti.
34.	or/27-33
35.	16 not 34
36.	limit 35 to English language
37.	Economics/
38.	Value of life/
39.	exp "Costs and Cost Analysis"/
40.	exp Economics, Hospital/
41.	exp Economics, Medical/
42.	Economics, Nursing/
43.	Economics, Pharmaceutical/
44.	exp "Fees and Charges"/
45.	exp Budgets/
46.	budget*.ti,ab.
47.	cost*.ti.
48.	(economic* or pharmaco?economic*).ti.
49.	(price* or pricing*).ti,ab.
50.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
51.	(financ* or fee or fees).ti,ab.
52.	(value adj2 (money or monetary)).ti,ab.
53.	or/37-52
54.	36 and 53

Embase (Ovid) search terms

1.	chronic fatigue syndrome/
2.	chronic* fatigue*.ti,ab.
3.	(fatigue* adj2 (disorder* or syndrome* or post viral or postviral or immune dysfunction* or post infection* or postinfection*)).ti,ab.
4.	((myalgic or post infection* or postinfection*) adj (encephalomyelitis or encephalopathy)).ti,ab.
5.	((ME adj CFS) or (CFS adj ME) or CFIDS or PVFS).ti,ab.
6.	(Systemic Exertion Intolerance Disease or SEID).ti,ab.
7.	((CFS adj SEID) or (SEID adj CFS) or (ME adj CFS adj SEID) or (ME adj SEID) or (SEID adj ME)).ti,ab.
8.	((Orthostatic intolerance or postural orthostatic tachycardia syndrome or postural tachycardia syndrome or POTS) adj6 (CFS or chronic* fatigue* or ME or myalgic or SEID or systemic exertion)).ti,ab.
9.	((Post-exertional or postexertional) adj2 malaise).ti,ab.

10.	(neurasthenic neuroses or epidemic neuromyasthenia or neurataxia or neuroasthenia or neurasthenia).ti,ab.
11.	((atypical or simulating or resembling) adj poliomyelitis).ti,ab.
12.	((chronic adj2 epstein Barr virus) or CEBV or CAEBV or chronic mononucleosis).ti,ab.
13.	xenotropic murine leukemia virus-related virus.ti,ab.
14.	effort syndrome*.ti,ab.
15.	((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)).ti,ab.
16.	or/1-15
17.	letter.pt. or letter/
18.	note.pt.
19.	editorial.pt.
20.	case report/ or case study/
21.	(letter or comment*).ti.
22.	or/17-21
23.	randomized controlled trial/ or random*.ti,ab.
24.	22 not 23
25.	animal/ not human/
26.	nonhuman/
27.	exp Animal Experiment/
28.	exp Experimental Animal/
29.	animal model/
30.	exp Rodent/
31.	(rat or rats or mouse or mice).ti.
32.	or/24-31
33.	16 not 32
34.	limit 33 to English language
35.	health economics/
36.	exp economic evaluation/
37.	exp health care cost/
38.	exp fee/
39.	budget/
40.	funding/
41.	budget*.ti,ab.
42.	cost*.ti.
43.	(economic* or pharmaco?economic*).ti.
44.	(price* or pricing*).ti,ab.
45.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
46.	(financ* or fee or fees).ti,ab.
47.	(value adj2 (money or monetary)).ti,ab.
48.	or/35-47
49.	34 and 48


NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Fatigue Syndrome, Chronic
-----	---

#2.	(chronic fatigue or fatigue syndrome*)
#3.	((myalgic adj (encephalomyelitis or encephalopathy)))
#4.	((((ME adj CFS) or (CFS adj ME)))
#5.	(post viral fatigue or post viral syndrome* or viral fatigue syndrome* or PVFS)
#6.	#1 OR #2 OR #3 OR #4 OR #5
#7.	(neurasthenic neuroses or epidemic neuromyasthenia or post infectious encephalomyelitis or neurataxia or neuroasthenia)
#8.	((((atypical or simulating or resembling) adj poliomyelitis))
#9.	(chronic epstein Barr virus or chronic mononucleosis)
#10.	(xenotropic murine leukemia virus-related virus)
#11.	((((chronic fatigue and immune dysfunction syndrome*) or cfids or chronic fatigue-fibromyalgia syndrome* or chronic fatigue disorder* or Systemic Exertion Intolerance Disease or SEID or effort syndrome or post infectious fatigue))
#12.	(((((akureyri or iceland or tapanui or royal free or royal free hospital) adj disease*) or ((yuppie or yuppy or tapanui) adj flu)))
#13.	#7 OR #8 OR #9 OR #10 OR #11 OR #12
#14.	#6 or #13

Appendix C Effectiveness evidence study selection

Figure 1: Flow chart of clinical study selection for the review of pre-diagnosis management strategies



Appendix D Effectiveness evidence

D.1 Pre-diagnosis management strategies

Study	Gill 2004 ¹⁹⁵
Study type	Retrospective cohort study
Number of studies (number of participants)	1 (n=10)
Countries and setting	Conducted in Australia; Setting: A tertiary referral hospital
Line of therapy	Unclear
Duration of study	Other: A questionnaire was designed and administered by telephone at a mean of 5.84 years after the initial examination.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis: Participants were divided into 3 groups: those with CFS, those with ICF (according to 1994 CDC criteria), and those with prominent fatigue/symptoms consistent with CFS but failed to meet the definition as symptom duration was less than 6 months. The third group is the population of interest for this review.
Stratum	young people - severity mixed or unclear : Adolescents
Subgroup analysis within study	Not applicable: NA
Inclusion criteria	Subjects referred with a possible diagnosis of CFS.
Exclusion criteria	Patients with other medical illnesses, including fatigue secondary to chronic pain states such as allodynia and fibromyalgia.
Recruitment/selection of patients	Consecutive patients referred with a possible diagnosis of CFS were identified.

Age, gender and ethnicity	Age - Mean (SD): 13.84 (2.07) years. Gender (M:F): 4/4. Ethnicity: NR
Further population details	<p>Diagnostic criteria used: CDC 1994.</p> <p>ME/CFS status: Analysis including final diagnosis ME/CFS and non-ME/CFS (no patients in subgroup of interest went on to be diagnosed with ME/CFS)</p> <p>Type of onset : Not stated / Unclear</p>
Extra comments	Number of minor criteria at baseline, mean (SD): 1.73 (1.56); symptom duration at baseline, mean (SD): 3.29 (1.52) months.
Indirectness of population	Very serious indirectness: 1) unclear if participants would have gone on to develop ME/CFS without intervention; 2) study used 1994 CDC criteria which does not include PEM as a compulsory feature.
Interventions	<p>(n=5) Intervention 1: Non-pharmacological – inpatient management. Admission to the hospital involved 1 to 4 weeks on the adolescent ward, daily physiotherapy to institute a graded exercise regime, attendance at the hospital school, and involvement of the adolescent counsellors of the psychiatry team. The subjects’ agreement to return to their own school at discharge was a condition of entering the program. Duration 1-4 weeks.</p> <p>Concurrent medication/care: Adolescents referred with symptoms suggestive of CFS attend the infectious diseases/immunology clinic for assessment, investigation, and treatment. If other medical illnesses are identified, patients are appropriately referred. The remainder are managed with a combination of education, exercise, counselling, and in some cases, admission to the hospital for 1 to 4 weeks. Once management has been instituted, most return to their local paediatrician or general practitioner for ongoing care.</p> <p>Indirectness: No indirectness; Indirectness comment: NA Further details: 1. Timing of management: Not stated / Unclear</p> <p>(n=3) Intervention 2: Non-pharmacological – outpatient management. Subjects managed as outpatients were educated about the course and management of CFS and encouraged to return to school and engage in a graded exercise program. Duration Unclear.</p> <p>Concurrent medication/care: Adolescents referred with symptoms suggestive of CFS attend the infectious diseases/immunology clinic for assessment, investigation, and treatment. If other medical illnesses are identified, patients</p>

are appropriately referred. The remainder are managed with a combination of education, exercise, counselling, and in some cases, admission to the hospital for 1 to 4 weeks. Once management has been instituted, most return to their local paediatrician or general practitioner for ongoing care.
Indirectness: No indirectness; Indirectness comment: NA
Further details: 1. Timing of management: Not stated / Unclear

Funding Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: INPATIENT MANAGEMENT versus OUTPATIENT MANAGEMENT

Protocol outcome 1: Quality of life at longest follow ups

- Actual outcome for young people - severity mixed or unclear: Near or complete improvement at mean 5.84 years (SD 2.07); Group 1: 5/5, Group 2: 3/3; Comments: The responses to each survey question were compared across the subject groups. A qualitative assessment of each subject's responses by a single investigator enabled allocation to one of the following groups: complete or near complete recovery, improvement but with ongoing symptoms, or no improvement or worse and likely to still meet the CDC definition for CFS.

All patients reported to have made a complete or near complete recovery, with little fatigue and fewer than 1 symptom. None reported no improvement/worsening or met the CFS definition.

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - Retrospective study design (questionnaire); Indirectness of outcome: No indirectness, Comments: NA; Baseline details: Baseline details only reported for whole study population. Participants who were admitted to hospital may have had a more severe illness than those who were managed as outpatients. Details obtained from medical records/notes which is heavily reliant on accurate/adequate documentation. ; Key confounders: Severity of symptoms; Group 1 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population. ; Group 2 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population.

- Actual outcome for young people - severity mixed or unclear: No improvement or worsening and meet CFS definition at mean 5.84 years (SD 2.07); Group 1: 0/5, Group 2: 0/3; Comments: The responses to each survey question were compared across the subject groups. A qualitative assessment of each subject's responses by a single investigator enabled allocation to one of the following groups: complete or near complete recovery, improvement but with ongoing symptoms, or no improvement or worse and likely to still meet the CDC definition for CFS.

All patients reported to have made a complete or near complete recovery, with little fatigue and fewer than 1 symptom. None reported no improvement/worsening or met the CFS definition.

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover -

Low, Comments - Retrospective study design (questionnaire); Indirectness of outcome: No indirectness, Comments: NA; Baseline details: Baseline details only reported for whole study population. Participants who were admitted to hospital may have had a more severe illness than those who were managed as outpatients. Details obtained from medical records/notes which is heavily reliant on accurate/adequate documentation. ; Key confounders: Severity of symptoms; Group 1 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population. ; Group 2 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population.

Protocol outcome 2: Ability to resume occupation/school/study at longest follow up

- Actual outcome for young people - severity mixed or unclear : Number who have "resumed normal activities" at mean 5.84 years (SD 2.07); Group 1: 5/5, Group 2: 3/3
Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - Retrospective study design (questionnaire); Indirectness of outcome: No indirectness, Comments: NA; Baseline details: Baseline details only reported for whole study population. Participants who were admitted to hospital may have had a more severe illness than those who were managed as outpatients. Details obtained from medical records/notes which is heavily reliant on accurate/adequate documentation. ; Key confounders: Severity of symptoms; Group 1 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population. ; Group 2 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population.

- Actual outcome for young people - severity mixed or unclear : Number who attended school or work part-time for >2 years from diagnosis at mean 5.84 years (SD 2.07); Group 1: 0/5, Group 2: 0/3

Risk of bias: All domain - Very high, Selection - Very high, Blinding - High, Incomplete outcome data - High, Outcome reporting - Low, Measurement - High, Crossover - Low, Comments - Retrospective study design (questionnaire); Indirectness of outcome: No indirectness, Comments: NA; Baseline details: Baseline details only reported for whole study population. Participants who were admitted to hospital may have had a more severe illness than those who were managed as outpatients. Details obtained from medical records/notes which is heavily reliant on accurate/adequate documentation; Key confounders: Severity of symptoms; Group 1 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population. ; Group 2 Number missing: unclear, Reason: 2 participants were lost to follow-up, but unclear which intervention they received. Reported that outpatients were surveyed at a significantly longer interval from diagnosis than those admitted, but this is for study as a whole and is not reported separately for this population.

Protocol outcomes not reported by the study

Fatigue/fatiguability at longest follow up; Patient satisfaction at longest follow-up; Physical/cognitive functioning at longest follow up; Psychological status at longest follow up; Pain at longest follow up; Sleep quality at longest follow up;

Treatment-related adverse effects at longest follow up; Care needs at longest follow up; Impact on families/carers at longest follow up

Appendix E Forest plots

E.1 Pre-diagnosis management strategies

E.1.1 Inpatient versus outpatient management

Figure 2: Quality of life: near or complete improvement in symptoms




Figure 3: Quality of life: no improvement or worsening and meet CFS criteria




Figure 4: Ability to resume occupation/school/study: number who have resumed normal activities





Figure 5: Ability to resume occupation/school/study: number who attended school or work part time for more than 2 years from diagnosis



Appendix F GRADE tables

F.1 Pre-diagnosis management strategies


Table 7: Clinical evidence profile: inpatient versus outpatient management

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Inpatient versus outpatient management	Control	Relative (95% CI)	Absolute		
Quality of life: near or complete improvement (follow-up mean 5.84 years)												
1	observational studies	very serious ¹	no serious inconsistency	very serious ²	very serious ³	none	5/5 (100%)	100%	RR 1 (0.64 to 1.56)	0 fewer per 1000 (from 360 fewer to 560 more)	⊕000 VERY LOW	CRITICAL
Quality of life: no improvement or worsening and meet CFS definition (follow-up mean 5.84 years)												
1	observational studies	very serious ¹	no serious inconsistency	very serious ²	very serious ⁴	none	0/5 (0%)	0%	RD 0 (-0.39 to 0.39)	0 fewer per 1000 (from 390 fewer to 390 more)	⊕000 VERY LOW	CRITICAL
Ability to resume occupation/school/study: number who have resumed normal activities (follow-up mean 5.84 years)												
1	observational studies	very serious ¹	no serious inconsistency	very serious ²	very serious ³	none	5/5 (100%)	100%	RR 1 (0.64 to 1.56)	0 fewer per 1000 (from 360 fewer to 560 more)	⊕000 VERY LOW	IMPORTANT
Ability to resume occupation/school/study: number who attended school or work part time for more than 2 years from diagnosis (follow-up mean 5.84 years)												
1	observational studies	very serious ¹	no serious inconsistency	very serious ²	very serious ⁴	none	0/5 (0%)	0%	RD 0 (-0.39 to 0.39)	0 fewer per 1000 (from 390 fewer to 390 more)	⊕000 VERY LOW	IMPORTANT

- ¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
- ² Downgraded by 1 increment if the majority of the evidence included an indirect population or by 2 increments if the majority of the evidence included a very indirect population. Downgraded by 2; 1) unclear if participants would have gone on to develop ME/CFS without intervention; 2) study used 1994 CDC criteria which does not include PEM as a compulsory feature
- ³ Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs (MID = minimally important difference, see Methods Chapter of guideline for more information)
- ⁴ Zero events in both arms - downgraded by 1 increment if the sample size is between 70 and 350, and downgraded by 2 increments if the sample size is less than 70

Appendix G Economic evidence study selection

Figure 6: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

NB. Two papers were included in both the non-pharma and the multidisciplinary care reviews, in parallel with the review of clinical effectiveness.

Appendix H Economic evidence tables

None.

Appendix I Health economic model

No economic modelling was undertaken.

Appendix J Excluded studies

J.1 Pre-diagnosis management strategies

J.1.1 Clinical studies

Table 8: Studies excluded from the clinical review

Study	Exclusion reason
Aelfers 2013 ⁸	Study protocol
Akagi 2001 ¹⁰	Not review population (participants diagnosed with ME/CFS at the time of intervention); Incorrect study design (non-comparative study)
Ali 2017 ¹¹	Not review population (participants had various 'functional somatic syndromes'); Incorrect study design (non-comparative study)
Anon 2010 ¹⁸⁰	Incorrect study design (no intervention)
Anonymous 2012 ¹⁷	Abstract
Anonymous 2016 ²⁰	Abstract of excluded study
Anonymous 2017 ¹⁹	Erratum to excluded study
Bakker 2011 ²⁸	Not review population (unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Bazelmans 2005 ³⁶	Not review population (participants diagnosed with ME/CFS at the time of intervention)
Behan 1990 ³⁹	Not review population (participants diagnosed with post-viral fatigue syndrome at the time of intervention)
Behan 1990 ⁴⁰	Incorrectly cited
Bethune 2003 ⁴⁴	Incorrect study design (no intervention)
Bleijenberg 2009 ⁴⁶	Trial registry record; not review population (participants diagnosed with ICF)
Bombardier 1996 ⁴⁹	Incorrect study design (no intervention)
Bonner 1994 ⁵¹	Not review population (participants diagnosed with ME/CFS at the time of intervention); Incorrect study design (non-comparative study)
Candy 2004 ⁷⁷	Not review population (unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Castro-Marrero 2016 ⁸⁴	Not review population (participants diagnosed with ME/CFS at the time of intervention)
Chalder 1997 ⁹⁶	Not review population (12% of participants diagnosed with ME/CFS at the time of intervention)
Chan 2013 ⁹⁸	Not review population (participants diagnosed with CFS-like illness at the time of intervention)
Chan 2014 ⁹⁷	Not review population (participants diagnosed with CFS-like illness at the time of intervention)
Chisholm 2001 ¹⁰³	HE evaluation of excluded study (see record #117)
Cho 2009 ¹⁰⁴	Not review population (participants with chronic fatigue >6 months, unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Collin 2017 ¹¹¹	Incorrect study design (no intervention)
Comiskey 2010 ¹²⁰	Incorrect study design (no intervention)

Study	Exclusion reason
Crawley 2011 ¹³²	Incorrect study design (no intervention)
Crawley 2013 ¹²⁸	Not review population (participants diagnosed with ME/CFS at the time of intervention)
Darbishire 2005 ¹³⁷	Sub-analysis of excluded study
Dotsenko 2004 ¹⁵⁸	Article not in English
Featherstone 1998 ¹⁷³	Incorrect study design (qualitative study)
Friedberg 2013 ¹⁸²	Not review population (participants diagnosed with unexplained chronic fatigue or CFS at the time of intervention)
Goodwin 2011 ¹⁹⁸	Incorrect study design (no intervention)
Hall 1998 ²⁰²	Incorrect study design (no intervention)
Hall 2009 ²⁰³	Incorrect study design (webpage with information and patient feedback on mindfulness course)
Hamilton 2001 ²⁰⁴	Incorrect study design (no intervention)
Hana 1996 ²⁰⁵	Incorrect study design (no intervention)
Hartz 2003 ²⁰⁸	Not review population (participants diagnosed with ICF at the time of intervention)
Hartz 2004 ²⁰⁷	Not review population (participants diagnosed with ICF at the time of intervention)
Henderson 2014 ²¹⁸	Not review population (participants diagnosed with ME/CFS at the time of intervention); Incorrect study design (non-comparative study)
Ho 2012 ²²⁰	Not review population (participants diagnosed chronic fatigue or CFS at the time of intervention)
Houghton 2011 ²²³	Not review population (participants with chronic fatigue >6 months, unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Huang 2010 ²²⁴	Incorrect study design (no intervention)
Huibers 2004 ²³⁰	Incorrect study design (no intervention)
Huibers 2004 ²²⁹	Incorrect study design (no intervention)
Huibers 2005 ²²⁷	Article not in English
Janse 2016 ²⁴²	Not review population (participants diagnosed with ICF at the time of intervention)
Jason 2000 ²⁵⁰	Incorrect study design (no intervention)
Jason 2011 ²⁴⁹	Incorrect study design (no intervention)
Khawaja 1998 ²⁶³	Not review population (participants diagnosed with ME/CFS at the time of intervention)
Kim 2013 ²⁶⁵	Not review population (participants diagnosed with ICF at the time of intervention)
Kim 2013 ²⁶⁴	Not review population (participants diagnosed with ICF at the time of intervention)
Kim 2015 ²⁶⁶	Not review population (participants diagnosed with CFS or ICF at the time of intervention)
King 1999 ²⁸¹	Citation only
Knight 2013 ²⁸³	Incorrect study design (no intervention)
Krilov 1998 ²⁹⁴	Not review population (unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS); Incorrect study design (non-comparative study)

Study	Exclusion reason
Lee 2015 ³⁰²	Not review population (participants diagnosed with ICF at the time of intervention)
Leone 2006 ³⁰³	Not review population (unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Malaguarnera 2008 ³²⁴	Not review population (elderly people with chronic fatigue)
Malik 2020 ³²⁵	Not review population (some participants met diagnostic criteria for ME/CFS at baseline)
Marques 2017 ³²⁶	Not review population (participants diagnosed with ICF at the time of intervention)
Mehta 1995 ³⁴⁰	Incorrect study design (n=1 case study)
Meng 2014 ³⁴²	Not review population (participants with chronic fatigue >6 months, unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Moss-Morris 2011 ³⁵⁴	Incorrect study design (no intervention)
O'Dowd 2020 ³⁷⁹	Not review population (participants with fatigue 1-4 months, unclear if participants went on to receive a diagnosis of ME/CFS)
Patel 2003 ³⁹⁴	Not review population (participants diagnosed with ME/CFS at the time of intervention); Incorrect study design (non-comparative study)
Pheley 1999 ⁴⁰⁹	Incorrect study design (no intervention)
Prins 2004 ⁴¹⁷	Sub-analysis of excluded study
Puetz 2008 ⁴¹⁹	Not review population (participants with persistent fatigue, unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Ridsdale 2001 ⁴³⁰	Not review population (28% of participants diagnosed with ME/CFS at the time of intervention)
Ridsdale 2004 ⁴²⁹	Not review population (29% of participants diagnosed with ME/CFS at the time of intervention)
Ridsdale 2012 ⁴³¹	Not review population (unclear if participants were assessed for or went on to receive a diagnosis of ME/CFS)
Russo 1998 ⁴⁴⁴	Incorrect study design (no intervention)
Sabes-Figuera 2012 ⁴⁴⁵	HE evaluation of excluded study (see record #257)
Saidi 2006 ⁴⁴⁶	Incorrect study design (no intervention)
Sankey 2006 ⁴⁴⁷	Not review population (participants diagnosed with ME/CFS at the time of intervention); Incorrect study design (non-comparative study)
Schmaling 2003 ⁴⁵⁴	Incorrect study design (no intervention)
Sharpe 1992 ⁴⁶³	Incorrect study design (no intervention)
Skapinakis 2003 ⁴⁶⁷	Incorrect study design (no intervention)
Stubhaug 2008 ⁴⁸⁷	Not review population (majority of participants diagnosed with ME/CFS at the time of intervention)
Tiev 1999 ⁵¹⁸	Article not in English
Toussaint 2012 ⁵²¹	Not review population (participants diagnosed with fibromyalgia, chronic fatigue and/or CFS)
Unger 2017 ⁵³¹	Incorrect study design (no intervention)
Vermeulen 2006 ⁵⁴⁷	Not review population (participants diagnosed with ME/CFS at the time of intervention); Incorrect study design (non-comparative study)

Study	Exclusion reason
Westendorp 2016 ⁵⁶⁶	Not review population (participants had severe chronic pain or chronic fatigue); Incorrect study design (non-comparative study)
White 2001 ⁵⁷⁰	Incorrect study design (no intervention)

A call for evidence was sent out for three review questions for which the committee anticipated that there would be limited published evidence. Some articles were submitted with a clear indication of which of the three review questions they related to, but for many there was no clear indication. Regardless, all articles were assessed for eligibility for inclusion in all three reviews and one main table was created for all studies/articles submitted that were subsequently excluded. For some articles, there were multiple reasons for exclusion across the three review questions. The exclusion reason listed is the main reason for exclusion from the review that the article was judged to be most relevant to. For example, a quantitative study on the effectiveness of an intervention in people diagnosed with ME/CFS was considered to be most relevant to the experiences of interventions question, but the review protocol specified only qualitative studies to be included, so the main reason for exclusion would be incorrect study design. Some articles were relevant to the guideline in general but did not specifically attempt to answer any of the three review questions.

Table 9: Studies excluded from call for evidence

Study	Exclusion reason
Action for ME 2001 ²	Incorrect study design (quantitative survey)
Action for ME 2014 ³⁹⁵	No relevant themes
Action for ME 2019 Results from our big survey ¹ (unpublished)	Incorrect study design (quantitative survey)
Action for ME and Association of Young People with ME (UK) 2008 ³	Incorrect study design (qualitative survey)
Adamowicz 2014 ⁴	Systematic review with different PICO
Adamson ⁵ (unpublished)	Incorrect study design (cohort)
Adedeji 2012 ⁶	Study/article does not address any of the call for evidence review questions
Adelakun ⁷	No useable data - qualitative data reported as most frequently occurring words
Ahmed 2020 ⁹	Incorrect study design (systematic review; no qualitative data)
All-Party Parliamentary Group on ME 2010 ¹²	Not a qualitative study
Allwright 2019 ¹³	No relevant themes
Anderson 1997 ¹⁵	Mixed method study design with no extractable themes
Anderson ¹⁴ (unpublished)	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Anon ⁴⁹¹	Incorrect study design (quantitative survey)
Anon ⁴⁵⁷	Incorrect study design (non-comparative intervention study)
Anon ¹⁶	Incorrect study design (non-comparative intervention study with quantitative outcomes)
Anon 2013 ³⁹⁶ (unpublished)	Incorrect study design (quantitative survey)
Anon 2015 ¹⁰⁹	Trial registry record; no results posted
Anon 2015 ⁴⁵⁸	Incorrect study design (quantitative)

Study	Exclusion reason
Anon 2015 ¹⁸	Unable to obtain
Anon 2016 ³⁴ (unpublished)	Letter/commentary/expert opinion
Anon 2016 ⁴²⁵	Study/article does not address any of the call for evidence review questions
Anon 2017 ¹⁶⁹	Study/article does not address any of the call for evidence review questions
Anon 2018 ⁴¹⁴	Not research article
Antcliff 2019 ²¹	Incorrect population (HCPs)
Antiel 2011 ²²	Incorrect interventions (no intervention)
Armstrong 2012 ²³	Study/article does not address any of the call for evidence review questions
Arnold 2015 ²⁴	Incorrect study design (RCT)
Ates 2016 ²⁵	Study/article does not address any of the call for evidence review questions
Augusto 2018 ²⁶	Study/article does not address any of the call for evidence review questions
BACME 2019 ²⁷	Incorrect population (survey of 'CFS/ME' services)
Balaguru 2012 ²⁹	Study/article does not address any of the call for evidence review questions
Baos 2019 ³⁰	RCT protocol
Baraniuk 2017 ³²	Study/article does not address any of the call for evidence review questions
Baraniuk 2018 ³¹	Study/article does not address any of the call for evidence review questions (BMJ best practice)
Barnden 2016 ³³	Study/article does not address any of the call for evidence review questions
Bazelmans 2004 ³⁵	Incorrect population (therapists)
Bazelmans 2005 ³⁶	Incorrect study design (quantitative)
Bazilevskaya 2006 ³⁷	Study/article does not address any of the call for evidence review questions
Beasant ³⁸ (unpublished)	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Belgian Ministry of Social Affairs, Public Health and Environment 2000 ⁴¹	Guidelines including systematic review of the evidence (unclear source of data on patient experience of CBT)
Bell 2016 ⁴²	Letter/commentary/expert opinion
Berkovitz 2009 ⁴³	Incorrect interventions (no intervention)
Blease 2017 ⁴⁵	Incorrect study design (review article)
Blout 2015 ⁴⁷	Incorrect study design (quantitative)
Blue Ribbon for the Awareness of Myalgic Encephalomyelitis 2010 ⁴⁸ (unpublished)	Incorrect study design (quantitative survey; no qualitative data)
Boneva 2019 ⁵⁰	Incorrect interventions (no intervention)
Bould 2011 ⁵³	Narrative review
Bould 2013 ⁵²	Not relevant to any call for evidence questions

Study	Exclusion reason
Bowers 2019 ⁵⁴	Study/article does not address any of the call for evidence review questions
Brigden 2018 ⁵⁷	No intervention
Brigden 2018 ⁵⁵	No relevant themes
Brigden 2016 ⁵⁶	RCT protocol
Brigden ⁵⁸ (unpublished)	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Bringsli 2014 ⁵⁹	Incorrect study design (quantitative survey)
Bristol CFS/ME Service ⁶⁰ (unpublished)	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Bristol CFS/ME Service ³⁷²	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Britain 2019 ⁶¹	Conference abstract
Brooks 2011 ⁶²	Incorrect study design (quantitative)
Broughton 2017 ⁶³	Incorrect interventions (specialist services rather than specific interventions)
Brouwers 2002 ⁶⁴	Incorrect study design (RCT)
Brown 2012 ⁶⁶	Study/article does not address any of the call for evidence review questions
Brown 2005 ⁶⁷	Study/article does not address any of the call for evidence review questions
Brown 2015 ⁶⁵	Study/article does not address any of the call for evidence review questions
Buchachenko 2013 ⁷²	Study/article does not address any of the call for evidence review questions
Buchachenko 2005 ⁷⁰	Study/article does not address any of the call for evidence review questions
Buchachenko 2006 ⁷¹	Study/article does not address any of the call for evidence review questions
Buchachenko 2017 ⁶⁹	Study/article does not address any of the call for evidence review questions
Buchachenko 2019 ⁶⁸	Study/article does not address any of the call for evidence review questions
Burgess 2012 ⁷³	Incorrect study design (RCT)
Burke 1986 ⁷⁴	Study/article does not address any of the call for evidence review questions
Butland 1982 ⁷⁵	Study/article does not address any of the call for evidence review questions
Calello 2018 ⁷⁶	Study/article does not address any of the call for evidence review questions
Carpenter 2013 ⁷⁸	Study/article does not address any of the call for evidence review questions
Carruthers 2011 ⁸¹	Study/article does not address any of the call for evidence review questions
Carruthers 2012 ⁸⁰	Study/article does not address any of the call for evidence review questions
Carruthers 2003 ⁷⁹	Guidelines

Study	Exclusion reason
Casanova 2011 ⁸²	Study/article does not address any of the call for evidence review questions
Castro-Marrero 2016 ⁸⁴	Incorrect study design (RCT)
Castro-Marrero 2017 ⁸³	Study/article does not address any of the call for evidence review questions
Cella 2011 ⁸⁶	Incorrect study design (quantitative)
Cella 2011 ⁸⁵	Incorrect study design (quantitative)
Centers for Disease Control and Prevention 2019 ⁸⁷	Study/article does not address any of the call for evidence review questions
CFS/ME National Outcomes Database Team 2016 ⁸⁸	Incorrect study design (non-comparative observational study)
CFS/ME Service for South Yorkshire and North Derbyshire 2019 ⁸⁹	Incorrect study design (quantitative survey)
CFS/ME Service for South Yorkshire and North Derbyshire ⁹⁰	Incorrect study design (quantitative survey)
CFS/ME Working Group 2002 ⁹¹ (unpublished)	No relevant themes
Chaudhuri 2003 ¹⁰¹	Study/article does not address any of the call for evidence review questions
Chalder 1993 ⁹³	Study/article does not address any of the call for evidence review questions
Chalder 2010 ⁹⁴	Incorrect study design (RCT)
Chalder 2010 ⁹²	Incorrect study design (review, not qualitative)
Chalder 2015 ⁹⁵	Incorrect study design (quantitative)
Chan 2019 ⁹⁹	Not a qualitative study
Chang 2012 ¹⁰⁰	Incorrect interventions (no intervention)
Childs 2019 ¹⁰²	Incorrect study design (quantitative survey); no qualitative data
Chu 2018 ¹⁰⁵	Study/article does not address any of the call for evidence review questions
Claypoole 2007 ¹⁰⁶	Incorrect interventions (no intervention)
Cleare 2004 ¹⁰⁷	Incorrect study design (quantitative)
Cliff 2019 ¹⁰⁸	Study/article does not address any of the call for evidence review questions
Cockshell 2010 ¹¹⁰	Incorrect interventions (no intervention)
Collin 2018 ¹¹⁵	Study/article does not address any of the call for evidence review questions
Collin 2017 ¹¹³	Incorrect study design (non-comparative cohort study)
Collin 2017 ¹¹¹	Incorrect study design (case-control)
Collin 2017 ¹¹²	Study/article does not address any of the call for evidence review questions
Collin 2016 ¹¹⁶	Study/article does not address any of the call for evidence review questions
Collin 2015 ¹¹⁷	Study/article does not address any of the call for evidence review questions
Collin 2012 ¹¹⁸	Incorrect study design (quantitative survey)

Study	Exclusion reason
Collin 2011 ¹¹⁴	Study/article does not address any of the call for evidence review questions
Comhaire 2018 ¹¹⁹	Incorrect study design (quantitative)
Cook 2017 ¹²¹	Incorrect interventions (no intervention)
Cooper 2019 ¹²²	No relevant themes (qualitative data on an ME/CFS service, not specific interventions)
Corsius 2019 ¹²³	Report summary; full report in Dutch
Costa 1995 ¹²⁴	Study/article does not address any of the call for evidence review questions
Crawford 2010 ¹²⁶	Study/article does not address any of the call for evidence review questions
Crawford 2012 ¹²⁵	Letter/commentary/expert opinion
Crawford 2012 ¹²⁷	Study advertisement
Crawley 2018 ¹³³	Not relevant to monitoring/review question
Crawley 2013 ¹³⁰	Incorrect interventions
Crawley 2013 ¹²⁸	No relevant outcomes
Crawley 2011 ¹³²	No intervention
Crawley 2009 ¹²⁹	Study/article does not address any of the call for evidence review questions
Crawley 2009 ¹³¹	Study/article does not address any of the call for evidence review questions
Crowhurst 2005 ¹³⁴	Letter/commentary/expert opinion
Crowhurst 2007 ¹³⁵	No relevant themes
Currell ¹³⁶	No relevant themes (qualitative data on a specialist service, not specific interventions)
DARPA 2017 ¹³⁸	Study/article does not address any of the call for evidence review questions
Davenport 2010 ¹⁴³	Incorrect study design (conceptual model; not qualitative)
Davenport 2019 ¹³⁹	Study/article does not address any of the call for evidence review questions
Davenport 2011 ¹⁴¹	Study/article does not address any of the call for evidence review questions
Davenport 2011 ¹⁴⁰	Incorrect study design (quantitative)
Davenport 2019 ¹⁴²	Letter/commentary/expert opinion
Davies 2008 ¹⁴⁴	Study/article does not address any of the call for evidence review questions
Dawes 2019 ¹⁷⁰	Executive summary of an excluded survey
Deale 2001 ¹⁵²	Incorrect study design (RCT)
Deale 1998 ¹⁵¹	Incorrect study design (quantitative)
Deale 1997 ¹⁵⁰	Incorrect study design (RCT)
De Becker 2000 ¹⁴⁶	Study/article does not address any of the call for evidence review questions
De Becker 2001 ¹⁴⁵	Study/article does not address any of the call for evidence review questions
de Carvalho 2011 ¹⁴⁷	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Deftereos 2016 ¹⁵³	Incorrect population (expert clinicians)
de Lange 2008 ¹⁴⁸	Incorrect study design (quantitative)
DeLuca 2004 ¹⁵⁴	Incorrect interventions (no intervention)
de Vega 2017 ¹⁴⁹	Study/article does not address any of the call for evidence review questions
Devasahayam 2012 ¹⁵⁵	Study/article does not address any of the call for evidence review questions
Diao 2017 ¹⁵⁶	Study/article does not address any of the call for evidence review questions
Dobson 2007 ¹⁵⁷	Study/article does not address any of the call for evidence review questions
Dougall 2014 ¹⁵⁹	Incorrect study design (RCT)
Doukrou 2019 ¹⁶⁰	Incorrect study design (no qualitative data)
Dowsett 1997 ¹⁶¹	Study/article does not address any of the call for evidence review questions
Duyn 2017 ¹⁶²	Study/article does not address any of the call for evidence review questions
Dyda 2018 ¹⁶³	Study/article does not address any of the call for evidence review questions
Effective Health Care Program: Agency for Healthcare Research and Quality ¹⁶⁴	Systematic review protocol
Emerge Australia 2018 ¹⁶⁵	Incorrect study design (quantitative survey)
Emerge Australia 2019 ¹⁶⁶	Incorrect study design (quantitative survey)
Encephalitis Society 2017 ¹⁶⁷	Study/article does not address any of the call for evidence review questions (website information)
Eroshenko 2004 ¹⁶⁸	Study/article does not address any of the call for evidence review questions
Falk Hvidberg 2015 ¹⁷¹	Incorrect interventions (no intervention)
Faulkner 2016 ¹⁷²	Letter/commentary/expert opinion
Fisher 2013 ¹⁷⁴	No relevant themes
Fisk 1994 ¹⁷⁵	Not relevant to any call for evidence questions
Flo 2014 ¹⁷⁶	Incorrect study design (quantitative)
Fluge 2019 ¹⁷⁸	Incorrect study design (RCT)
Fluge 2015 ¹⁷⁹	Incorrect study design (quantitative)
Fluge 2016 ¹⁷⁷	Study/article does not address any of the call for evidence review questions
Forward ME Survey 2019 ³⁸⁵	Not review population (people already diagnosed with ME/CFS); Incorrect study design (survey)
Franklin 2018 ¹⁸¹	Incorrect study design (quantitative)
Fukuda 2016 ¹⁸³	Incorrect study design (RCT)
Garner 2019 ¹⁸⁴	Study/article does not address any of the call for evidence review questions
Geraghty 2018 ¹⁸⁸	Incorrect study design (narrative review)
Geraghty 2016 ¹⁹⁰	Incorrect study design (debate article)
Geraghty 2019 ¹⁸⁹	Incorrect study design (literature review)

Study	Exclusion reason
Geraghty 2019 ¹⁸⁶	Letter/commentary/expert opinion
Geraghty 2017 ¹⁸⁵	Incorrect study design (analysis of quantitative survey data)
Geraghty 2019 ¹⁸⁷	Study/article does not address any of the call for evidence review questions
Ghatineh 2017 ¹⁹¹	Review of an RCT
Gielissen 2007 ¹⁹²	Study/article does not address any of the call for evidence review questions
Gieré 2016 ¹⁹³	Study/article does not address any of the call for evidence review questions
Gilder 2018 ¹⁹⁴	Study/article does not address any of the call for evidence review questions
Gladwell 2013 ¹⁹⁶	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Goedendorp 2009 ¹⁹⁷	Study/article does not address any of the call for evidence review questions
Haig-Ferguson 2019 ¹⁹⁹	No relevant themes
Haig-Ferguson 2009 ²⁰⁰	No relevant themes
Halapy 2017 ²⁰¹	Letter/commentary/expert opinion
Harada 1999 ²⁰⁶	Study/article does not address any of the call for evidence review questions
Haywood 2012 ²¹⁰	Study/article does not address any of the call for evidence review questions
Haywood 2014 ²⁰⁹	Systematic review with different PICO
Heald 2019 ²¹¹	Study/article does not address any of the call for evidence review questions
Healthwatch Trafford 2017 ²¹³	No relevant themes
Healthwatch Lancashire 2017 ²¹²	Different focus to review question
Heins 2013 ²¹⁵	Incorrect study design (quantitative)
Heins 2013 ²¹⁴	Incorrect study design (quantitative)
Heins 2011 ²¹⁶	Incorrect study design (quantitative)
Heins 2010 ²¹⁷	Incorrect study design (quantitative)
Hives 2017 ²¹⁹	Incorrect study design (diagnostic accuracy study)
Hodges 2018 ²²¹	Incorrect interventions (no intervention)
Holtzman 2019 ²²²	Study/article does not address any of the call for evidence review questions
Hughes 2002 ²²⁶	Review article
Hughes 2018 ²²⁵	Study/article does not address any of the call for evidence review questions
Huibers 2004 ²²⁸	Incorrect population (some met criteria for CFS, some did not and results not reported separately)
Ickmans 2014 ²³¹	Incorrect interventions (no intervention)
ICNIRP Project Group 2017 ²³²	Study/article does not address any of the call for evidence review questions
Ingman 2016 ²³⁵	Incorrect study design (quantitative)

Study	Exclusion reason
Ingman ²³⁴	Unable to obtain
Ingman ²³³	Unable to obtain
Institute of Medicine 2015 ²³⁶	Study/article does not address any of the call for evidence review questions
ISRCTN Registry 2015 ²³⁷	Study/article does not address any of the call for evidence review questions
Jackson 2012 ²³⁸	Study/article does not address any of the call for evidence review questions
Janse 2019 ²³⁹	Prognostic study looking at predictors of outcome of CBT - none relevant to CFE questions
Janse 2019 ²⁴¹	Incorrect study design (non-randomised quantitative study)
Janse 2018 ²⁴³	Incorrect study design (RCT)
Janse 2017 ²⁴⁰	Incorrect study design (RCT)
Janse 2016 ²⁴²	Incorrect population (idiopathic chronic fatigue); incorrect study design (RCT)
Janse 2015 ²⁴⁴	RCT protocol
Jason 2006 ²⁴⁶	Study/article does not address any of the call for evidence review questions
Jason 2008 ²⁵¹	Study/article does not address any of the call for evidence review questions
Jason 2009 ²⁴⁵	Incorrect study design (quantitative)
Jason 2009 ²⁴⁷	Study/article does not address any of the call for evidence review questions
Jason 2015 ²⁵²	Review article
Jason 2018 ²⁴⁸	Not relevant to any call for evidence question
Jelinek 2001 ²⁵³	Study/article does not address any of the call for evidence review questions
Jenkins 2005 ²⁵⁴	Study/article does not address any of the call for evidence review questions
Jones 2012 ²⁵⁵	Incorrect study design (quantitative)
Josev 2019 ²⁵⁶	Incorrect interventions (no intervention)
Juutilainen 2018 ²⁵⁷	Study/article does not address any of the call for evidence review questions
Kapitein 2015 ²⁵⁸	Study/article does not address any of the call for evidence review questions
Kasevich 2002 ²⁵⁹	Study/article does not address any of the call for evidence review questions
Keller 2014 ²⁶⁰	Incorrect interventions (no intervention)
Kempke 2013 ²⁶¹	Study/article does not address any of the call for evidence review questions
Kenyon 2019 ²⁶²	Incorrect study design (quantitative)
Kim 2019 ²⁶⁷	Study/article does not address any of the call for evidence review questions
Kindlon 2011 ²⁷⁵	Letter/commentary/expert opinion
Kindlon 2017 ²⁶⁹	Letter/commentary/expert opinion
Kindlon 2009 ²⁶⁸	Letter/commentary/expert opinion
Kindlon 2010 ²⁷⁷	Letter/commentary/expert opinion

Study	Exclusion reason
Kindlon 2010 ²⁷⁹	Letter/commentary/expert opinion
Kindlon 2011 ²⁷¹	Letter/commentary/expert opinion
Kindlon 2012 ²⁷²	Letter/commentary/expert opinion
Kindlon 2012 ²⁷³	Letter/commentary/expert opinion
Kindlon 2015 ²⁷⁰	Letter/commentary/expert opinion
Kindlon 2015 ²⁷⁸	Letter/commentary/expert opinion
Kindlon 2015 ²⁸⁰	Letter/commentary/expert opinion
Kindlon 2011 ²⁷⁴	Letter/commentary/expert opinion
Kindlon 2009 ²⁷⁶	Letter/commentary/expert opinion
Kingdon 2018 ²⁸²	Study/article does not address any of the call for evidence review questions
Knoester 2019 ²⁸⁴	Study/article does not address any of the call for evidence review questions
Knoop 2008 ²⁸⁹	Incorrect study design (RCT)
Knoop 2007 ²⁸⁸	Incorrect study design (quantitative)
Knoop 2007 ²⁸⁶	Incorrect study design (quantitative)
Knoop 2007 ²⁸⁵	Incorrect study design (quantitative)
Knoop 2008 ²⁸⁷	Incorrect study design (RCT)
Knudsen 2011 ²⁹⁰	Study/article does not address any of the call for evidence review questions
Kodama 2013 ²⁹¹	Study/article does not address any of the call for evidence review questions
Kreyberg 2007 ²⁹²	Guidelines
Kreyberg 2007 ²⁹³	Incorrect population (nursing staff)
Lacerda 2018 ²⁹⁵	Study/article does not address any of the call for evidence review questions
Lacerda 2019 ²⁹⁶	No relevant themes
LaManca 1998 ²⁹⁷	Incorrect interventions (no intervention)
Lapp 2019 ²⁹⁸	Letter/commentary/expert opinion
Larun 2014 ²⁹⁹	Incorrect study design (systematic review of RCTs)
Leaman 1997 ³⁰⁰	Study/article does not address any of the call for evidence review questions
Leone 2006 ³⁰⁴	Not relevant to any call for evidence question
Lewis 2013 ³⁰⁵	Incorrect interventions (no intervention)
Lien 2019 ³⁰⁶	Study/article does not address any of the call for evidence review questions
Light 2009 ³⁰⁷	Incorrect study design (quantitative)
Lincolnshire Partnership 2019 ³⁰⁸	Qualitative data in the form of quotes - no thematic analysis
Liu 2018 ³⁰⁹	Study/article does not address any of the call for evidence review questions
Lloyd 2012 ³¹¹	Incorrect study design (quantitative)
Lloyd 2012 ³¹⁰	Incorrect study design (RCT)
Loades 2016 ³¹⁵	Systematic review with different PICO

Study	Exclusion reason
Loades 2019 ³¹² (unpublished)	Incorrect population (already diagnosed with ME/CFS); incorrect study design (cross-sectional epidemiological study with no interventions)
Loades 2019 ³¹⁶	Incorrect study design (qualitative); also excluded from experiences of interventions review due incorrect population (healthcare professionals)
Loades 2019 ³¹³	Incorrect study design (quantitative)
Loades 2018 ³¹⁴	Study/article does not address any of the call for evidence review questions
Loy 2016 ³¹⁷	Incorrect study design (quantitative)
Lyshevski 2001 ³¹⁸	Study/article does not address any of the call for evidence review questions
Maes 2006 ³²¹	Study/article does not address any of the call for evidence review questions
Maes 2009 ³²²	Study/article does not address any of the call for evidence review questions
Maes 2012 ³²³	Study/article does not address any of the call for evidence review questions
Marshall 1997 ³²⁷	Not relevant to any call for evidence question
Marshall 1996 ³²⁸	Incorrect study design (quantitative)
Mathew 2009 ³²⁹	Study/article does not address any of the call for evidence review questions
May 2010 ³³⁰	Study/article does not address any of the call for evidence review questions
McCourt 2019 ³³¹	Study/article does not address any of the call for evidence review questions
McDermott 2006 ³³²	Study/article does not address any of the call for evidence review questions
McGregor 2016 ³³³	Study/article does not address any of the call for evidence review questions
McGregor 2019 ³³⁴	Study/article does not address any of the call for evidence review questions
McManimen 2016 ³³⁶	Study/article does not address any of the call for evidence review questions
McManimen 2019 ³³⁵	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
McPhee 2019 ³³⁷	Qualitative section was related to information given to patients about possible harms, data about harm was quantitative
ME Action 2019 ³⁰¹	Not review population (people already diagnosed with ME/CFS); Incorrect study design (survey)
ME/cvs Vereniging 2016 ³³⁸	Report summary; full report in Dutch
Meeus 2015 ³³⁹	Incorrect study design (RCT)
ME Group 2019 ³²⁰	No qualitative findings/data analysis reported
ME Group 2014 ³¹⁹	No qualitative findings/data analysis reported
Melamed 2019 ³⁴¹	Study/article does not address any of the call for evidence review questions
Mihelicova 2016 ³⁴³	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
Miller 2015 ³⁴⁴	Study/article does not address any of the call for evidence review questions
Millions Missing Canada 2017 ³⁴⁵	Incorrect study design (quantitative survey)
Missen 2012 ³⁴⁶	No relevant outcomes
Moneghetti 2018 ³⁴⁷	Incorrect interventions (no intervention)
Montoya 2018 ³⁴⁸	Incorrect study design (RCT)
Montoya 2013 ³⁴⁹	Incorrect study design (RCT)
Moore 2000 ³⁵⁰	Study/article does not address any of the call for evidence review questions
Moore 2015 ³⁵¹	Study/article does not address any of the call for evidence review questions
Morens 2019 ³⁵²	Study/article does not address any of the call for evidence review questions
Morris 2014 ³⁵³	Study/article does not address any of the call for evidence review questions
Murdock 2017 ³⁵⁵	Study/article does not address any of the call for evidence review questions
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Advisory Committee 2019 ³⁵⁶	Study/article does not address any of the call for evidence review questions
Nacul 2011 ³⁵⁹	Study/article does not address any of the call for evidence review questions
Nacul 2011 ³⁶⁰	Study/article does not address any of the call for evidence review questions
Nacul 2018 ³⁶¹	Study/article does not address any of the call for evidence review questions
Nacul 2019 ³⁵⁸	Study/article does not address any of the call for evidence review questions
Nacul 2019 ³⁵⁷	Study/article does not address any of the call for evidence review questions
Nagy-Szakai 2018 ³⁶²	Study/article does not address any of the call for evidence review questions
Natelson 2017 ³⁶⁴	Study/article does not address any of the call for evidence review questions
Natelson 2017 ³⁶³	Study/article does not address any of the call for evidence review questions
National Centers for Environmental Information ³⁶⁵	Study/article does not address any of the call for evidence review questions
National Collaborating Centre for Primary Care 2007 ³⁶⁶	Study/article does not address any of the call for evidence review questions
Naviaux 2016 ³⁶⁹	Study/article does not address any of the call for evidence review questions
Naviaux 2017 ³⁶⁸	Study/article does not address any of the call for evidence review questions
Newberry 2018 ³⁷⁰	Study/article does not address any of the call for evidence review questions
Newton 2010 ³⁷¹	Study/article does not address any of the call for evidence review questions

Study	Exclusion reason
NHS North Bristol 2019 ³⁷²	No relevant themes (qualitative data on specialist services, not specific interventions)
Nijhof 2014 ³⁷⁶	Incorrect study design (quantitative)
Nijhof 2013 ³⁷⁵	Incorrect study design (quantitative)
Nijhof 2012 ³⁷³	Incorrect study design (RCT)
Nijhof 2011 ³⁷⁴	RCT protocol
Norfolk and Suffolk Service 2009 ³⁷⁷	Unable to obtain (web link unavailable)
Norris 2017 ³⁷⁸	Incorrect study design (cross-sectional analysis of quantitative data)
Ocon 2012 ³⁸⁰	Study/article does not address any of the call for evidence review questions
Odoom 2018 ³⁸¹	Study/article does not address any of the call for evidence review questions
Office for National Statistics 2018 ³⁸²	Not relevant to any call for evidence questions
Ojo-Amaize 1994 ³⁸³	Study/article does not address any of the call for evidence review questions
Oliver 2018 ³⁸⁴	Incorrect study design (quantitative survey)
PACE Trial participant dataset ³⁸⁶	Study/article does not address any of the call for evidence review questions
Packer 1997 ³⁸⁷	Study/article does not address any of the call for evidence review questions
Pakpoor 2017 ³⁸⁸	Study/article does not address any of the call for evidence review questions
Parslow 2018 ³⁹⁰	No relevant themes
Parslow 2017 ³⁹²	Incorrect study design (qualitative)
Parslow 2017 ³⁹¹	Systematic review with different PICO
Parslow 2015 ³⁸⁹	Incorrect study design (qualitative; assessed for monitoring and review question)
Pastula 2014 ³⁹³	Study/article does not address any of the call for evidence review questions
Patrick Neary 2008 ³⁹⁷	Incorrect interventions (no intervention)
Peci 2015 ³⁹⁸	Study/article does not address any of the call for evidence review questions
Peckerman 2003 ³⁹⁹	Study/article does not address any of the call for evidence review questions
Pemberton 2014 ⁴⁰¹	No relevant themes
Pemberton 2014 ⁴⁰⁰	No relevant themes
Peterson 1991 ⁴⁰⁶	Not relevant to any call for evidence question
Peterson 1994 ⁴⁰⁷	Incorrect interventions (no intervention)
Perrin 1993 ⁴⁰³	Review; study/article does not address any of the call for evidence review questions
Perrin 1998 ⁴⁰⁴	Incorrect study design (non-randomised quantitative study)
Perrin 2011 ⁴⁰⁵	Incorrect study design (non-randomised quantitative study)
Pheby 2009 ⁴⁰⁸	Incorrect study design (survey) and no useable data

Study	Exclusion reason
Physios for M.E ⁴¹⁰ (unpublished)	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Plascencia-Villa 2016 ⁴¹¹	Study/article does not address any of the call for evidence review questions
Polli 2019 ⁴¹²	Incorrect study design (quantitative)
Polo 2019 ⁴¹³	Incorrect study design (no qualitative data)
Prins 2005 ⁴¹⁵	Incorrect study design (quantitative)
Prins 2001 ⁴¹⁶	Incorrect study design (RCT)
Prokhorov 2016 ⁴¹⁸	Study/article does not address any of the call for evidence review questions
Puri 2011 ⁴²⁰	Incorrect study design (diagnostic accuracy study)
Quarmby 2007 ⁴²¹	Incorrect study design (quantitative)
Raine 2004 ⁴²²	Incorrect population (GPs)
Rand Corporation ⁴²³	Study/article does not address any of the call for evidence review questions
Rawlins 2008 ⁴²⁴	Study/article does not address any of the call for evidence review questions
Regland 2015 ⁴²⁶	Incorrect study design (quantitative)
Reynolds 2014 ⁴²⁷	Incorrect interventions (no intervention)
Richardson 2002 ⁴²⁸	Review article
Rimes 2014 ⁴³²	Incorrect study design (quantitative)
Roberts 2016 ⁴³⁵	Study/article does not address any of the call for evidence review questions
Roberts 2009 ⁴³³	Incorrect study design (quantitative)
Roberts 2018 ⁴³⁴	Study/article does not address any of the call for evidence review questions
Roe ⁴³⁶	No relevant themes (qualitative data on a specialist service, not specific interventions)
Roerink 2017 ⁴³⁹	Study/article does not address any of the call for evidence review questions
Roerink 2017 ⁴³⁷	Incorrect study design (RCT)
Roerink 2015 ⁴³⁸	RCT protocol
Roma 2019 ⁴⁴⁰	Incorrect interventions (no intervention)
Rowe 2019 ⁴⁴¹	Incorrect study design (questionnaire with closed and open ended questions; no thematic analysis)
Rowe 2017 ⁴⁴²	Review article
Ruggieri 2017 ⁴⁴³	Study/article does not address any of the call for evidence review questions
Santini 2018 ⁴⁴⁸	Study/article does not address any of the call for evidence review questions
Šarić 2016 ⁴⁴⁹	Study/article does not address any of the call for evidence review questions
Scheeres 2009 ⁴⁵⁰	Study/article does not address any of the call for evidence review questions
Scheeres 2008 ⁴⁵²	Incorrect study design (quantitative)
Scheeres 2008 ⁴⁵¹	Incorrect study design (quantitative)

Study	Exclusion reason
Scheeres 2007 ⁴⁵³	Study/article does not address any of the call for evidence review questions
Schmalig 2019 ⁴⁵⁵	Study/article does not address any of the call for evidence review questions
Schweitzer 1995 ⁴⁵⁶	Not relevant to any call for evidence question
Severens 2004 ⁴⁵⁹	Letter/commentary/expert opinion
Shakespeare 2017 ⁴⁶⁰	Study/article does not address any of the call for evidence review questions
Shan 2018 ⁴⁶¹	Study/article does not address any of the call for evidence review questions
Sharpe 1991 ⁴⁶⁴	Study/article does not address any of the call for evidence review questions
Sharpe 2015 ⁴⁶²	Incorrect study design (RCT)
Shukla 2015 ⁴⁶⁵	Incorrect study design (quantitative)
Shungu 2012 ⁴⁶⁶	Study/article does not address any of the call for evidence review questions
Smith 2014 ⁴⁶⁹	Incorrect study design (systematic review of RCTs)
Smith 2013 ⁴⁷⁰	Systematic review with different PICO
Smith 2015 ⁴⁶⁸	Incorrect study design (systematic review of RCTs)
Snell 2013 ⁴⁷¹	Study/article does not address any of the call for evidence review questions
Snounou 2019 ⁴⁷²	Not review population (people already diagnosed with ME/CFS); Incorrect study design (qualitative)
Solomon-Moore 2019 ⁴⁷³	Incorrect study design (baseline cross-sectional data from an RCT)
Stahl 2014 ⁴⁷⁴	Incorrect study design (quantitative)
Staud 2017 ⁴⁷⁶	Incorrect study design (RCT)
Staud 2018 ⁴⁷⁵	Incorrect study design (quantitative)
Steffen 2002 ⁴⁷⁷	Study/article does not address any of the call for evidence review questions
Stevellink 2019 ⁴⁷⁸	Study/article does not address any of the call for evidence review questions
Stevens 2018 ⁴⁷⁹	Study/article does not address any of the call for evidence review questions
Stevens 2010 ⁴⁸⁰	Incorrect study design (case study)
Stoll 2017 ⁴⁸¹	Systematic review with different PICO
Stordeur 2008 ⁴⁸²	Study/article does not address any of the call for evidence review questions
Strassheim 2018 ⁴⁸³	Study/article does not address any of the call for evidence review questions
Strawbridge 2019 ⁴⁸⁴	Not relevant to any call for evidence question
Strayer 2012 ⁴⁸⁵	Incorrect study design (RCT)
Strbak 2011 ⁴⁸⁶	Study/article does not address any of the call for evidence review questions
Stulemeijer 2005 ⁴⁸⁸	Incorrect study design (RCT)
Sumathipala 2008 ⁴⁸⁹	Incorrect population (medically unexplained symptoms)
Sunnquist 2018 ⁴⁹⁰	Incorrect study design (quantitative)

Study	Exclusion reason
Suvorov 1998 ⁴⁹²	Study/article does not address any of the call for evidence review questions
Swinscow 1997 ⁴⁹³	Study/article does not address any of the call for evidence review questions
Taylor 2004 ⁴⁹⁶	Incorrect study design (RCT)
Taylor 2019 Leeds and York CFS/ME Service ⁴⁹⁵ (unpublished)	No qualitative data
Taylor 2016 ⁴⁹⁴	Study/article does not address any of the call for evidence review questions
Teitelbaum 2001 ⁴⁹⁷	Incorrect study design (RCT)
Terzi 2016 ⁴⁹⁸	Study/article does not address any of the call for evidence review questions
The 2010 ⁵¹¹	Incorrect study design (RCT)
The 2007 ⁵¹²	Incorrect study design (RCT)
The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee 1997 ⁵¹⁰	Not relevant to any call for evidence questions
The 25% ME Group 2010 ⁴⁹⁹	Different focus to review question
The 25% ME Group 2014 ⁵⁰⁰ (unpublished)	Report on a research presentation; no qualitative data from people with ME/CFS
The 25% ME Group 2004 ⁵⁰⁹	Incorrect study design (quantitative survey)
The 25% ME Group 2000 ⁵⁰⁶	Incorrect study design (quantitative survey)
The 25% ME Group 2001 ⁵⁰¹	Incorrect study design (quantitative survey)
The 25% ME Group ⁵⁰⁸	Article; no qualitative data from people with ME/CFS
The 25% ME Group 2002 ⁵⁰⁵ (unpublished)	Incorrect study design (quantitative survey)
The 25% ME Group 2017 ⁵⁰³	Not relevant to any call for evidence questions
The 25% ME Group 2018 ⁵⁰²	Not relevant to any call for evidence questions
The 25% ME Group 2001 ⁵⁰⁴	Incorrect study design (quantitative survey)
The 25% ME Group 2016 ⁵⁰⁷	Study/article does not address any of the call for evidence review questions (newsletter)
The ME Association 2010 ⁵¹³	Incorrect study design (quantitative survey)
The ME Association 2015 ⁵¹⁴	Survey including quantitative and qualitative data, but no analysis on the qualitative data
The Neurological Alliance 2019 ⁵¹⁵	Incorrect study design (quantitative survey)
Thomas 2009 ⁵¹⁶	Incorrect interventions (no intervention)
Tiersky 2001 ⁵¹⁷	Incorrect study design (quantitative)
Timbol 2019 ⁵¹⁹	No relevant themes
Togo 2015 ⁵²⁰	Incorrect interventions (no intervention)
Trabal 2012 ⁵²²	Study/article does not address any of the call for evidence review questions
Tummers 2013 ⁵²⁵	Incorrect study design (quantitative)
Tummers 2012 ⁵²⁴	Incorrect study design (RCT)
Tummers 2010 ⁵²³	Incorrect study design (quantitative)

Study	Exclusion reason
Twisk 2014 ⁵³⁰	Letter/commentary/expert opinion
Twisk 2017 ⁵²⁷	Letter/commentary/expert opinion
Twisk 2018 ⁵²⁶	Report summary; full report in Dutch
Twisk 2015 ⁵²⁹	Study/article does not address any of the call for evidence review questions
Twisk 2015 ⁵²⁸	Incorrect study design (review article)
Van Campen 2018 ⁵³²	Incorrect interventions (no intervention)
Van Campen 2018 ⁵³⁴	Study/article does not address any of the call for evidence review questions
Van Campen 2019 ⁵³³	Incorrect study design (quantitative)
Van Den Eede 2011 ⁵³⁵	Study/article does not address any of the call for evidence review questions
Van Der Schaaf 2015 ⁵³⁷	RCT protocol
Van Der Schaaf 2017 ⁵³⁶	Study/article does not address any of the call for evidence review questions
Van Der Werf 2002 ⁵³⁸	Study/article does not address any of the call for evidence review questions
Van Konynenburg 2010 ⁵³⁹	Conference abstract
Van Kuppeveld 2010 ⁵⁴⁰	Study/article does not address any of the call for evidence review questions
VanNess 2007 ⁵⁴¹	Incorrect interventions (no intervention)
VanNess 2010 ⁵⁴²	Incorrect intervention (exercise test)
Velleman 2016 ⁵⁴³	Incorrect population (siblings) and no relevant themes
Vercoulen 1996 ⁵⁴⁵	Incorrect study design (RCT)
Vercoulen 1996 ⁵⁴⁴	Study/article does not address any of the call for evidence review questions
Vermeulen 2010 ⁵⁴⁶	Study/article does not address any of the call for evidence review questions
Vermeulen 2014 ⁵⁴⁸	Study/article does not address any of the call for evidence review questions
Vernon 2004 ⁵⁴⁹	Unable to obtain
Verspaandonk 2015 ⁵⁵⁰	Incorrect study design (quantitative)
Vink 2017 ⁵⁵¹	Incorrect study design (quantitative)
Vink 2018 ⁵⁵⁴	Review of an RCT
Vink 2018 ⁵⁵³	Incorrect study design (reanalysis of a Cochrane review); no qualitative data
Vink 2019 ⁵⁵⁵	Systematic review: references checked
Vink 2019 ⁵⁵²	Incorrect study design (reanalysis of a Cochrane review); no qualitative data
Wallis 2016 ⁵⁵⁷	Study/article does not address any of the call for evidence review questions
Wallis 2018 ⁵⁵⁶	Incorrect study design (quantitative)
Wang 2017 ⁵⁵⁹	Study/article does not address any of the call for evidence review questions
Watt 2012 ⁵⁶⁰	Incorrect study design (quantitative)

Study	Exclusion reason
Wearden 2006 ⁵⁶³	Study/article does not address any of the call for evidence review questions
Wearden 2010 ⁵⁶¹	Incorrect study design (RCT)
Wearden 2013 ⁵⁶²	Incorrect study design (prognostic)
Webb 2011 ⁵⁶⁴	No relevant themes
Werbach 2000 ⁵⁶⁵	Incorrect study design (literature review)
White 2007 ⁵⁶⁹	RCT protocol
White 2011 ⁵⁶⁸	Incorrect study design (RCT)
White 2013 ⁵⁶⁷	Study/article does not address any of the call for evidence review questions
Whitehead 2009 ⁵⁷¹	Study/article does not address any of the call for evidence review questions
Whitehead 2002 ⁵⁷²	Study/article does not address any of the call for evidence review questions
Wiborg 2010 ⁵⁷⁴	Incorrect study design (reanalysis of RCTs)
Wiborg 2014 ⁵⁷⁶	Incorrect study design (quantitative)
Wiborg 2015 ⁵⁷⁵	Incorrect study design (RCT)
Wiborg 2011 ⁵⁷³	Incorrect study design (quantitative)
Wieczorek 2017 ⁵⁵⁸	Study/article does not address any of the call for evidence review questions
Wilshire 2018 ⁵⁸⁰	Incorrect study design (reanalysis of an RCT)
Wilshire 2019 ⁵⁷⁹	Letter/commentary/expert opinion
Wilshire 2017 ⁵⁷⁷	Incorrect study design (critical commentary and reanalysis of an RCT)
Wilshire 2017 ⁵⁷⁸	Letter/commentary/expert opinion
Worm-Smeitink 2019 ⁵⁸²	Incorrect study design (RCT)
Worm-Smeitink 2017 ⁵⁸¹	Study/article does not address any of the call for evidence review questions
Worm-Smeitink 2016 ⁵⁸³	Incorrect study design (quantitative)
Yorkshire Fatigue Clinic ⁴⁰²	Not review population (people already diagnosed with ME/CFS); Incorrect study design (survey)
Zablotskii 2016 ⁵⁸⁴	Study/article does not address any of the call for evidence review questions
Zablotskii 2018 ⁵⁸⁵	Study/article does not address any of the call for evidence review questions
Zhi 2017 ⁵⁸⁶	Study/article does not address any of the call for evidence review questions
Zielinski 2019 ⁵⁸⁷	Study/article does not address any of the call for evidence review questions

J.1.2 Health Economic studies

Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.

References

1. Action for ME. Results from our Big Survey [Unpublished]. 2019.
2. Action for ME. Severely neglected: M.E. in the UK. Membership survey. London. Action for ME, 2001.
3. Action for ME, Association of Young People with ME. Action for M.E. and AYME survey 2008 - results. 2008. Available from: <https://afme.wordpress.com/> Last accessed: 29/11/2019.
4. Adamowicz JL, Caikauskaite I, Friedberg F. Defining recovery in chronic fatigue syndrome: A critical review. *Quality of Life Research*. 2014; 23(9):2407-2416
5. Adamson J, Ali S, Santhouse A, Wessely S, Chalder T. Routine clinic outcomes after cognitive behavior therapy (CBT) and graded exercise therapy (GET) from South London and Maudsley NHS Trust & King's College London service compared to trials of CBT and GET respectively [Unpublished].
6. Adedeji AO, Okonko IO, Adu FD. Sabin and wild type polioviruses from children who presented with acute flaccid paralysis in Nigeria. *African Health Sciences*. 2012; 12(3):345-354
7. Adelakun S, Meriwoode J. An evaluation of CFS/ME group members' experience of engaging in a self management treatment programme in an NHS specialist CFS/ME service in the UK. Specialist Occupational Therapist Sussex-wide CFS/ME Service, 2019.
8. Aelfers E, Bosma H, Houkes I, van Eijk JT. Effectiveness of a minimal psychological intervention to reduce mild to moderate depression and chronic fatigue in a working population: the design of a randomized controlled trial. *BMC Public Health*. 2013; 13:129
9. Ahmed SA, Mewes JC, Vrijhoef H. Assessment of the scientific rigour of randomized controlled trials on the effectiveness of cognitive behavioural therapy and graded exercise therapy for patients with myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review. *Journal of Health Psychology*. 2020; 25(2):240-255
10. Akagi H, Klimes I, Bass C. Cognitive behavioral therapy for chronic fatigue syndrome in a general hospital--feasible and effective. *General Hospital Psychiatry*. 2001; 23(5):254-260
11. Ali A, Weiss TR, Dutton A, McKee D, Jones KD, Kashikar-Zuck S et al. Mindfulness-based stress reduction for adolescents with functional somatic syndromes: A pilot cohort study. *Journal of Pediatrics*. 2017; 183:184-190
12. All-Party Parliamentary Group on ME. Inquiry into NHS Service Provision for ME/CFS. 2010. Available from: <https://www.meassociation.org.uk/wp-content/uploads/2013/02/APPG-Report-v3.pdf>
13. Allwright E, Murihead N. Understanding the role of the general practitioner in caring for patients with myalgic encephalomyelitis/chronic fatigue syndrome in the community. 2019.
14. Anderson E, Parslow R, Hollingworth W, Mills N, Beasant L, Gaunt D et al. Testing the feasibility of recruiting adolescents with CFS/ME to internet-delivered therapy:

- internal pilot within a randomised controlled trial investigating online cognitive behavioural therapy (Fatigue In Teenagers on the interNET in the NHS – “FITNET-NHS”) compared to skype-delivered activity management for adolescents with CFS/ME [Unpublished].
15. Anderson JS, Ferrans CE. The quality of life of persons with chronic fatigue syndrome. *Journal of Nervous and Mental Disease*. 1997; 185(6):359-367
 16. Anonymous. Evaluating the effects of change in the content and format of a lifestyle management group on standardized outcome measures of chronic fatigue syndrome/myalgic encephalomyelitis. University of Surrey.
 17. Anonymous. *Lactobacillus acidophilus* can attenuate the symptoms of chronic fatigue syndrome. *Nature Reviews Gastroenterology and Hepatology*. 2012; 9:186
 18. Anonymous. Neuropsychological performance in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Gulf war illness (GWI). Implications for interventions and patient management. [Submission for Doctoral level Qualification in Counselling Psychology]. 2015.
 19. Anonymous. Re: "Multi-site clinical assessment of myalgic encephalomyelitis/chronic fatigue syndrome (Mcam): Design and implementation of a prospective/retrospective rolling cohort study". *American Journal of Epidemiology*. 2017; 186(1):129
 20. Anonymous. Supplements for chronic fatigue syndrome? *P & T*. 2016; 41(9):587-588
 21. Antcliff D, Keenan AM, Keeley P, Woby S, McGowan L. Survey of activity pacing across healthcare professionals informs a new activity pacing framework for chronic pain/fatigue. *Musculoskeletal Care*. 2019; 17(4):335-345
 22. Antiel RM, Caudill JS, Burkhardt BE, Brands CK, Fischer PR. Iron insufficiency and hypovitaminosis D in adolescents with chronic fatigue and orthostatic intolerance. *Southern Medical Journal*. 2011; 104(8):609-611
 23. Armstrong CW, McGregor NR, Sheedy JR, Buttfeld I, Butt HL, Gooley PR. NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome. *Clinica Chimica Acta*. 2012; 413(19-20):1525-1531
 24. Arnold LM, Blom TJ, Welge JA, Mariutto E, Heller A. A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome. *Psychosomatics*. 2015; 56(3):242-253
 25. Ates K, Carlak HF, Ozen S. Magnetic field exposures due to underground power cables: A simulation study. *Proceedings of the 2nd World Congress on Electrical Engineering and Computer Systems and Science*. 2016:EEE 133
 26. Augusto CRA, Navia CE, de Oliveira MN, Nepomuceno AA, Fauth AC, Kopenkin V et al. Relativistic proton levels from region AR 12673 (GLE #72) and the heliospheric current sheet as a sun–earth magnetic connection. *Publications of the Astronomical Society of the Pacific*. 2018; 131(996):024401
 27. BACME. CFS/ME national services survey February 2018. 2019. Available from: <https://www.bacme.info/sites/bacme.info/files/BACME%20CFS%20ME%20National%20services%20survey%20March19.pdf>

28. Bakker RJ, van de Putte EM, Kuis W, Sinnema G. Effects of an educational video film in fatigued children and adolescents: A randomised controlled trial. *Archives of Disease in Childhood*. 2011; 96(5):457-460
29. Balaguru S, Uppal R, Vaid RP, Kumar BP. Investigation of the spinal cord as a natural receptor antenna for incident electromagnetic waves and possible impact on the central nervous system. *Electromagnetic Biology and Medicine*. 2012; 31(2):101-111
30. Baos S, Brigden A, Anderson E, Hollingworth W, Price S, Mills N et al. Investigating the effectiveness and cost-effectiveness of FITNET-NHS (Fatigue In Teenagers on the interNET in the NHS) compared to Activity Management to treat paediatric chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME): Protocol for a randomised controlled trial. *Trials*. 2018; 19(1):136
31. Baraniuk JN. BMJ Best Practice: Chronic fatigue syndrome/Myalgic encephalomyelitis. 2018. Available from: <https://bestpractice.bmj.com/topics/en-gb/277> Last accessed: 29/11/2019.
32. Baraniuk JN, Shivapurkar N. Exercise - induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects. *Scientific Reports*. 2017; 7:15338
33. Barnden LR, Kwiatek R, Crouch B, Burnet R, Del Fante P. Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in chronic fatigue syndrome. *NeuroImage Clinical*. 2016; 11:530-537
34. Barriers to access to social care for patients very severely affected by myalgic encephalomyelitis (ME). Submission to APPG on ME April 19th 2016 Roundtable Meeting on Social Care, chaired by Daniel Zeichner MP. 2016.
35. Bazelmans E, Prins JB, Hoogveld S, Bleijenberg G. Manual-based cognitive behaviour therapy for chronic fatigue syndrome: Therapists' adherence and perceptions. *Cognitive Behaviour Therapy*. 2004; 33(3):143-150
36. Bazelmans E, Prins JB, Lulofs R, van der Meer JW, Bleijenberg G, Netherlands Fatigue Research Group N. Cognitive behaviour group therapy for chronic fatigue syndrome: A non-randomised waiting list controlled study. *Psychotherapy and Psychosomatics*. 2005; 74(4):218-224
37. Bazilevskaya GA, Makhmutov VS, Sladkova AI. Gnevyshev gap effects in solar energetic particle activity. *Advances in Space Research*. 2006; 38(3):484-488
38. Beasant L, Brigden A, Anderson E, Mills N, Trist A, Crawley E. "All the programmes are designed around you": Families views on graded exercise therapy for paediatric CFS/ME [Unpublished].
39. Behan PO, Behan WM, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. *Acta Neurologica Scandinavica*. 1990; 82(3):209-216
40. Behan PO, Behan WMH, Horrobin DF. A placebo-controlled trial of n-3 and n-6 essential fatty acids in the treatment of post-viral fatigue syndrome. *Acta Neurologica Scandinavica*. 1990; 82(3):209-216
41. Belgian Ministry of Social Affairs, Public Health and Environment. Aanbevelingen betreffende de medischsociale, economische en juridische aspecten voor patienten

- met syndroom van chronische vermoeidheid. 2000. Available from: <https://tinyurl.com/belgiumreportpdf>
42. Bell DS. Prognosis of ME/CFS. 2016. Available from: <https://www.omf.ngo/2016/08/01/prognosis-of-mecfs/> Last accessed: 26/11/2019.
 43. Berkovitz S, Ambler G, Jenkins M, Thurgood S. Serum 25-hydroxy vitamin D levels in chronic fatigue syndrome: A retrospective survey. *International Journal for Vitamin and Nutrition Research*. 2009; 79(4):250-254
 44. Bethune CA, Wright LJ, Stoker SRG, Ong ELC, Snow MH, Spickett GP. An audit of the investigation of patients with suspected chronic fatigue syndrome. *CPD Bulletin Immunology and Allergy*. 2003; 3(2):51-53
 45. Blease C, Carel H, Geraghty K. Epistemic injustice in healthcare encounters: evidence from chronic fatigue syndrome. *Journal of Medical Ethics*. 2017; 43(8):549-557
 46. Bleijenberg G. The effect of self-instructions in the treatment of patients with Chronic Fatigue Syndrome type Idiopathic Chronic Fatigue (CFS-ICF): A randomised controlled study. NTR1660. 2009. Available from: <https://www.trialregister.nl/trial/1581> Last accessed: 29/10/2019.
 47. Bloot L, Heins MJ, Donders R, Bleijenberg G, Knoop H. The process of change in pain during cognitive-behavior therapy for chronic fatigue syndrome. *Clinical Journal of Pain*. 2015; 31(10):914-921
 48. Blue Ribbon for the Awareness of Myalgic Encephalomyelitis. Results of recent patient surveys on CBT, GET, PACING, REST [Unpublished]. 2010.
 49. Bombardier CH, Buchwald D. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia. Disability and health-care use. *Medical Care*. 1996; 34(9):924-930
 50. Boneva RS, Lin JS, Wieser F, Nater UM, Ditzen B, Taylor RN et al. Endometriosis as a comorbid condition in chronic fatigue syndrome (CFS): Secondary analysis of data from a CFS case-control study. *Frontiers in Pediatrics*. 2019; 7:195
 51. Bonner D, Ron M, Chalder T, Butler S, Wessely S. Chronic fatigue syndrome: a follow up study. *Journal of Neurology, Neurosurgery and Psychiatry*. 1994; 57(5):617-621
 52. Bould H, Collin SM, Lewis G, Rimes K, Crawley E. Depression in paediatric chronic fatigue syndrome. *Archives of Disease in Childhood*. 2013; 98(6):425-428
 53. Bould H, Lewis G, Emond A, Crawley E. Depression and anxiety in children with CFS/ME: Cause or effect? *Archives of Disease in Childhood*. 2011; 96(3):211-214
 54. Bowers JR, Valentine M, Harrison V, Fofanov VY, Gillece J, Delisle J et al. Genomic analyses of acute flaccid myelitis cases among a cluster in arizona provide further evidence of enterovirus D68 role. *mBio*. 2019; 10(1):e02262-02218
 55. Brigden A, Barnett J, Parslow RM, Beasant L, Crawley E. Using the internet to cope with chronic fatigue syndrome/myalgic encephalomyelitis in adolescence: A qualitative study. *BMJ Paediatrics Open*. 2018; 2:e000299

56. Brigden A, Beasant L, Hollingworth W, Metcalfe C, Gaunt D, Mills N et al. Managed Activity Graded Exercise iN Teenagers and pre-Adolescents (MAGENTA) feasibility randomised controlled trial: Study protocol. *BMJ Open*. 2016; 6:e011255
57. Brigden A, Parslow RM, Gaunt D, Collin SM, Jones A, Crawley E. Defining the minimally clinically important difference of the SF-36 physical function subscale for paediatric CFS/ME: Triangulation using three different methods. *Health & Quality of Life Outcomes*. 2018; 16(1):202
58. Brigden AB, Beasant LB, Gaunt DG, Hollingworth WH, Mills NM, Solomon-Moore E et al. Results of the feasibility phase of the Managed Activity Graded Exercise iN Teenagers and Pre-Adolescents (MAGENTA) randomised controlled trial of treatments for chronic fatigue syndrome/myalgic encephalomyelitis [Unpublished].
59. Bringsli GJ, Gilje AM, Getz Wold BK. The Norwegian ME Association National Survey 2014. Oslo. 2014. Available from: <http://www.me-foreningen.info/wp-content/uploads/2016/09/ME-Nat-Norwegian-Survey-Abr-Eng-Ver.pdf>
60. Bristol CFS/ME Service. A qualitative evaluation of the Foundation Phase seminars [Unpublished].
61. Britain E, Muirhead NL, Finlay AY, Vyas J. The impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the family: measuring quality of life (QOL) using the WHOQOL-BREF and from-16 questionnaires. *Journal of liMER*,. 2019; 13(1):21
62. Brooks SK, Rimes KA, Chalder T. The role of acceptance in chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2011; 71(6):411-415
63. Broughton J, Harris S, Beasant L, Crawley E, Collin SM. Adult patients' experiences of NHS specialist services for chronic fatigue syndrome (CFS/ME): A qualitative study in England. *BMC Health Services Research*. 2017; 17:384
64. Brouwers FM, Van Der Werf S, Bleijenberg G, Van Der Zee L, Van Der Meer JW. The effect of a polynutrient supplement on fatigue and physical activity of patients with chronic fatigue syndrome: A double-blind randomized controlled trial. *QJM*. 2002; 95(10):677-683
65. Brown AE, Jones DE, Walker M, Newton JL. Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome. *PloS One*. 2015; 10(4):e0122982
66. Brown MM, Bell DS, Jason LA, Christos C, Bell DE. Understanding long-term outcomes of chronic fatigue syndrome. *Journal of Clinical Psychology*. 2012; 68(9):1028-1035
67. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: An overview of environmental risk factors. *Environmental Health Perspectives*. 2005; 113(9):1250-1256
68. Buchachenko A, Bukhvostov A, Ermakov K, Kuznetsov D. Nuclear spin selectivity in enzymatic catalysis: A caution for applied biophysics. *Archives of Biochemistry and Biophysics*. 2019; 667:30-35
69. Buchachenko A, Lawler RG. New possibilities for magnetic control of chemical and biochemical reactions. *Accounts of Chemical Research*. 2017; 50(4):877-884

70. Buchachenko AL, Kouznetsov DA, Arkhangelsky SE, Orlova MA, Markarian AA. Spin biochemistry: Magnetic 24Mg-25Mg-26Mg isotope effect in mitochondrial ADP phosphorylation. *Cell Biochemistry and Biophysics*. 2005; 43(2):243-251
71. Buchachenko AL, Kuznetsov DA, Berdinskii VL. [New mechanisms of biological effects of electromagnetic fields]. *Biofizika*. 2006; 51(3):545-552
72. Buchachenko AL, Orlov AP, Kuznetsov DA, Breslavskaya NN. Magnetic isotope and magnetic field effects on the DNA synthesis. *Nucleic Acids Research*. 2013; 41(17):8300-8307
73. Burgess M, Andiappan M, Chalder T. Cognitive behaviour therapy for chronic fatigue syndrome in adults: face to face versus telephone treatment: A randomized controlled trial. *Behavioural and Cognitive Psychotherapy*. 2012; 40(2):175-191
74. Burke HE. *Handbook of magnetic phenomena*. New York, NY. Van Nostrand Reinhold. 1986.
75. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. *British Medical Journal (Clinical Research Ed)*. 1982; 284(6329):1607-1608
76. Calello M. Two Virginia children diagnosed with polio-like illness AFM. 2018. Available from: <https://eu.newsleader.com/story/news/2018/11/26/two-virginia-kids-diagnosed-polio-like-illness-afm-cdc-virginia-department-health/2115535002/> Last accessed: 05/12/2019.
77. Candy B, Chalder T, Cleare AJ, Wessely S, Hotopf M. A randomised controlled trial of a psycho-educational intervention to aid recovery in infectious mononucleosis. *Journal of Psychosomatic Research*. 2004; 57(1):89-94
78. Carpenter DO. Human disease resulting from exposure to electromagnetic fields. *Reviews on Environmental Health*. 2013; 28(4):159-172
79. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lemer AM et al. Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols. *Journal of Chronic Fatigue Syndrome*. 2003; 11(1):7-115
80. Carruthers BM, Van de Sande MI. Myalgic encephalomyelitis-adult & pediatric: International Consensus Primer for Medical Practitioners. 2012. Available from: <http://www.investinme.org/index.shtml>
81. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T et al. Myalgic encephalomyelitis: International Consensus Criteria. *Journal of Internal Medicine*. 2011; 270(4):327-338
82. Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP et al. The 6-min walk distance in healthy subjects: Reference standards from seven countries. *European Respiratory Journal*. 2011; 37(1):150-156
83. Castro-Marrero J, Saez-Francas N, Santillo D, Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: All roads lead to Rome. *British Journal of Pharmacology*. 2017; 174(5):345-369
84. Castro-Marrero J, Saez-Francas N, Segundo MJ, Calvo N, Faro M, Aliste L et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on

- maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial. *Clinical Nutrition*. 2016; 35(4):826-834
85. Cella M, Chalder T, White PD. Does the heterogeneity of chronic fatigue syndrome moderate the response to cognitive behaviour therapy? An exploratory study. *Psychotherapy and Psychosomatics*. 2011; 80(6):353-358
86. Cella M, Stahl D, Reme SE, Chalder T. Therapist effects in routine psychotherapy practice: an account from chronic fatigue syndrome. *Psychotherapy research: Journal of the Society for Psychotherapy Research*. 2011; 21(2):168-178
87. Centers for Disease Control and Prevention. Acute flaccid myelitis. 2019. Available from: https://www.cdc.gov/acute-flaccid-myelitis/cases-in-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Facute-flaccid-myelitis%2Fafm-cases.html Last accessed: 04/12/2019.
88. CFS/ME National Outcomes Database Team, SW London and Surrey CFS service NOD local Surrey. Report on Epsom and St Helier CFS/ME service. University of Bristol, 2016.
89. CFS/ME Service for South Yorkshire and North Derbyshire. CFS/ME Service for South Yorkshire and North Derbyshire outcomes up to 2018/19: clinical global improvement scale. 2019.
90. CFS/ME Service for South Yorkshire and North Derbyshire. Feedback after therapy: Summary comparing 2016 (54 replies) and 2018 (47 replies).
91. CFS/ME Working Group. Chief medical officer report of the CFS/ME working group: Annex 3 patient evidence [Unpublished]. 2002.
92. Chalder T. Assessing predictors of outcome and mediators of change in chronic fatigue syndrome after cognitive behaviour therapy. *International Journal of Behavioural Medicine*. 2010; 17(Suppl 1):228
93. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. Development of a fatigue scale. *Journal of Psychosomatic Research*. 1993; 37(2):147-153
94. Chalder T, Deary V, Husain K, Walwyn R. Family-focused cognitive behaviour therapy versus psycho-education for chronic fatigue syndrome in 11- to 18-year-olds: A randomized controlled treatment trial. *Psychological Medicine*. 2010; 40(8):1269-1279
95. Chalder T, Goldsmith KA, White PD, Sharpe M, Pickles AR. Rehabilitative therapies for chronic fatigue syndrome: A secondary mediation analysis of the PACE trial. *The Lancet Psychiatry*. 2015; 2(2):141-152
96. Chalder T, Wallace P, Wessely S. Self-help treatment of chronic fatigue in the community: A randomized controlled trial. *British Journal of Health Psychology*. 1997; 2(3):189-197
97. Chan JS, Ho RT, Chung KF, Wang CW, Yao TJ, Ng SM et al. Qigong exercise alleviates fatigue, anxiety, and depressive symptoms, improves sleep quality, and shortens sleep latency in persons with chronic fatigue syndrome-like illness. *Evidence-Based Complementary and Alternative Medicine*. 2014; 2014:106048

98. Chan JS, Ho RT, Wang CW, Yuen LP, Sham JS, Chan CL. Effects of qigong exercise on fatigue, anxiety, and depressive symptoms of patients with chronic fatigue syndrome-like illness: A randomized controlled trial. *Evidence-Based Complementary and Alternative Medicine*. 2013; 2013:485341
99. Chan JSM, Ng S-M, Yuen L-P, Chan CLW. Chapter Five - Qigong exercise for chronic fatigue syndrome. 'In:' Yau S-Y, So K-F, editors. *International Review of Neurobiology*. 147: Academic Press. 2019. p. 121-153.
100. Chang CM, Warren JL, Engels EA. Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. *Cancer*. 2012; 118(23):5929-5936
101. Chaudhuri A, Condon BR, Gow JW, Brennan D, Hadley DM. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. *Neuroreport*. 2003; 14(2):225-228
102. Childs K, Krockakova Lerari A, Pattinson P, Smith L, Woodvine K. Parental perspectives of diagnosis and management of ME/CFS in children and young people [Unpublished]. 2019.
103. Chisholm D, Godfrey E, Ridsdale L, Chalder T, King M, Seed P et al. Chronic fatigue in general practice: Economic evaluation of counselling versus cognitive behaviour therapy. *British Journal of General Practice*. 2001; 51(462):15-18
104. Cho JH, Cho CK, Shin JW, Son JY, Kang W, Son CG. Myelophil, an extract mix of *Astragalus Radix* and *Salviae Radix*, ameliorates chronic fatigue: A randomised, double-blind, controlled pilot study. *Complementary Therapies in Medicine*. 2009; 17(3):141-146
105. Chu L, Valencia IJ, Garvert DW, Montoya JG. Deconstructing post-exertional malaise in myalgic encephalomyelitis/ chronic fatigue syndrome: A patient-centered, cross-sectional survey. *PloS One*. 2018; 13(6):e0197811
106. Claypoole KH, Noonan C, Mahurin RK, Goldberg J, Erickson T, Buchwald D. A twin study of cognitive function in chronic fatigue syndrome: The effects of sudden illness onset. *Neuropsychology*. 2007; 21(4):507-513
107. Cleare AJ, Roberts A, Papadopoulos A, Chalder T, Wessely S. P.6.077 Cognitive behavioural therapy normalises HPA axis dysfunction in chronic fatigue syndrome. *European Neuropsychopharmacology*. 2004; 14(Suppl 3):S389
108. Cliff JM, King EC, Lee JS, Sepulveda N, Wolf AS, Kingdon C et al. Cellular immune function in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Frontiers in Immunology*. 2019; 10:796
109. Clinical trial to measure the maximum HR after ReConnect® supplementation vs. Placebo in CFS (ReConnect) [NCT02063126]. 2015. Available from: <https://www.clinicaltrials.gov/ct2/show/NCT02063126?recrs=ae&type=Intr&cond=Cfs&draw=7> Last accessed: 29/11/2019.
110. Cockshell SJ, Mathias JL. Cognitive functioning in chronic fatigue syndrome: A meta-analysis. *Psychological Medicine*. 2010; 40(8):1253-1267
111. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Health care resource use by patients before and after a diagnosis of chronic fatigue syndrome (CFS/ME): A clinical practice research datalink study. *BMC Family Practice*. 2017; 18(1):60

112. Collin SM, Bakken IJ, Nazareth I, Crawley E, White PD. Trends in the incidence of chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: A Clinical Practice Research Datalink study. *Journal of the Royal Society of Medicine*. 2017; 110(6):231-244
113. Collin SM, Crawley E. Specialist treatment of chronic fatigue syndrome/ME: A cohort study among adult patients in England. *BMC Health Services Research*. 2017; 17(1):488
114. Collin SM, Crawley E, May MT, Sterne JA, Hollingworth W, UK CFS/ME National Outcomes Database. The impact of CFS/ME on employment and productivity in the UK: A cross-sectional study based on the CFS/ME national outcomes database. *BMC Health Services Research*. 2011; 11:217
115. Collin SM, Heron J, Nikolaus S, Knoop H, Crawley E. Chronic fatigue syndrome (CFS/ME) symptom-based phenotypes and 1-year treatment outcomes in two clinical cohorts of adult patients in the UK and The Netherlands. *Journal of Psychosomatic Research*. 2018; 104:29-34
116. Collin SM, Nikolaus S, Heron J, Knoop H, White PD, Crawley E. Chronic fatigue syndrome (CFS) symptom-based phenotypes in two clinical cohorts of adult patients in the UK and The Netherlands. *Journal of Psychosomatic Research*. 2016; 81:14-23
117. Collin SM, Nuevo R, van de Putte EM, Nijhof SL, Crawley E. Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) is different in children compared to in adults: A study of UK and Dutch clinical cohorts. *BMJ Open*. 2015; 5(10):e008830
118. Collin SM, Sterne JA, Hollingworth W, May MT, Crawley E. Equity of access to specialist chronic fatigue syndrome (CFS/ME) services in England (2008-2010): A national survey and cross-sectional study. *BMJ Open*. 2012; 2:e001417
119. Comhaire F. Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: An open-label, proof-of-principle pilot trial. *Medical Hypotheses*. 2018; 114:45-48
120. Comiskey C, Larkan F. A national cross-sectional survey of diagnosed sufferers of myalgic encephalomyelitis/chronic fatigue syndrome: pathways to diagnosis, changes in quality of life and service priorities. *Irish Journal of Medical Science*. 2010; 179(4):501-505
121. Cook DB, Light AR, Light KC, Broderick G, Shields MR, Dougherty RJ et al. Neural consequences of post-exertion malaise in myalgic encephalomyelitis/chronic fatigue syndrome. *Brain, Behavior, and Immunity*. 2017; 62:87-99
122. Cooper M. North of Tyne CFS/ME service evaluation report: October 2018-January 2019. The New Castle Upon Tyne Hospitals NHS Foundation Trust, 2019.
123. Corsius LAMM, Crijnen BGPJM, Hogeweg AA, Kuijper JSM. Zorg voor beterebehandeling bij ME. Enquête onder ME-patiënten naar hun ervaringen met behandelingen bij ME. 2019. Available from: <https://www.me-cvsvereniging.nl/sites/default/files/documenten/Rapport%20Zorg%20voor%20betere%20behandeling.pdf>
124. Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. *QJM*. 1995; 88(11):767-773

125. Crawford J. Internet-based CBT for adolescents with chronic fatigue syndrome. *Lancet*. 2012; 380(9841):561-562
126. Crawford JS. Effect of a demanding cognitive task on neuropsychological performance in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and Persian Gulf War illness (GWI). *Proceedings of the British Psychological Society*. 2010; 18(1)
127. Crawford JS, Reeves A. The patient's voice: An exploration of what aids or hinders patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in the counselling process? *Proceedings of the British Psychological Society*. 2012; 20(1)
128. Crawley E, Collin SM, White PD, Rimes K, Sterne JA, May MT et al. Treatment outcome in adults with chronic fatigue syndrome: A prospective study in England based on the CFS/ME National Outcomes Database. *QJM*. 2013; 106(6):555-565
129. Crawley E, Hunt L, Stallard P. Anxiety in children with CFS/ME. *European Child and Adolescent Psychiatry*. 2009; 18(11):683-689
130. Crawley E, Mills N, Beasant L, Johnson D, Collin SM, Deans Z et al. The feasibility and acceptability of conducting a trial of specialist medical care and the Lightning Process in children with chronic fatigue syndrome: feasibility randomized controlled trial (SMILE study). *Trials*. 2013; 14:415
131. Crawley E, Sterne JA. Association between school absence and physical function in paediatric chronic fatigue syndrome/myalgic encephalopathy. *Archives of Disease in Childhood*. 2009; 94(10):752-756
132. Crawley EM, Emond AM, Sterne JA. Unidentified chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school absence: Surveillance outcomes from school-based clinics. *BMJ Open*. 2011; 1:e000252
133. Crawley EM, Gaunt DM, Garfield K, Hollingworth W, Sterne JAC, Beasant L et al. Clinical and cost-effectiveness of the Lightning Process in addition to specialist medical care for paediatric chronic fatigue syndrome: Randomised controlled trial. *Archives of Disease in Childhood*. 2018; 103(2):155-164
134. Crowhurst G. Supporting people with severe myalgic encephalomyelitis. *Nursing Standard*. 2005; 19(21):38-43
135. Crowhurst G, Crowhurst L. A survey of severe ME patients in Norfolk and Suffolk, November 2007. 2007.
136. Currell S. North of Tyne CFS/ME rehabilitation and management team: Service evaluation 2017/18. The Newcastle Upon Tyne Hospitals NHS Foundation Trust.
137. Darbishire L, Seed P, Ridsdale L. Predictors of outcome following treatment for chronic fatigue. *British Journal of Psychiatry*. 2005; 186:350-351
138. DARPA. RadioBio: What role does electromagnetic signaling have in biological systems? 2017. Available from: <https://www.darpa.mil/news-events/2017-02-07> Last accessed: 04/12/2019.
139. Davenport TE, Lehnen M, Stevens SR, VanNess JM, Stevens J, Snell CR. Chronotropic intolerance: An overlooked determinant of symptoms and activity limitation in myalgic encephalomyelitis/chronic fatigue syndrome? *Frontiers in Pediatrics*. 2019; 7:82

140. Davenport TE, Stevens SR, Baroni K, Van Ness JM, Snell CR. Reliability and validity of Short Form 36 Version 2 to measure health perceptions in a sub-group of individuals with fatigue. *Disability and Rehabilitation*. 2011; 33(25-26):2596-2604
141. Davenport TE, Stevens SR, Baroni K, Van Ness M, Snell CR. Diagnostic accuracy of symptoms characterising chronic fatigue syndrome. *Disability and Rehabilitation*. 2011; 33(19-20):1768-1775
142. Davenport TE, Stevens SR, VanNess JM, Stevens J, Snell CR. Checking our blind spots: Current status of research evidence summaries in ME/CFS. *British Journal of Sports Medicine*. 2019; 53(19):1198
143. Davenport TE, Stevens SR, VanNess MJ, Snell CR, Little T. Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis. *Physical Therapy*. 2010; 90(4):602-614
144. Davies S, Crawley E. Chronic fatigue syndrome in children aged 11 years old and younger. *Archives of Disease in Childhood*. 2008; 93(5):419-421
145. De Becker P, McGregor N, De Meirleir K. A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome. *Journal of Internal Medicine*. 2001; 250(3):234-240
146. De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K. Exercise capacity in chronic fatigue syndrome. *Archives of Internal Medicine*. 2000; 160(21):3270-3277
147. de Carvalho Leite JC, de LDM, Killett A, Kale S, Nacul L, McArthur M et al. Social support needs for equity in health and social care: a thematic analysis of experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis. *International Journal for Equity in Health*. 2011; 10:46
148. de Lange FP, Koers A, Kalkman JS, Bleijenberg G, Hagoort P, van der Meer JW et al. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. *Brain*. 2008; 131(Pt 8):2172-2180
149. de Vega WC, Herrera S, Vernon SD, McGowan PO. Epigenetic modifications and glucocorticoid sensitivity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *BMC Medical Genomics*. 2017; 10(1):11
150. Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: A randomized controlled trial. *American Journal of Psychiatry*. 1997; 154(3):408-414
151. Deale A, Chalder T, Wessely S. Illness beliefs and treatment outcome in chronic fatigue syndrome. *Journal of Psychosomatic Research*. 1998; 45(1):77-83
152. Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: A 5-year follow-up study. *American Journal of Psychiatry*. 2001; 158(12):2038-2042
153. Deftereos SN, Vernon SD, Persidis A. Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: Results of an online survey. *Fatigue: Biomedicine, Health and Behavior*. 2016; 4(1):39-51

154. DeLuca J, Christodoulou C, Diamond BJ, Rosenstein ED, Kramer N, Ricker JH et al. The Nature of Memory Impairment in Chronic Fatigue Syndrome. *Rehabilitation Psychology*. 2004; 49(1):62-70
155. Devasahayam A, Lawn T, Murphy M, White PD. Alternative diagnoses to chronic fatigue syndrome in referrals to a specialist service: Service evaluation survey. *JRSM Short Reports*. 2012; 3:4
156. Diao YL, Sun WN, He YQ, Leung SW, Siu YM. Equivalent magnetic vector potential model for low-frequency magnetic exposure assessment. *Physics in Medicine and Biology*. 2017; 62(19):7905-7922
157. Dobson J. Magnetic properties of biological material. Bioengineering and biophysical aspects of electromagnetic fields. 3rd ed: CRC Press, 2007.
158. Dotsenko VA, Mosiichuk LV, Paramonov AE. Biologically active food additives for correction of the chronic fatigue syndrome. *Voprosy Pitaniia*. 2004; 73(2):17-21
159. Dougall D, Johnson A, Goldsmith K, Sharpe M, Angus B, Chalder T et al. Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2014; 77(1):20-26
160. Doukrou M, Hiremath S, Ferin K, Jones S, Begent J, Segal T. G612(P) Characterisation of population, review of service provision, and outcomes for young people with chronic fatigue syndrome in a tertiary care inpatient setting. *Archives of Disease in Childhood*. 2019; 104(Suppl 2):A247-A247
161. Dowsett EG, Colby J. Long-term sickness absence due to ME/CFS in UK schools: An epidemiological study with medical and educational implications. *Journal of Chronic Fatigue Syndrome*. 1997; 3(2):29-42
162. Duyn JH, Schenck J. Contributions to magnetic susceptibility of brain tissue. *NMR in Biomedicine*. 2017; 30(4):1-37
163. Dyda A, Stelzer-Braid S, Adam D, Chughtai AA, MacIntyre CR. The association between acute flaccid myelitis (AFM) and Enterovirus D68 (EV-D68) - what is the evidence for causation? *Euro Surveillance*. 2018; 23(3):17-00310
164. Effective Health Care Program: Agency for Healthcare Research and Quality (AHRQ). Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. U.S. Department of Health & Human Services, 2014. Available from: https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-fatigue_research-protocol.pdf
165. Emerge Australia. Health and wellbeing survey 2018. 2018.
166. Emerge Australia. Health and wellbeing survey 2019. 2019. Available from: <https://www.emerge.org.au/health-and-wellbeing-survey-report>
167. Encephalitis Society. What is encephalitis? 2017. Available from: <https://www.encephalitis.info/what-is-encephalitis> Last accessed: 29/11/2019.
168. Eroshenko E, Belov A, Mavromichalaki H, Mariatos G, Oleneva V, Plainaki C et al. Cosmic-ray variations during the two greatest bursts of solar activity in the 23rd solar cycle. *Solar Physics*. 2004; 224(1):345-358

169. Evidence submissions to Health Select Committee Inquiry into aspects of the work of the National Institute for Health and Clinical Excellence (NICE). House of Commons, 2017. Available from: <https://publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we01.htm>
170. Executive Summary from Forward ME of survey conducted by Prof. Helen Dawes. 2019. Available from: <http://www.mereseach.org.uk/wp-content/uploads/2019/04/Amended-Final-Consolidated-Report.pdf>
171. Falk Hvidberg M, Brinth LS, Olesen AV, Petersen KD, Ehlers L. The health-related quality of life for patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *PloS One*. 2015; 10(7):e0132421
172. Faulkner G. In the expectation of recovery: Misleading medical research and welfare reform. The centre for Welfare Reform, 2016. Available from: <https://www.centreforwelfarereform.org/uploads/attachment/492/in-the-expectation-of-recovery.pdf>
173. Featherstone C. Treating chronic fatigue syndrome with complementary therapies. *British Journal of Therapy & Rehabilitation*. 1998; 5(2):98-105
174. Fisher H, Crawley E. Why do young people with CFS/ME feel anxious? A qualitative study. *Clinical Child Psychology and Psychiatry*. 2013; 18(4):556-573
175. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. *Clinical Infectious Diseases*. 1994; 18(Suppl 1):S79-83
176. Flo E, Chalder T. Prevalence and predictors of recovery from chronic fatigue syndrome in a routine clinical practice. *Behaviour Research and Therapy*. 2014; 63:1-8
177. Fluge O, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. *JCI Insight*. 2016; 1(21):e89376
178. Fluge O, Rekeland IG, Lien K, Thurmer H, Borchgrevink PC, Schafer C et al. B-Lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine*. 2019; 170(9):585-593
179. Fluge O, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D et al. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. *PloS One*. 2015; 10(7):e0129898
180. Follow-up study of adolescent chronic fatigue syndrome. *Brown University Child & Adolescent Behavior Letter*. 2010; 26(11):4-5
181. Franklin JD, Atkinson G, Atkinson JM, Batterham AM. Peak oxygen uptake in chronic fatigue syndrome/myalgic encephalomyelitis: A meta-analysis. *International Journal of Sports Medicine*. 2018; 40(2):77-87
182. Friedberg F, Napoli A, Coronel J, Adamowicz J, Seva V, Caikauskaite I et al. Chronic fatigue self-management in primary care: A randomized trial. *Psychosomatic Medicine*. 2013; 75(7):650-657

183. Fukuda S, Nojima J, Kajimoto O, Yamaguti K, Nakatomi Y, Kuratsune H et al. Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome. *Biofactors*. 2016; 42(4):431-440
184. Garner R, Baraniuk JN. Orthostatic intolerance in chronic fatigue syndrome. *Journal of Translational Medicine*. 2019; 17:185
185. Geraghty K, Hann M, Kurtev S. Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys. *Journal of Health Psychology*. 2017; 24(10):1318-1333
186. Geraghty K, Jason L, Sunnquist M, Tuller D, Blease C, Adeniji C. The 'cognitive behavioural model' of chronic fatigue syndrome: Critique of a flawed model. *Health Psychology Open*. 2019; 6(1):1-14
187. Geraghty KJ, Adeniji C. The importance of accurate diagnosis of ME/CFS in children and adolescents: A commentary. *Frontiers in Pediatrics*. 2019; 6:435
188. Geraghty KJ, Blease C. Cognitive behavioural therapy in the treatment of chronic fatigue syndrome: A narrative review on efficacy and informed consent. *Journal of Health Psychology*. 2018; 23(1):127-138
189. Geraghty KJ, Blease C. Myalgic encephalomyelitis/chronic fatigue syndrome and the biopsychosocial model: A review of patient harm and distress in the medical encounter *Disability and Rehabilitation*. 2019; 41(25):3092-3102
190. Geraghty KJ, Esmail A. Chronic fatigue syndrome: Is the biopsychosocial model responsible for patient dissatisfaction and harm? *British Journal of General Practice*. 2016; 66(649):437-438
191. Ghatineh S, Vink M. FITNET's internet-based cognitive behavioural therapy is ineffective and may impede natural recovery in adolescents with myalgic encephalomyelitis/chronic fatigue syndrome. A review. *Behavioral Sciences*. 2017; 7(3):11
192. Gielissen MF, Knoop H, Servaes P, Kalkman JS, Huibers MJ, Verhagen S et al. Differences in the experience of fatigue in patients and healthy controls: Patients' descriptions. *Health & Quality of Life Outcomes*. 2007; 5:36
193. Gieré R. Magnetite in the human body: Biogenic vs. anthropogenic. *Proceedings of the National Academy of Sciences*. 2016; 113(43):11986-11987
194. Gilder SA, Wack M, Kaub L, Roud SC, Petersen N, Heinsen H et al. Distribution of magnetic remanence carriers in the human brain. *Scientific Reports*. 2018; 8:11363
195. Gill AC, Dosen A, Ziegler JB. Chronic fatigue syndrome in adolescents: a follow-up study. *Archives of Pediatrics and Adolescent Medicine*. 2004; 158(3):225-229
196. Gladwell PW, Pheby D, Rodriguez T, Poland F. Use of an online survey to explore positive and negative outcomes of rehabilitation for people with CFS/ME. *Disability and Rehabilitation*. 2014; 36(5):387-394
197. Goedendorp MM, Knoop H, Schippers GM, Bleijenberg G. The lifestyle of patients with chronic fatigue syndrome and the effect on fatigue and functional impairments. *Journal of Human Nutrition & Dietetics*. 2009; 22(3):226-231

198. Goodwin L, White PD, Hotopf M, Stansfeld SA, Clark C. Psychopathology and physical activity as predictors of chronic fatigue syndrome in the 1958 british birth cohort: a replication study of the 1946 and 1970 birth cohorts. *Annals of Epidemiology*. 2011; 21(5):343-350
199. Haig-Ferguson A, Loades M, Whittle C, Read R, Higson-Sweeney N, Beasant L et al. "It's not one size fits all"; the use of videoconferencing for delivering therapy in a Specialist Paediatric Chronic Fatigue Service. *Internet Interventions*. 2019; 15:43-51
200. Haig-Ferguson A, Tucker P, Eaton N, Hunt L, Crawley E. Memory and attention problems in children with chronic fatigue syndrome or myalgic encephalopathy. *Archives of Disease in Childhood*. 2009; 94(10):757-762
201. Halapy E, Parlor M. Trends in the Canadian Community Health Survey Data - 2005, 2010, 2014. *Quest*. 2017; 112(Fall)
202. Hall GH, Hamilton WT, Round AP. Increased illness experience preceding chronic fatigue syndrome: a case control study. *Journal of the Royal College of Physicians of London*. 1998; 32(1):44-48
203. Hall L. Meditation for ME/Chronic Fatigue Syndrome and related conditions. 2009. Available from: <http://www.positivehealth.com/article/cfs-me/meditation-for-me-chronic-fatigue-syndrome-and-related-conditions> Last accessed: 23 July 2020.
204. Hamilton WT, Hall GH, Round AP. Frequency of attendance in general practice and symptoms before development of chronic fatigue syndrome: a case-control study. *British Journal of General Practice*. 2001; 51(468):553-558
205. Hana I, Vrabel J, Pekarek J, Cech K. The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections. *Biotherapy*. 1996; 9(1-3):91-95
206. Harada ND, Chiu V, Stewart AL. Mobility-related function in older adults: Assessment with a 6-minute walk test. *Archives of Physical Medicine and Rehabilitation*. 1999; 80(7):837-841
207. Hartz AJ, Bentler S, Noyes R, Hoehns J, Logemann C, Sinift S et al. Randomized controlled trial of Siberian ginseng for chronic fatigue. *Psychological Medicine*. 2004; 34(1):51-61
208. Hartz AJ, Bentler SE, Brake KA, Kelly MW. The effectiveness of citalopram for idiopathic chronic fatigue. *Journal of Clinical Psychiatry*. 2003; 64(8):927-935
209. Haywood KL, Collin SM, Crawley E. Assessing severity of illness and outcomes of treatment in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review of patient-reported outcome measures (PROMs). *Child: Care, Health and Development*. 2014; 40(6):806-824
210. Haywood KL, Staniszezwska S, Chapman S. Quality and acceptability of patient-reported outcome measures used in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review. *Quality of Life Research*. 2012; 21(1):35-52
211. Heald A, Barber L, Jones HL, Farman S, Walther A. Service based comparison of group cognitive behavior therapy to waiting list control for chronic fatigue syndrome with regard to symptom reduction and positive psychological dimensions. *Medicine (Baltimore)*. 2019; 98(39):e16720

212. Healthwatch Lancashire. ME/CFS report. 2017. Available from: <https://www.healthwatch.co.uk/reports-library/me-cfs-patient-experience-report>
213. Healthwatch Trafford. Patient experience report: Tired of explaining: Experiences of services for ME/CFS patients in Trafford and Greater Manchester. 2017. Available from: <https://healthwatchtrafford.co.uk/wp-content/uploads/2015/03/Tired-of-explaining-ME-CFS-Report-by-Healthwatch-Trafford.pdf>
214. Heins MJ, Knoop H, Bleijenberg G. The role of the therapeutic relationship in cognitive behaviour therapy for chronic fatigue syndrome. *Behaviour Research and Therapy*. 2013; 51(7):368-376
215. Heins MJ, Knoop H, Burk WJ, Bleijenberg G. The process of cognitive behaviour therapy for chronic fatigue syndrome: which changes in perpetuating cognitions and behaviour are related to a reduction in fatigue? *Journal of Psychosomatic Research*. 2013; 75(3):235-241
216. Heins MJ, Knoop H, Lobbestael J, Bleijenberg G. Childhood maltreatment and the response to cognitive behavior therapy for chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2011; 71(6):404-410
217. Heins MJ, Knoop H, Prins JB, Stulemeijer M, van der Meer JW, Bleijenberg G. Possible detrimental effects of cognitive behaviour therapy for chronic fatigue syndrome. *Psychotherapy and Psychosomatics*. 2010; 79(4):249-256
218. Henderson TA. Valacyclovir treatment of chronic fatigue in adolescents. *Advances in Mind-Body Medicine*. 2014; 28(1):4-14
219. Hives L, Bradley A, Richards J, Sutton C, Selfe J, Basu B et al. Can physical assessment techniques aid diagnosis in people with chronic fatigue syndrome/myalgic encephalomyelitis? A diagnostic accuracy study. *BMJ Open*. 2017; 7:e017521
220. Ho RT, Chan JS, Wang CW, Lau BW, So KF, Yuen LP et al. A randomized controlled trial of qigong exercise on fatigue symptoms, functioning, and telomerase activity in persons with chronic fatigue or chronic fatigue syndrome. *Annals of Behavioral Medicine*. 2012; 44(2):160-170
221. Hodges LD, Nielsen T, Baken D. Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: A pilot study. *Clinical Physiology and Functional Imaging*. 2018; 38(4):639-644
222. Holtzman CS, Bhatia S, Cotler J, Jason LA. Assessment of post-exertional malaise (PEM) in patients with myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS): A patient-driven survey. *Diagnostics*. 2019; 9(1):1-13
223. Houghton CA, Steels EL, Fassett RG, Coombes JS. Effects of a gliadin-combined plant superoxide dismutase extract on self-perceived fatigue in women aged 50-65 years. *Phytomedicine*. 2011; 18(6):521-526
224. Huang Y, Katz BZ, Mears C, Kielhofner GW, Taylor R. Postinfectious fatigue in adolescents and physical activity. *Archives of Pediatrics and Adolescent Medicine*. 2010; 164(9):803-809
225. Hughes AM, Hirsch CR, Nikolaus S, Chalder T, Knoop H, Moss-Morris R. Cross-cultural study of information processing biases in chronic fatigue syndrome:

- Comparison of Dutch and UK chronic fatigue patients. *International Journal of Behavioral Medicine*. 2018; 25(1):49-54
226. Hughes JL. Illness narrative and chronic fatigue syndrome/myalgic encephalomyelitis: A review. *The British Journal of Occupational Therapy*. 2002; 65(1):9-14
227. Huibers M, Beurskens A, Van Schayck C, Bazelmans E, Metsemakers J, Knottnerus A et al. Efficacy of cognitive behavioral therapy by general practitioners for unexplained fatigue among employees. A randomized comparative study. *Huisarts en Wetenschap*. 2005; 48(6):267-272
228. Huibers MJ, Beurskens AJ, Van Schayck CP, Bazelmans E, Metsemakers JF, Knottnerus JA et al. Efficacy of cognitive-behavioural therapy by general practitioners for unexplained fatigue among employees: Randomised controlled trial. *British Journal of Psychiatry*. 2004; 184:240-246
229. Huibers MJ, Kant IJ, Knottnerus JA, Bleijenberg G, Swaen GM, Kasl SV. Development of the chronic fatigue syndrome in severely fatigued employees: Predictors of outcome in the Maastricht cohort study. *Journal of Epidemiology and Community Health*. 2004; 58(10):877-882
230. Huibers MJH, Bleijenberg G, Van Amelsvoort LGPM, Beurskens AJHM, Van Schayck CP, Bazelmans E et al. Predictors of outcome in fatigued employees on sick leave: Results from a randomised trial. *Journal of Psychosomatic Research*. 2004; 57(5):443-449
231. Ickmans K, Meeus M, De Kooning M, Lambrecht L, Pattyn N, Nijs J. Can recovery of peripheral muscle function predict cognitive task performance in chronic fatigue syndrome with and without fibromyalgia? *Physical Therapy*. 2014; 94(4):511-522
232. ICNIRP Project Group. ICNIRP statement on diagnostic devices using non-ionizing radiation: Existing regulations and potential health risks. *Health Physics*. 2017; 112(3):305-321
233. Ingman T. A qualitative study investigating how people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) view recovery [Thesis].
234. Ingman T. A systematic literature review investigating the prognosis and predictors of outcome following treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
235. Ingman T, Ali S, Bhui K, Chalder T. Chronic fatigue syndrome: Comparing outcomes in White British and Black and minority ethnic patients after cognitive-behavioural therapy. *British Journal of Psychiatry*. 2016; 209:251-256
236. Institute of Medicine. *Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness*. Washington, DC. The National Academies Press. 2015. Available from: <https://dx.doi.org/10.17226/19012>
237. ISRCTN. A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. 2015. Available from: <http://www.isrctn.com/ISRCTN54285094> Last accessed: 11/12/2019.
238. Jackson ML, Bruck D. Sleep abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: A review. *Journal of Clinical Sleep Medicine*. 2012; 8(6):719-728

239. Janse A, Bleijenberg G, Knoop H. Prediction of long-term outcome after cognitive behavioral therapy for chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2019; 121:93-99
240. Janse A, Nikolaus S, Wiborg JF, Heins M, van der Meer JWM, Bleijenberg G et al. Long-term follow-up after cognitive behaviour therapy for chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2017; 97:45-51
241. Janse A, van Dam A, Pijpers C, Wiborg JF, Bleijenberg G, Tummers M et al. Implementation of stepped care for patients with chronic fatigue syndrome in community-based mental health care: Outcomes at post-treatment and long-term follow-up. *Behavioural and Cognitive Psychotherapy*. 2019; 47(5):548-558
242. Janse A, Wiborg JF, Bleijenberg G, Tummers M, Knoop H. The efficacy of guided self-instruction for patients with idiopathic chronic fatigue: A randomized controlled trial. *Journal of Consulting and Clinical Psychology*. 2016; 84(5):377-388
243. Janse A, Worm-Smeitink M, Bleijenberg G, Donders R, Knoop H. Efficacy of web-based cognitive-behavioural therapy for chronic fatigue syndrome: Randomised controlled trial. *British Journal of Psychiatry*. 2018; 212(2):112-118
244. Janse A, Worm-Smeitink M, Bussel-Lagarde J, Bleijenberg G, Nikolaus S, Knoop H. Testing the efficacy of web-based cognitive behavioural therapy for adult patients with chronic fatigue syndrome (CBIT): Study protocol for a randomized controlled trial. *BMC Neurology*. 2015; 15:137
245. Jason L, Benton M, Torres-Harding S, Muldowney K. The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. *Patient Education and Counseling*. 2009; 77(2):237-241
246. Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S. Causes of death among patients with chronic fatigue syndrome. *Health Care for Women International*. 2006; 27(7):615-626
247. Jason LA, Jessen T, Porter N, Boulton A, Gloria-Njoku M, Friedberg F. Examining types of fatigue among individuals with ME/CFS. *Disability Studies Quarterly*. 2009; 29(3):1-16
248. Jason LA, McManimen SL, Sunnquist M, Holtzman CS. Patient perceptions of post exertional malaise. *Fatigue: Biomedicine, Health and Behavior*. 2018; 6(2):92-105
249. Jason LA, Porter N, Hunnell J, Brown A, Rademaker A, Richman JA. A natural history study of chronic fatigue syndrome. *Rehabilitation Psychology*. 2011; 56(1):32-42
250. Jason LA, Taylor RR, Kennedy CL, Song S, Johnson D, Torres S. Chronic fatigue syndrome: Occupation, medical utilization, and subtypes in a community-based sample. *Journal of Nervous and Mental Disease*. 2000; 188(9):568-576
251. Jason LA, Torres-Harding S, Brown M, Sorenson M, Donalek J, Corradi K et al. Predictors of change following participation in non-pharmacologic interventions for CFS. *Japanese Society of Tropical Medicine*. 2008; 36(1):22-32
252. Jason LA, Zinn ML, Zinn MA. Myalgic Encephalomyelitis: Symptoms and Biomarkers. *Current Neuropharmacology*. 2015; 13(5):701-734
253. Jelínek F, Pokorný Jí. Microtubules in biological cells as circular waveguides and resonators. *Electro- and Magnetobiology*. 2001; 20(1):75-80

254. Jenkins M, Rayman M. Nutrient intake is unrelated to nutrient status in patients with chronic fatigue syndrome. *Journal of Nutritional and Environmental Medicine*. 2005; 15(4):177-189
255. Jones DE, Hollingsworth KG, Jakovljevic DG, Fattakhova G, Pairman J, Blamire AM et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: A case-control study. *European Journal of Clinical Investigation*. 2012; 42(2):186-194
256. Josev EK, Malpas CB, Seal ML, Scheinberg A, Lubitz L, Rowe K et al. Resting-state functional connectivity, cognition, and fatigue in response to cognitive exertion: a novel study in adolescents with chronic fatigue syndrome. *Brain Imaging and Behavior*. 2019;
257. Juutilainen J, Herrala M, Luukkonen J, Naarala J, Hore PJ. Magnetocarcinogenesis: Is there a mechanism for carcinogenic effects of weak magnetic fields? *Proceedings: Biological Sciences*. 2018; 285:20180590
258. Kapitein LC, Hoogenraad CC. Building the neuronal microtubule cytoskeleton. *Neuron*. 2015; 87(3):492-506
259. Kasevich R. Cellphones radars & health. *IEEE Spectrum*. 2002; 39(8):15-16
260. Keller BA, Pryor JL, Giloteaux L. Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO₂peak indicates functional impairment. *Journal of Translational Medicine*. 2014; 12:104
261. Kempke S, Van Den Eede F, Schotte C, Claes S, Van Wambeke P, Van Houdenhove B et al. Prevalence of DSM-IV personality disorders in patients with chronic fatigue syndrome: A controlled study. *International Journal of Behavioral Medicine*. 2013; 20(2):219-228
262. Kenyon JN, Coe S, Izadi H. A retrospective outcome study of 42 patients with chronic fatigue syndrome, 30 of whom had irritable bowel syndrome. Half were treated with oral approaches, and half were treated with faecal microbiome transplantation. *Human Microbiome Journal*. 2019; 13:100061
263. Khawaja SS, Van Boxel P. Chronic fatigue syndrome in childhood: seven-year follow-up study. *Psychiatric Bulletin*. 1998; 22(4):198-202
264. Kim HG, Cho JH, Yoo SR, Lee JS, Han JM, Lee NH et al. Antifatigue effects of Panax ginseng C.A. Meyer: A randomised, double-blind, placebo-controlled trial. *PloS One*. 2013; 8(4):e61271
265. Kim HG, Yoo SR, Park HJ, Son CG. Indirect moxibustion (CV4 and CV8) ameliorates chronic fatigue: A randomized, double-blind, controlled study. *Journal of Alternative and Complementary Medicine*. 2013; 19(2):134-140
266. Kim JE, Seo BK, Choi JB, Kim HJ, Kim TH, Lee MH et al. Acupuncture for chronic fatigue syndrome and idiopathic chronic fatigue: A multicenter, nonblinded, randomized controlled trial. *Trials*. 2015; 16:314
267. Kim JH, Lee JK, Kim HG, Kim KB, Kim HR. Possible effects of radiofrequency electromagnetic field exposure on central nerve system. *Biomolecules & Therapeutics*. 2019; 27(3):265-275

268. Kindlon T. Change in grey matter volume cannot be assumed to be due to cognitive behavioural therapy. *Brain: A Journal of Neurology*. 2009; 132(1-2):e119
269. Kindlon T. Do graded activity therapies cause harm in chronic fatigue syndrome? *Journal of Health Psychology*. 2017; 22(9):1146-1154
270. Kindlon T. Elements of rehabilitative strategies associated with negative outcomes in CFS/ME: The need for further investigations. *Disability and Rehabilitation*. 2015; 37(5):466-467
271. Kindlon T. Harms of cognitive behaviour therapy designed to increase activity levels in chronic fatigue syndrome: Questions remain. *Psychotherapy and Psychosomatics*. 2011; 80(2):110-111; author reply 112
272. Kindlon T. Internet-based CBT for adolescents with chronic fatigue syndrome. *The Lancet*. 2012; 380(9841):561
273. Kindlon T. Objective compliance and outcome measures should be used in trials of exercise interventions for chronic fatigue syndrome. *European Journal of Clinical Investigation*. 2012; 42(12):1360-1361; author reply 1363-1365
274. Kindlon T. The PACE trial in chronic fatigue syndrome. *Lancet*. 2011; 377(9780):1833-1835
275. Kindlon T. Reporting of harms associated with graded exercise therapy and cognitive behavioural therapy in myalgic encephalomyelitis/chronic fatigue syndrome. *Bulletin of the IACFS/ME*. 2011; 19:59-111
276. Kindlon T. Response to: A pilot study of the process of change in a group chronic fatigue syndrome management programme. *Bulletin of the IACFS/ME*. 2009; 17:84-85
277. Kindlon T. Stratification using biological factors should be performed in more CFS studies. *Psychological Medicine*. 2010; 40:352
278. Kindlon T, Baldwin A. Response to: Reports of recovery in chronic fatigue syndrome may present less than meets the eye. *Evidence-Based Mental Health*. 2015; 18(2):e5
279. Kindlon T, Goudsmit EM. Graded exercise for chronic fatigue syndrome: Too soon to dismiss reports of adverse reactions. *Journal of Rehabilitation Medicine*. 2010; 42(2):184-186
280. Kindlon T, Shepherd C. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome. *Annals of Internal Medicine*. 2015; 163(11):887-888
281. King MB. Randomised controlled trial of counselling or CBT for patients with chronic fatigue in general practitioners. *National Research Register*. 1999;
282. Kingdon CC, Bowman EW, Curran H, Nacul L, Lacerda EM. Functional status and well-being in people with myalgic encephalomyelitis/chronic fatigue syndrome compared with people with multiple sclerosis and healthy controls. *PharmacoEconomics Open*. 2018; 2:381-392
283. Knight S, Harvey A, Lubitz L, Rowe K, Reveley C, Veit F et al. Paediatric chronic fatigue syndrome: complex presentations and protracted time to diagnosis. *Journal of Paediatrics and Child Health*. 2013; 49(11):919-924

284. Knoester M, Helfferich J, Poelman R, Van Leer-Buter C, Brouwer OF, Niesters HGM. Twenty-nine cases of enterovirus-D68-associated acute flaccid myelitis in europe 2016: A case series and epidemiologic overview. *Pediatric Infectious Disease Journal*. 2019; 38(1):16-21
285. Knoop H, Bleijenberg G, Gielissen MF, van der Meer JW, White PD. Is a full recovery possible after cognitive behavioural therapy for chronic fatigue syndrome? *Psychotherapy and Psychosomatics*. 2007; 76(3):171-176
286. Knoop H, Prins JB, Stulemeijer M, van der Meer JW, Bleijenberg G. The effect of cognitive behaviour therapy for chronic fatigue syndrome on self-reported cognitive impairments and neuropsychological test performance. *Journal of Neurology, Neurosurgery and Psychiatry*. 2007; 78(4):434-436
287. Knoop H, Stulemeijer M, de Jong LW, Fiselier TJ, Bleijenberg G. Efficacy of cognitive behavioral therapy for adolescents with chronic fatigue syndrome: long-term follow-up of a randomized, controlled trial. *Pediatrics*. 2008; 121(3):e619-625
288. Knoop H, Stulemeijer M, Prins JB, van der Meer JW, Bleijenberg G. Is cognitive behaviour therapy for chronic fatigue syndrome also effective for pain symptoms? *Behaviour Research and Therapy*. 2007; 45(9):2034-2043
289. Knoop H, van der Meer JW, Bleijenberg G. Guided self-instructions for people with chronic fatigue syndrome: Randomised controlled trial. *British Journal of Psychiatry*. 2008; 193(4):340-341
290. Knudsen AK, Henderson M, Harvey SB, Chalder T. Long-term sickness absence among patients with chronic fatigue syndrome. *British Journal of Psychiatry*. 2011; 199:430-431
291. Kodama K. Application of broadband alternating current magnetic susceptibility to the characterization of magnetic nanoparticles in natural materials. *Journal of Geophysical Research: Solid Earth*. 2013; 118(1):1-12
292. Kreyberg S. Myalgic Encephalomyelitis/Postviral fatigue syndrome (G93.3). Basic concepts and guidelines for the diagnosis. 2007.
293. Kreyberg SE. [Caring for seriously ill ME-patients: A small survey]. *Norwegian Journal of Nursing Research*. 2007; 9(2):16-26
294. Krilov LR, Fisher M, Friedman SB, Reitman D, Mandel FS. Course and outcome of chronic fatigue in children and adolescents. *Pediatrics*. 1998; 102(2 Pt 1):360-366
295. Lacerda EM, Kingdon CC, Bowman EW, Nacul L. Using a participatory approach to develop and implement the UK ME/CFS Biobank. *Fatigue*. 2018; 6(1):1-4
296. Lacerda EM, McDermott C, Kingdon CC, Butterworth J, Cliff JM, Nacul L. Hope, disappointment and perseverance: Reflections of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis participating in biomedical research. A qualitative focus group study. *Health Expectations*. 2019; 22(3):373-384
297. LaManca JJ, Sisto SA, DeLuca J, Johnson SK, Lange G, Pareja J et al. Influence of exhaustive treadmill exercise on cognitive functioning in chronic fatigue syndrome. *American Journal of Medicine*. 1998; 105(3 Suppl. 1):59S-65S

298. Lapp CW. Initiating care of a patient with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Frontiers in Pediatrics*. 2019; 6:415
299. Larun L, Odgaard-Jensen J, Brurberg KG, Chalder T, Dybwad M, Moss-Morris RE et al. Exercise therapy for chronic fatigue syndrome (individual patient data). *Cochrane Database of Systematic Reviews* 2014, Issue 4. Art. No.: CD011040. DOI: <http://dx.doi.org/10.1002/14651858.CD011040>.
300. Leaman D. Magnetic rocks - Their effect on compass use and navigation in Tasmania. *Papers and Proceedings of the Royal Society of Tasmania*. 1997; 131:73-75
301. Leary S, Sylvester J, Shorter E, Moreno E. Your experience of ME services. Survey Report by #MEAction UK. 2019. Available from: <https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf> <https://www.meaction.net/wp-content/uploads/2019/10/Your-experience-of-ME-services-Survey-report-by-MEAction-UK.pdf>
302. Lee JH, Kim SK, Ko SJ, Lee SH, Lee JH, Kim MJ et al. The effect of oriental medicine music therapy on idiopathic chronic fatigue. *Journal of Alternative and Complementary Medicine*. 2015; 21(7):422-429
303. Leone SS, Huibers MJ, Kant I, van Amelsvoort LG, van Schayck CP, Bleijenberg G et al. Long-term efficacy of cognitive-behavioral therapy by general practitioners for fatigue: A 4-year follow-up study. *Journal of Psychosomatic Research*. 2006; 61(5):601-607
304. Leone SS, Huibers MJ, Kant I, Van Schayck CP, Bleijenberg G, André Knottnerus J. Long-term predictors of outcome in fatigued employees on sick leave: A 4-year follow-up study. *Psychological Medicine*. 2006; 36(9):1293-1300
305. Lewis I, Pairman J, Spickett G, Newton JL. Clinical characteristics of a novel subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia syndrome. *Journal of Internal Medicine*. 2013; 273(5):501-510
306. Lien K, Johansen B, Veierod MB, Haslestad AS, Bohn SK, Melsom MN et al. Abnormal blood lactate accumulation during repeated exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome. *Physiological Reports*. 2019; 7(11):e14138
307. Light AR, White AT, Hughen RW, Light KC. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. *Journal of Pain*. 2009; 10(10):1099-1112
308. Lincolnshire Partnership. Lincolnshire Chronic Fatigue Syndrome/ME Service. Lincolnshire Partnership NHS Foundation Trust, 2019.
309. Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: First analysis of efficacy and safety. *Therapeutic Advances in Neurological Disorders*. 2018; 11:1-12
310. Lloyd S, Chalder T, Rimes KA. Family-focused cognitive behaviour therapy versus psycho-education for adolescents with chronic fatigue syndrome: Long-term follow-up of an RCT. *Behaviour Research and Therapy*. 2012; 50(11):719-725

311. Lloyd S, Chalder T, Sallis HM, Rimes KA. Telephone-based guided self-help for adolescents with chronic fatigue syndrome: A non-randomised cohort study. *Behaviour Research and Therapy*. 2012; 50(5):304-312
312. Loades ME, Read R, Smith L, Higson-Sweeney NT, Laffan A, Stallard P et al. Depression and anxiety in adolescent chronic fatigue syndrome (CFS): A clinical cohort study [Unpublished]. 2019;
313. Loades ME, Rimes KA, Ali S, Chalder T. Depressive symptoms in adolescents with chronic fatigue syndrome (CFS): Are rates higher than in controls and do depressive symptoms affect outcome? *Clinical Child Psychology and Psychiatry*. 2019; 24(3):580-592
314. Loades ME, Rimes KA, Ali S, Lievesley K, Chalder T. The presence of co-morbid mental health problems in a cohort of adolescents with chronic fatigue syndrome. *Clinical Child Psychology and Psychiatry*. 2018; 23(3):398-408
315. Loades ME, Sheils EA, Crawley E. Treatment for paediatric chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME) and comorbid depression: A systematic review. *BMJ Open*. 2016; 6:e012271
316. Loades ME, Smith L, Higson-Sweeney N, Beasant L, Stallard P, Kessler D et al. Obstacles to recruitment in paediatric studies focusing on mental health in a physical health context: The experiences of clinical gatekeepers in an observational cohort study. *BMC Medical Research Methodology*. 2019; 19(1):89
317. Loy BD, O'Connor PJ, Dishman RK. Effect of acute exercise on fatigue in people with ME/CFS/SEID: A Meta-analysis. *Medicine and Science in Sports and Exercise*. 2016; 48(10):2003-2012
318. Lyshevski SE, Tsouri GR. Molecular and biomolecular communication: Waveguides and possible role of microtubules. 2011 11th IEEE International Conference on Nanotechnology. 2011;
319. M.E. Group. Richmond & Kingston local area survey 2014. 2014.
320. M.E. Group. Richmond & Kingston local area survey 2019. 2019.
321. Maes M, Mihaylova I, De Ruyter M. Lower serum zinc in chronic fatigue syndrome (CFS): Relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. *Journal of Affective Disorders*. 2006; 90(2-3):141-147
322. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuroendocrinology Letters*. 2009; 30(4):470-476
323. Maes M, Twisk FN, Ringel K. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: Inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. *Psychotherapy and Psychosomatics*. 2012; 81(5):286-295
324. Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. *Archives of Gerontology and Geriatrics*. 2008; 46(2):181-190

325. Malik S, Asprusten TT, Pedersen M, Mangersnes J, Trondalen G, van Roy B et al. Cognitive-behavioural therapy combined with music therapy for chronic fatigue following Epstein-Barr virus infection in adolescents: a feasibility study. *BMJ Paediatrics Open*. 2020; 4(1):e000620
326. Marques MM, de Gucht V, Leal I, Maes S. Efficacy of a randomized controlled self-regulation based physical activity intervention for chronic fatigue: Mediation effects of physical activity progress and self-regulation skills. *Journal of Psychosomatic Research*. 2017; 94:24-31
327. Marshall PS, Forstot M, Callies A, Peterson PK, Schenck CH. Cognitive slowing and working memory difficulties in chronic fatigue syndrome. *Psychosomatic Medicine*. 1997; 59(1):58-66
328. Marshall PS, Watson D, Steinberg P, Cornblatt B, Peterson PK, Callies A et al. An assessment of cognitive function and mood in chronic fatigue syndrome. *Biological Psychiatry*. 1996; 39(3):199-206
329. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: An in vivo 3.0 T (1)H MRS imaging study. *NMR in Biomedicine*. 2009; 22(3):251-258
330. May M, Emond A, Crawley E. Phenotypes of chronic fatigue syndrome in children and young people. *Archives of Disease in Childhood*. 2010; 95(4):245-249
331. McCourt A, Maile E, Gregorowski A, Hargreaves D, Segal T. G599(P) Characteristics of a patient population attending a specialist outpatient service for chronic fatigue syndrome. *Archives of Disease in Childhood*. 2019; 104(Suppl 2):A242-A242
332. McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. *QJM*. 2006; 99(7):461-468
333. McGregor NR, Armstrong CW, Lewis DP, Butt HL, Gooley PR. Widespread pain and altered renal function in ME/CFS patients. *Fatigue: Biomedicine, Health and Behavior*. 2016; 4(3):132-145
334. McGregor NR, Armstrong CW, Lewis DP, Gooley PR. Post-exertional malaise is associated with hypermetabolism, hypoacetylation and purine metabolism deregulation in ME/CFS cases. *Diagnostics*. 2019; 9(3):70
335. McManimen S, McClellan D, Stoothoff J, Gleason K, Jason LA. Dismissing chronic illness: A qualitative analysis of negative health care experiences. *Health Care for Women International*. 2019; 40(3):241-258
336. McManimen SL, Devendorf AR, Brown AA, Moore BC, Moore JH, Jason LA. Mortality in patients with myalgic encephalomyelitis and chronic fatigue syndrome. *Fatigue*. 2016; 4(4):195-207
337. McPhee G, Baldwin A, Kindlon T, Hughes BM. Monitoring treatment harm in myalgic encephalomyelitis/chronic fatigue syndrome: A freedom-of-information study of National Health Service specialist centres in England. *Journal of Health Psychology*. 2019; <https://doi.org/10.1177/1359105319854532>
338. ME/cvs Vereniging. Report survey summary 'Zorg voor ME' (Care for ME). 2016. Available from: <https://www.me->

cvsvereniging.nl/sites/default/files/documenten/Report%20Survey%20Summary%20%27Zorg%20voor%20ME%27%20%28%E2%80%98Care%20for%20ME%E2%80%99%29.pdf

339. Meeus M, Hermans L, Ickmans K, Struyf F, Van Cauwenbergh D, Bronckaerts L et al. Endogenous pain modulation in response to exercise in patients with rheumatoid arthritis, patients with chronic fatigue syndrome and comorbid fibromyalgia, and healthy controls: A double-blind randomized controlled trial. *Pain Practice*. 2015; 15(2):98-106
340. Mehta VK, Blume GB. A randomized trial of fluoxetine in a patient with persistent fatigue. *Journal of the American Board of Family Practice*. 1995; 8(3):230-232
341. Melamed KH, Santos M, Oliveira RKF, Urbina MF, Felsenstein D, Opatowsky AR et al. Unexplained exertional intolerance associated with impaired systemic oxygen extraction. *European Journal of Applied Physiology*. 2019; 119(10):2375-2389
342. Meng H, Friedberg F, Castora-Binkley M. Cost-effectiveness of chronic fatigue self-management versus usual care: A pilot randomized controlled trial. *BMC Family Practice*. 2014; 15:184
343. Mihelicova M, Siegel Z, Evans M, Brown A, Jason L. Caring for people with severe myalgic encephalomyelitis: An interpretative phenomenological analysis of parents' experiences. *Journal of Health Psychology*. 2016; 21(12):2824-2837
344. Miller RR, Reid WD, Mattman A, Yamabayashi C, Steiner T, Parker S et al. Submaximal exercise testing with near-infrared spectroscopy in myalgic encephalomyelitis/chronic fatigue syndrome patients compared to healthy controls: A case-control study. *Journal of Translational Medicine*. 2015; 13:159
345. Millions Missing Canada. Iatrogenic harm: Spring survey results [Unpublished]. 2017.
346. Missen A, Hollingworth W, Eaton N, Crawley E. The financial and psychological impacts on mothers of children with chronic fatigue syndrome (CFS/ME). *Child: Care, Health and Development*. 2012; 38(4):505-512
347. Moneghetti KJ, Skhiri M, Contrepois K, Kobayashi Y, Maecker H, Davis M et al. Value of circulating cytokine profiling during submaximal exercise testing in myalgic encephalomyelitis/chronic fatigue syndrome. *Scientific Reports*. 2018; 8:2779
348. Montoya JG, Anderson JN, Adolphs DL, Bateman L, Klimas N, Levine SM et al. KPAX002 as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A prospective, randomized trial. *International Journal of Clinical and Experimental Medicine*. 2018; 11(3):2890-2900
349. Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. *Journal of Medical Virology*. 2013; 85(12):2101-2109
350. Moore L. Chronic fatigue syndrome: All in the mind? An occupational therapy perspective. *British Journal of Occupational Therapy*. 2000; 63(4):163-170
351. Moore R, Derry S, Aldington D, Cole P, Wiffen P. Amitriptyline for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No.: CD008242. DOI: 10.1002/14651858.CD008242.pub3.

352. Morens DM, Folkers GK, Fauci AS. Acute flaccid myelitis: Something old and something new. *mBio*. 2019; 10(2):e00521-00519
353. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. *Metabolic Brain Disease*. 2014; 29:19-36
354. Moss-Morris R, Spence MJ, Hou R. The pathway from glandular fever to chronic fatigue syndrome: can the cognitive behavioural model provide the map? *Psychological Medicine*. 2011; 41(5):1099-1107
355. Murdock KW, Wang XS, Shi Q, Cleeland CS, Fagundes CP, Vernon SD. The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Quality of Life Research*. 2017; 26(4):913-921
356. Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Advisory Committee. Report to the NHMRC Chief Executive Officer. 2019. Available from: <https://www.nhmrc.gov.au/about-us/publications/mecfs-advisory-committee-report-nhmrc-chief-executive-officer#block-views-block-file-attachments-content-block-1>
357. Nacul L, de Barros B, Kingdon CC, Cliff JM, Clark TG, Mudie K et al. Evidence of clinical pathology abnormalities in people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) from an analytic cross-sectional study. *Diagnostics*. 2019; 9(2):1-16
358. Nacul L, Lacerda EM, Kingdon CC, Curran H, Bowman EW. How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? *Journal of Health Psychology*. 2019; 24(12):1765-1769
359. Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler Mde L, Leite JC et al. The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. *BMC Public Health*. 2011; 11:402
360. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. *BMC Medicine*. 2011; 9:91
361. Nacul LC, Mudie K, Kingdon CC, Clark TG, Lacerda EM. Hand grip strength as a clinical biomarker for ME/CFS and disease severity. *Frontiers in Neurology*. 2018; 9:992
362. Nagy-Szakal D, Barupal DK, Lee B, Che X, Williams BL, Kahn EJ et al. Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics. *Scientific Reports*. 2018; 8:10056
363. Natelson BH, Mao X, Stegner AJ, Lange G, Vu D, Blate M et al. Multimodal and simultaneous assessments of brain and spinal fluid abnormalities in chronic fatigue syndrome and the effects of psychiatric comorbidity. *Journal of the Neurological Sciences*. 2017; 375:411-416
364. Natelson BH, Vu D, Coplan JD, Mao X, Blate M, Kang G et al. Elevations of ventricular lactate levels occur in both chronic fatigue syndrome and fibromyalgia. *Fatigue*. 2017; 5(1):15-20

365. National Centers for Environmental Information. Geomagnetism. Available from: <https://www.ngdc.noaa.gov/geomag/geomag.shtml> Last accessed: 04/12/2019.
366. National Collaborating Centre for Primary Care. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): Diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) in adults and children. NICE clinical guideline 53. London. Royal College of General Practitioners, 2007. Available from: <http://guidance.nice.org.uk/CG53>
367. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [Updated 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
368. Naviaux RK, Gordon E. Reply to Roerink et al.: Metabolomics of chronic fatigue syndrome. *Proceedings of the National Academy of Sciences*. 2017; 114(6):E911
369. Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L et al. Metabolic features of chronic fatigue syndrome. *Proceedings of the National Academy of Sciences of the United States of America*. 2016; 113(37):E5472-5480
370. Newberry F, Hsieh SY, Wileman T, Carding SR. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome? *Clinical Science*. 2018; 132(5):523-542
371. Newton JL, Mabillard H, Scott A, Hoad A, Spickett G. The Newcastle NHS Chronic Fatigue Syndrome Service: Not all fatigue is the same. *Journal of the Royal College of Physicians of Edinburgh*. 2010; 40(4):304-307
372. NHS North Bristol. Survey of patients attending NHS specialist CFS/ME Services conducted April-July 2019. North Bristol NHS Trust, 2019.
373. Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpfen JL, van de Putte EM. Effectiveness of internet-based cognitive behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): A randomised controlled trial. *Lancet*. 2012; 379(9824):1412-1418
374. Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpfen JL, van de Putte EM. Fatigue In Teenagers on the interNET--the FITNET Trial. A randomized clinical trial of web-based cognitive behavioural therapy for adolescents with chronic fatigue syndrome: Study protocol. *BMC Neurology*. 2011; 11:23
375. Nijhof SL, Priesterbach LP, Uiterwaal CSPM, Bleijenberg G, Kimpfen JLL, Van De Putte EM. Internet-based therapy for adolescents with chronic fatigue syndrome: Long-term follow-up. *Pediatrics*. 2013; 131(6):e1788-e1795
376. Nijhof SL, Rutten JM, Uiterwaal CS, Bleijenberg G, Kimpfen JL, Putte EM. The role of hypocortisolism in chronic fatigue syndrome. *Psychoneuroendocrinology*. 2014; 42:199-206
377. Norfolk and Suffolk Service. Patient survey report. 2009. Available from: <http://nandsme.blogspot.com/p/patient-survey.html>
378. Norris T, Hawton K, Hamilton-Shield J, Crawley E. Obesity in adolescents with chronic fatigue syndrome: An observational study. *Archives of Disease in Childhood*. 2017; 102(1):35-39

379. O'Dowd H, Beasant L, Ingram J, Montgomery A, Hollingworth W, Gaunt D et al. The feasibility and acceptability of an early intervention in primary care to prevent chronic fatigue syndrome (CFS) in adults: randomised controlled trial. *Pilot & Feasibility Studies*. 2020; 6:65
380. Ocon AJ, Messer ZR, Medow MS, Stewart JM. Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome with postural tachycardia syndrome. *Clinical Science*. 2012; 122(5):227-238
381. Odoom JK, Adziati I, Quansah E, Attiku K, Ntim NAA, Arthur-Quarm J et al. High serotype diversity of non-polio enteroviruses isolated in Ghana during acute flaccid paralysis surveillance, 2010-2014. *Advances in Research*. 2018; 16(6):1-9
382. Office for National Statistics. Mentions of postviral fatigue syndrome (benign myalgic encephalomyelitis), deaths registered in England and Wales, 2001 to 2016. 2018. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/008461mentionsofpostviralfatiguesyndromebenignmyalgicencephalomyelitisdeathsregisteredinenglandandwales2001to2016> Last accessed: 29/11/2019.
383. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. *Clinical Infectious Diseases*. 1994; 18(Suppl 1):S157-159
384. Oliver C. University Hospitals of Derby & Burton Foundation Trust: CFS service outcomes 17-18 April. University Hospitals of Derby & Burton Foundation Trust, 2018.
385. Oxford Clinical Allied Technology and Trials Services Unit. Forward-ME Group CBT & GET Survey. 2019.
386. PACE Trial participant dataset. Available from: https://sites.google.com/site/pacefoir/pace-ipd_foia-qmul-2014-f73.xlsx Last accessed: 03/12/2019.
387. Packer TL, Foster DM, Brouwer B. Fatigue and activity patterns of people with chronic fatigue syndrome. *Occupational Therapy Journal of Research*. 1997; 17(3):186-199
388. Pakpoor J, Goldacre M. Neuroepidemiology: The increasing burden of mortality from neurological diseases. *Nature Reviews: Neurology*. 2017; 13:518-519
389. Parslow R, Patel A, Beasant L, Haywood K, Johnson D, Crawley E. What matters to children with CFS/ME? A conceptual model as the first stage in developing a PROM. *Archives of Disease in Childhood*. 2015; 100(12):1141-1147
390. Parslow RM, Anderson N, Byrne D, Shaw A, Haywood KL, Crawley E. Adolescent's descriptions of fatigue, fluctuation and payback in chronic fatigue syndrome/myalgic encephalopathy (CFS/ME): Interviews with adolescents and parents. *BMJ Paediatrics Open*. 2018; 2:e000281
391. Parslow RM, Harris S, Broughton J, Alattas A, Crawley E, Haywood K et al. Children's experiences of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review and meta-ethnography of qualitative studies. *BMJ Open*. 2017; 7:e012633
392. Parslow RM, Shaw A, Haywood KL, Crawley E. Important factors to consider when treating children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME):

- Perspectives of health professionals from specialist services. *BMC Pediatrics*. 2017; 17:43
393. Pastula DM, Aliabadi N, Haynes AK, Messacar K, Schreiner T, Maloney J et al. Acute neurologic illness of unknown etiology in children - Colorado, August-September 2014. *MMWR: Morbidity and Mortality Weekly Report*. 2014; 63(40):901-902
394. Patel MX, Smith DG, Chalder T, Wessely S. Chronic fatigue syndrome in children: a cross sectional survey. *Archives of Disease in Childhood*. 2003; 88(10):894-898
395. Pates A. My life stopped ... voices from action for M.E. 2014 survey: severe M.E. time to deliver report. Action for ME, 2014. Available from: <https://www.actionforme.org.uk/uploads/pdfs/my-life-stopped-severe-ME-report.pdf>
396. Patient survey results for FDA drug development meeting for ME and CFS, April 25-26, 2013 [Unpublished]. 2013.
397. Patrick Neary J, Roberts AD, Leavins N, Harrison MF, Croll JC, Sexsmith JR. Prefrontal cortex oxygenation during incremental exercise in chronic fatigue syndrome. *Clinical Physiology and Functional Imaging*. 2008; 28(6):364-372
398. Peci A, Winter A-L, Warshawsky B, Booth TF, Eshaghi A, Li A et al. Epidemiology of Enterovirus D68 in Ontario. *PloS One*. 2015; 10(11):e0142841
399. Peckerman A, LaManca JJ, Dahl KA, Chemitiganti R, Qureishi B, Natelson BH. Abnormal impedance cardiography predicts symptom severity in chronic fatigue syndrome. *American Journal of the Medical Sciences*. 2003; 326(2):55-60
400. Pemberton S, Cox D. Perspectives of time and occupation: Experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis. *Journal of Occupational Science*. 2014; 21(4):488-503
401. Pemberton S, Cox DL. Experiences of daily activity in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and their implications for rehabilitation programmes. *Disability and Rehabilitation*. 2014; 36(21):1790-1797
402. Pemberton S, Dunn N, Bradley J, McKeever V. Survey of patient outcomes and experience for adults and young people accessing a ME/CFS rehabilitation service. 2019.
403. Perrin RN. Chronic fatigue syndrome, a review from the biomechanical perspective. *British Osteopathic Journal*. 1993; 11:15-23
404. Perrin RN, Edwards J, Hartley P. An evaluation of the effectiveness of osteopathic treatment on symptoms associated with myalgic encephalomyelitis. A preliminary report. *Journal of Medical Engineering and Technology*. 1998; 22(1):1-13
405. Perrin RN, Richards JD, Pentreath V, Percy DF. Muscle fatigue in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and its response to a manual therapeutic approach: A pilot study. *International Journal of Osteopathic Medicine*. 2011; 14(3):96-105
406. Peterson PK, Schenck CH, Sherman R. Chronic fatigue syndrome in Minnesota. *Minnesota Medicine*. 1991; 74(5):21-26

407. Peterson PK, Sirt SA, Grammith FC, Schenck CH, Pheley AM, Hu S et al. Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. *Clinical and Diagnostic Laboratory Immunology*. 1994; 1(2):222-226
408. Pheby D, Saffron L. Risk factors for severe ME/CFS. *Biology and Medicine*. 2009; 1(4):50-74
409. Pheley AM, Melby D, Schenck C, Mandel J, Peterson PK. Can we predict recovery in chronic fatigue syndrome? *Minnesota Medicine*. 1999; 82(11):52-56
410. Physios for M.E. An exploratory study of the experiences of M.E patients and physiotherapy [Unpublished].
411. Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Jiménez MJ, Zhu X, Rogers JT et al. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. *Scientific Reports*. 2016; 6(1):24873
412. Polli A, Van Oosterwijk J, Meeus M, Lambrecht L, Nijs J, Ickmans K. Exercise-induce hyperalgesia, complement system and elastase activation in myalgic encephalomyelitis/chronic fatigue syndrome - a secondary analysis of experimental comparative studies. *Scandinavian Journal of Pain*. 2018; 19(1):183-192
413. Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Fatigue: Biomedicine, Health & Behavior*. 2019; 7(4):207-217
414. Preparing children for starting primary school. 2018. Available from: <https://www.thetimes.co.uk/article/preparing-children-for-starting-primary-school-6q6hv8nl3#> Last accessed: 05/12/2019.
415. Prins J, Bleijenberg G, Rouweler EK, van der Meer J. Effect of psychiatric disorders on outcome of cognitive-behavioural therapy for chronic fatigue syndrome. *British Journal of Psychiatry*. 2005; 187:184-185
416. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL et al. Cognitive behaviour therapy for chronic fatigue syndrome: A multicentre randomised controlled trial. *Lancet*. 2001; 357(9259):841-847
417. Prins JB, Bos E, Huibers MJ, Servaes P, van der Werf SP, van der Meer JW et al. Social support and the persistence of complaints in chronic fatigue syndrome. *Psychotherapy and Psychosomatics*. 2004; 73(3):174-182
418. Prokhorov BE, Förster M, Stolle C, Lesur V, Namgalagze AA, Holschneider M. The ionospheric current system and its contribution to the Earth's magnetic field. *Geophysical Research Abstracts*. 2016; 18
419. Puetz TW, Flowers SS, O'Connor PJ. A randomized controlled trial of the effect of aerobic exercise training on feelings of energy and fatigue in sedentary young adults with persistent fatigue. *Psychotherapy and Psychosomatics*. 2008; 77(3):167-174
420. Puri BK, Gunatilake KD, Fernando KA, Gurusinghe AI, Agour M, Treasaden IH. Increased tenderness in the left third intercostal space in adult patients with myalgic encephalomyelitis: A controlled study. *Journal of International Medical Research*. 2011; 39(1):212-214

421. Quarmby L, Rimes KA, Deale A, Wessely S, Chalder T. Cognitive-behaviour therapy for chronic fatigue syndrome: Comparison of outcomes within and outside the confines of a randomised controlled trial. *Behaviour Research and Therapy*. 2007; 45(6):1085-1094
422. Raine R, Carter S, Sensky T, Black N. General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: Qualitative study. *BMJ*. 2004; 328(7452):1354-1357
423. Rand Corporation. 36-Item Short Form Survey Instrument (SF-36). Available from: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html Last accessed: 03/12/2019.
424. Rawlins M. De Testimonio: On the evidence for decisions about the use of therapeutic interventions. *Clinical Medicine (London, England)*. 2008; 8(6):579-588
425. Reactive oxygen species in biology and human health. Ahmad SI. 1st ed. Boca Raton. CRC Press. 2016.
426. Regland B, Forsmark S, Halaouate L, Matousek M, Peilot B, Zachrisson O et al. Response to vitamin B12 and folic acid in myalgic encephalomyelitis and fibromyalgia. *PLoS One*. 2015; 10(4):e0124648
427. Reynolds GK, Lewis DP, Richardson AM, Lidbury BA. Comorbidity of postural orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian cohort. *Journal of Internal Medicine*. 2014; 275(4):409-417
428. Richardson J. Myalgic encephalomyelitis: guidelines for doctors. *Journal of Chronic Fatigue Syndrome*. 2002; 10(1):65-80
429. Ridsdale L, Darbishire L, Seed PT. Is graded exercise better than cognitive behaviour therapy for fatigue? A UK randomized trial in primary care. *Psychological Medicine*. 2004; 34(1):37-49
430. Ridsdale L, Godfrey E, Chalder T, Seed P, King M, Wallace P et al. Chronic fatigue in general practice: Is counselling as good as cognitive behaviour therapy? A UK randomised trial. *British Journal of General Practice*. 2001; 51(462):19-24
431. Ridsdale L, Hurley M, King M, McCrone P, Donaldson N. The effect of counselling, graded exercise and usual care for people with chronic fatigue in primary care: A randomized trial. *Psychological Medicine*. 2012; 42(10):2217-2224
432. Rimes KA, Papadopoulos AS, Cleare AJ, Chalder T. Cortisol output in adolescents with chronic fatigue syndrome: Pilot study on the comparison with healthy adolescents and change after cognitive behavioural guided self-help treatment. *Journal of Psychosomatic Research*. 2014; 77(5):409-414
433. Roberts AD, Papadopoulos AS, Wessely S, Chalder T, Cleare AJ. Salivary cortisol output before and after cognitive behavioural therapy for chronic fatigue syndrome. *Journal of Affective Disorders*. 2009; 115(1-2):280-286
434. Roberts D. Chronic fatigue syndrome and quality of life. *Patient Related Outcome Measures*. 2018; 9:253-262
435. Roberts E, Wessely S, Chalder T, Chang CK, Hotopf M. Mortality of people with chronic fatigue syndrome: A retrospective cohort study in England and Wales from the South London and Maudsley NHS Foundation Trust Biomedical Research Centre

- (SLaM BRC) Clinical Record Interactive Search (CRIS) Register. *Lancet*. 2016; 387(10028):1638-1643
436. Roe A. North of Tyne CFS/ME rehabilitation and management team: Service evaluation 2016.
437. Roerink ME, Bredie SJH, Heijnen M, Dinarello CA, Knoop H, Van der Meer JWM. Cytokine inhibition in patients with chronic fatigue syndrome: A randomized trial. *Annals of Internal Medicine*. 2017; 166(8):557-564
438. Roerink ME, Knoop H, Bredie SJ, Heijnen M, Joosten LA, Netea MG et al. Cytokine inhibition in chronic fatigue syndrome patients: Study protocol for a randomized controlled trial. *Trials*. 2015; 16:439
439. Roerink ME, Knoop H, Bronkhorst EM, Mouthaan HA, Hawinkels LJAC, Joosten LAB et al. Cytokine signatures in chronic fatigue syndrome patients: A case control study and the effect of anakinra treatment. *Journal of Translational Medicine*. 2017; 15:267
440. Roma M, Marden CL, Flaherty MAK, Jasion SE, Cranston EM, Rowe PC. Impaired health-related quality of life in adolescent myalgic encephalomyelitis/chronic fatigue syndrome: The impact of core symptoms. *Frontiers in Pediatrics*. 2019; 7:26
441. Rowe KS. Long term follow up of young people with chronic fatigue syndrome attending a pediatric outpatient service. *Frontiers in Pediatrics*. 2019; 7:21
442. Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS et al. Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: A primer. *Frontiers in Pediatrics*. 2017; 5:121
443. Ruggieri V, Paz MI, Peretti MG, Rugilo C, Bologna R, Freire C et al. Enterovirus D68 infection in a cluster of children with acute flaccid myelitis, Buenos Aires, Argentina, 2016. *European Journal of Paediatric Neurology*. 2017; 21(6):884-890
444. Russo J, Katon W, Clark M, Kith P, Sintay M, Buchwald D. Longitudinal changes associated with improvement in chronic fatigue patients. *Journal of Psychosomatic Research*. 1998; 45(1):67-76
445. Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. Cost-effectiveness of counselling, graded-exercise and usual care for chronic fatigue: Evidence from a randomised trial in primary care. *BMC Health Services Research*. 2012; 12:264
446. Saidi G, Haines L. The management of children with chronic fatigue syndrome-like illness in primary care: a cross-sectional study. *British Journal of General Practice*. 2006; 56(522):43-47
447. Sankey A, Hill CM, Brown J, Quinn L, Fletcher A. A follow-up study of chronic fatigue syndrome in children and adolescents: symptom persistence and school absenteeism. *Clinical Child Psychology and Psychiatry*. 2006; 11(1):126-138
448. Santini SJ, Cordone V, Falone S, Mijit M, Tatone C, Amicarelli F et al. Role of mitochondria in the oxidative stress induced by electromagnetic fields: Focus on reproductive systems. *Oxidative Medicine and Cellular Longevity*. 2018; 2018:5076271

449. Šarić A, Buell AK, Meisl G, Michaels TCT, Dobson CM, Linse S et al. Physical determinants of the self-replication of protein fibrils. *Nature Physics*. 2016; 12:874-880
450. Scheeres K, Knoop H, Meer v, Bleijenberg G. Clinical assessment of the physical activity pattern of chronic fatigue syndrome patients: A validation of three methods. *Health & Quality of Life Outcomes*. 2009; 7:29
451. Scheeres K, Wensing M, Bleijenberg G, Severens JL. Implementing cognitive behavior therapy for chronic fatigue syndrome in mental health care: A costs and outcomes analysis. *BMC Health Services Research*. 2008; 8(175)
452. Scheeres K, Wensing M, Knoop H, Bleijenberg G. Implementing cognitive behavioral therapy for chronic fatigue syndrome in a mental health center: A benchmarking evaluation. *Journal of Consulting and Clinical Psychology*. 2008; 76(1):163-171
453. Scheeres K, Wensing M, Mes C, Bleijenberg G. The impact of informational interventions about cognitive behavioral therapy for chronic fatigue syndrome on GPs referral behavior. *Patient Education and Counseling*. 2007; 68(1):29-32
454. Schmaling KB, Fiedelak JI, Katon WJ, Bader JO, Buchwald DS. Prospective study of the prognosis of unexplained chronic fatigue in a clinic-based cohort. *Psychosomatic Medicine*. 2003; 65(6):1047-1054
455. Schmaling KB, Patterson TL. The association of major life events with chronic fatigue. *Journal of Psychosomatic Research*. 2019; 125:109810
456. Schweitzer R, Kelly B, Foran A, Terry D, Whiting J. Quality of life in chronic fatigue syndrome. *Social Science and Medicine*. 1995; 41(10):1367-1372
457. Service related research project: a service evaluation of an eight-week lifestyle management programme run by a chronic fatigue syndrome.
458. Service related research project: executive summary. A service evaluation of a lifestyle management group programme at a chronic fatigue syndrome service. 2015.
459. Severens JL, Prins JB, van der Wilt GJ, van der Meer JW, Bleijenberg G. Cost-effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. *QJM*. 2004; 97(3):153-161
460. Shakespeare T, Watson N, Alghaib OA. Blaming the victim, all over again: Waddell and Aylward's biopsychosocial (BPS) model of disability. *Critical Social Policy*. 2017; 37(1):22-41
461. Shan ZY, Finegan K, Bhuta S, Ireland T, Staines DR, Marshall-Gradisnik SM et al. Brain function characteristics of chronic fatigue syndrome: A task fMRI study. *NeuroImage: Clinical*. 2018; 19:279-286
462. Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. Rehabilitative treatments for chronic fatigue syndrome: Long-term follow-up from the PACE trial. *The Lancet Psychiatry*. 2015; 2(12):1067-1074
463. Sharpe M, Hawton K, Seagroatt V, Pasvol G. Follow up of patients presenting with fatigue to an infectious diseases clinic. *BMJ*. 1992; 305(6846):147-152

464. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A et al. A report--chronic fatigue syndrome: Guidelines for research. *Journal of the Royal Society of Medicine*. 1991; 84(2):118-121
465. Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D et al. Changes in gut and plasma microbiome following exercise challenge in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *PloS One*. 2015; 10(12):e0145453
466. Shungu DC, Weiduschat N, Murrrough JW, Mao X, Pillemer S, Dyke JP et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR in Biomedicine*. 2012; 25(9):1073-1087
467. Skapinakis P, Lewis G, Mavreas V. One-year outcome of unexplained fatigue syndromes in primary care: Results from an international study. *Psychological Medicine*. 2003; 33(5):857-866
468. Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review for a national institutes of health pathways to prevention workshop. *Annals of Internal Medicine*. 2015; 162(12):841-850
469. Smith MEB, Nelson HD, Haney E, Pappas M, Daeges M, Wasson N et al. Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. *Evidence Report/Technology Assessment 2014*; (219):1-433
470. Smith SN, Crawley E. Is there effective behavioural treatment for children with chronic fatigue syndrome/myalgic encephalomyelitis? *Archives of Disease in Childhood*. 2013; 98(7):561-563
471. Snell CR, Stevens SR, Davenport TE, Van Ness JM. Discriminative validity of metabolic and workload measurements for identifying people with chronic fatigue syndrome. *Physical Therapy*. 2013; 93(11):1484-1492
472. Snounou R, Woods N, Henry L, Adams JA. Focus group evaluation of an eight-week group condition management programme for myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS).
473. Solomon-Moore E, Jago R, Beasant L, Brigden A, Crawley E. Physical activity patterns among children and adolescents with mild-to-moderate chronic fatigue syndrome/myalgic encephalomyelitis. *BMJ Paediatrics Open*. 2019; 3:e000425
474. Stahl D, Rimes KA, Chalder T. Mechanisms of change underlying the efficacy of cognitive behaviour therapy for chronic fatigue syndrome in a specialist clinic: A mediation analysis. *Psychological Medicine*. 2014; 44(6):1331-1344
475. Staud R, Boissoneault J, Craggs JG, Lai S, Robinson ME. Task related cerebral blood flow changes of patients with chronic fatigue syndrome: An arterial spin labeling study. *Fatigue*. 2018; 6(2):63-79
476. Staud R, Kizer T, Robinson ME. Muscle injections with lidocaine improve resting fatigue and pain in patients with chronic fatigue syndrome. *Journal of Pain Research*. 2017; 10:1477-1486

477. Steffen TM, Hacker TA, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. *Physical Therapy*. 2002; 82(2):128-137
478. Stevelink SAM, Fear NT, Hotopf M, Chalder T. Factors associated with work status in chronic fatigue syndrome. *Occupational Medicine*. 2019; 69(6):453-458
479. Stevens S, Snell C, Stevens J, Keller B, VanNess JM. Cardiopulmonary exercise test methodology for assessing exertion intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. *Frontiers in Pediatrics*. 2018; 6:242
480. Stevens SR, Davenport TE. Functional outcomes of anaerobic rehabilitation in a patient with chronic fatigue syndrome: Case report with 1-year follow up. *Bulletin of the IACFS/ME*. 2010; 18(3):93-98
481. Stoll SVE, Crawley E, Richards V, Lal N, Brigden A, Loades ME. What treatments work for anxiety in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)? Systematic review. *BMJ Open*. 2017; 7(9):e015481
482. Stordeur S, Thiry N, Eyssen M. Chronisch Vermoeidheidssyndroom: Diagnose, behandeling en zorgorganisatie. Brussel. Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2008. Available from: <https://kce.fgov.be/sites/default/files/atoms/files/d20081027358.pdf>
483. Strassheim VJ, Sunnquist M, Jason LA, Newton JL. Defining the prevalence and symptom burden of those with self-reported severe chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A two-phase community pilot study in the North East of England. *BMJ Open*. 2018; 8:e020775
484. Strawbridge R, Sartor ML, Scott F, Cleare AJ. Inflammatory proteins are altered in chronic fatigue syndrome-A systematic review and meta-analysis. *Neuroscience and Biobehavioral Reviews*. 2019; 107:69-83
485. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ et al. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. *PloS One*. 2012; 7(3):e31334
486. Strbak O, Kopcansky P, Frollo I. Biogenic magnetite in humans and new magnetic resonance hazard questions. *Mesurament Science Review*. 2011; 11(3):85-91
487. Stubhaug B, Lie SA, Ursin H, Eriksen HR. Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: Randomised placebo-controlled trial. *British Journal of Psychiatry*. 2008; 192(3):217-223
488. Stulemeijer M, de Jong LW, Fiselier TJ, Hoogveld SW, Bleijenberg G. Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: Randomised controlled trial. *BMJ*. 2005; 330(7481):14
489. Sumathipala A, Siribaddana S, Abeysingha MR, De Silva P, Dewey M, Prince M et al. Cognitive-behavioural therapy v. structured care for medically unexplained symptoms: Randomised controlled trial. *British Journal of Psychiatry*. 2008; 193(1):51-59
490. Sunnquist M, Jason LA. A reexamination of the cognitive behavioral model of chronic fatigue syndrome. *Journal of Clinical Psychology*. 2018; 74(7):1234-1245

491. Sutton and St Helier Hospitals. Chronic Fatigue Service Sutton and St Helier Hospitals Audit: Group programme satisfaction questionnaires. October 2006-May 2007.
492. Suvorov IM, Sushentsova TI, Posokhin VV, Chekodanova NV, Popova VI, Kormushina VV. [Microwave radiation as a factor in altering the health of the population]. *Meditsina Truda i Promyshlennaia Ekologiya*. 1998; (11):29-30
493. Swinscow TDV. Correlation and regression. *Statistics at square one*. 9th ed. 1997.
494. Taylor AP. Environmental magnetite in the human brain. 2016. Available from: <https://www.the-scientist.com/daily-news/environmental-magnetite-in-the-human-brain-32901> Last accessed: 04/12/2019.
495. Taylor D. Clinical outcome evaluation for the Leeds and York CFS/ME Service 18/19 [Unpublished]. 2019.
496. Taylor RR. Quality of life and symptom severity for individuals with chronic fatigue syndrome: Findings from a randomized clinical trial. *American Journal of Occupational Therapy*. 2004; 58(1):35-43
497. Teitelbaum JE, Bird B, Greenfield RM, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome and fibromyalgia - A randomized, double-blind, placebo-controlled, intent-to-treat study. *Journal of Chronic Fatigue Syndrome*. 2001; 8(2):3-28
498. Terzi M, Ozberk B, Deniz OG, Kaplan S. The role of electromagnetic fields in neurological disorders. *Journal of Chemical Neuroanatomy*. 2016; 75(Pt B):77-84
499. The 25% ME Group. Analysis report. 2010. Available from: www.25megroup.org/download/1819/?v=3069
500. The 25% ME Group. Exercise & ensuring patient safety [Unpublished]. 2014.
501. The 25% ME Group. Follow up survey on people with M.E., 2001. Available from: <https://25megroup.org/factsheets-and-leaflets>
502. The 25% ME Group. Input to consultation on draft scope for the Guideline Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management (in development). 2018.
503. The 25% ME Group. Input to consultation on NG74 'Intermediate care including reablement'. 2017.
504. The 25% ME Group. M.E. family/household members survey questionnaire results. 2001. Available from: <https://25megroup.org/download/1819/?v=1830>
505. The 25% ME Group. M.E. generic members survey questionnaire results [unpublished]. 2002.
506. The 25% ME Group. M.E. questionnaire results. 2000.
507. The 25% ME Group. Our newsletter. 2019. Available from: <https://25megroup.org/our-newsletter> Last accessed: 11/12/2019.
508. The 25% ME Group. Severe myalgic encephalomyelitis: Understanding and Remembrance Day (8th August) [pamphlet].

509. The 25% ME Group. Severely affected ME (myalgic encephalomyelitis) analysis report on questionnaire issued January 2004. 2004.
510. The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee. Multiple Sclerosis Quality of Life Inventory: A user's manual 1997. Available from: https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQLI_-_A-User-s-Manual.pdf
511. The GK, Bleijenberg G, Buitelaar JK, van der Meer JW. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: A randomized controlled trial. *Journal of Clinical Psychiatry*. 2010; 71(5):528-533
512. The GK, Bleijenberg G, van der Meer JW. The effect of acclidine in chronic fatigue syndrome: A randomized controlled trial. *PLoS Clinical Trials*. 2007; 2(5):e19
513. The ME Association. Managing my M.E. What people with ME/CFS and their carers want from the UK's health and social services. The results of the ME Association's major survey of illness management requirements. Buckinghamshire The ME Association, 2010.
514. The ME Association. ME/CFS illness management survey results: No decisions about me without me. Part 1. 2015. Available from: <https://www.meassociation.org.uk/wp-content/uploads/2015-ME-Association-Illness-Management-Report-No-decisions-about-me-without-me-30.05.15.pdf>
515. The Neurological Alliance, Quality Health. The National Neurology Patient Experience Survey 2018/2019: Technical report. 2019. Available from: <https://www.neural.org.uk/wp-content/uploads/2019/07/Neuro-Patience-Techincal-Report.pdf>
516. Thomas M, Smith A. An investigation into the cognitive deficits associated with chronic fatigue syndrome. *Open Neurology Journal*. 2009; 3:13-23
517. Tiersky LA, DeLuca J, Hill N, Dhar SK, Johnson SK, Lange G et al. Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome. *Applied Neuropsychology*. 2001; 8(1):41-50
518. Tiev KP, Cabane J, Imbert JC. Treatment of chronic postinfectious fatigue: Randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo. *La Revue de Medecine Interne*. 1999; 20(10):912-918
519. Timbol CR, Baraniuk JN. Chronic fatigue syndrome in the emergency department. *Open Access Emergency Medicine*. 2019; 11:15-28
520. Togo F, Lange G, Natelson BH, Quigley KS. Attention network test: Assessment of cognitive function in chronic fatigue syndrome. *Journal of Neuropsychology*. 2015; 9(1):1-9
521. Toussaint LL, Whipple MO, Abboud LL, Vincent A, Wahner-Roedler DL. A mind-body technique for symptoms related to fibromyalgia and chronic fatigue. *Explore: The Journal of Science & Healing*. 2012; 8(2):92-98
522. Trabal J, Leyes P, Fernandez-Sola J, Forga M, Fernandez-Huerta J. Patterns of food avoidance in chronic fatigue syndrome: Is there a case for dietary recommendations? *Nutrición Hospitalaria*. 2012; 27(2):659-662

523. Tummers M, Knoop H, Bleijenberg G. Effectiveness of stepped care for chronic fatigue syndrome: A randomized noninferiority trial. *Journal of Consulting and Clinical Psychology*. 2010; 78(5):724-731
524. Tummers M, Knoop H, van Dam A, Bleijenberg G. Implementing a minimal intervention for chronic fatigue syndrome in a mental health centre: A randomized controlled trial. *Psychological Medicine*. 2012; 42(10):2205-2215
525. Tummers M, Knoop H, van Dam A, Bleijenberg G. Moderators of the treatment response to guided self-instruction for chronic fatigue syndrome. *Journal of Psychosomatic Research*. 2013; 74(5):373-377
526. Twisk F. Dutch Health Council Advisory report on myalgic encephalomyelitis and chronic fatigue syndrome: Taking the wrong turn. *Diagnostics*. 2018; 8(2):34
527. Twisk F. Studies and surveys implicate potential iatrogenic harm of cognitive behavioral therapy and graded exercise therapy for myalgic encephalomyelitis and chronic fatigue syndrome patients. *Research on Chronic Diseases*. 2017; 1(2):13-14
528. Twisk F, Geraghty K. Deviant cellular and physiological responses to exercise in myalgic encephalomyelitis and chronic fatigue syndrome. *Jacobs Journal of Physiology*. 2015; 1(2):1-6
529. Twisk FN. Accurate diagnosis of myalgic encephalomyelitis and chronic fatigue syndrome based upon objective test methods for characteristic symptoms. *World Journal of Methodology*. 2015; 5(2):68-87
530. Twisk FNM. A definition of recovery in myalgic encephalomyelitis and chronic fatigue syndrome should be based upon objective measures. *Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*. 2014; 23(9)
531. Unger ER, Lin JS, Tian H, Natelson BH, Lange G, Vu D et al. Multi-site clinical assessment of myalgic encephalomyelitis/chronic fatigue syndrome (MCAM): Design and implementation of a prospective/retrospective rolling cohort study. *American Journal of Epidemiology*. 2017; 185(8):617-626
532. van Campen C, Rowe PC, Visser FC. Blood volume status in ME/CFS correlates with the presence or absence of orthostatic symptoms: Preliminary results. *Frontiers in Pediatrics*. 2018; 6:352
533. van Campen CM, Riepma K, Visser FC. Open trial of vitamin B12 nasal drops in adults with myalgic encephalomyelitis/chronic fatigue syndrome: Comparison of responders and non-responders. *Frontiers in Pharmacology*. 2019; 10:1102
534. Van Campen CMC, Visser FC. The abnormal cardiac index and stroke volume index changes during a normal tilt table test in ME/CFS patients compared to healthy volunteers, are not related to deconditioning. *Journal of Thrombosis and Circulation*. 2018:107
535. Van Den Eede F, Moorkens G, Hulstijn W, Maas Y, Schrijvers D, Stevens SR et al. Psychomotor function and response inhibition in chronic fatigue syndrome. *Psychiatry Research*. 2011; 186(2-3):367-372
536. van der Schaaf ME, De Lange FP, Schmits IC, Geurts DEM, Roelofs K, van der Meer JWM et al. Prefrontal structure varies as a function of pain symptoms in chronic fatigue syndrome. *Biological Psychiatry*. 2017; 81(4):358-365

537. van Der Schaaf ME, Schmits IC, Roerink M, Geurts DE, Toni I, Roelofs K et al. Investigating neural mechanisms of change of cognitive behavioural therapy for chronic fatigue syndrome: A randomized controlled trial. *BMC Psychiatry*. 2015; 15:144
538. van der Werf SP, de Vree B, Alberts M, van der Meer JW, Bleijenberg G, Netherlands Fatigue Research Group Nijmegen. Natural course and predicting self-reported improvement in patients with chronic fatigue syndrome with a relatively short illness duration. *Journal of Psychosomatic Research*. 2002; 53(3):749-753
539. Van Konynenburg R, Nayhan N. Application of Yasko Protocol to the treatment of chronic fatigue syndrome Boston. 2010.
540. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJ, Swanink CM et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: Retrospective analysis of samples from an established cohort. *BMJ*. 2010; 340:c1018
541. VanNess JM, Snell CR, Stevens SR. Diminished cardiopulmonary capacity during post-exertional malaise. *Journal of Chronic Fatigue Syndrome*. 2007; 14(2):77-85
542. VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR. Postexertional malaise in women with chronic fatigue syndrome. *Journal of Women's Health*. 2010; 19(2):239-244
543. Velleman S, Collin SM, Beasant L, Crawley E. Psychological wellbeing and quality-of-life among siblings of paediatric CFS/ME patients: A mixed-methods study. *Clinical Child Psychology and Psychiatry*. 2016; 21(4):618-633
544. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Prognosis in chronic fatigue syndrome: A prospective study on the natural course. *Journal of Neurology, Neurosurgery and Psychiatry*. 1996; 60(5):489-494
545. Vercoulen JHMM, Swanink CMA, Zitman FG, Vreden SGS, Hoofs MPE, Fennis JFM et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. *Lancet*. 1996; 347(9005):858-861
546. Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. *Journal of Translational Medicine*. 2010; 8:93
547. Vermeulen RC, Scholte HR. Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data. *Journal of Translational Medicine*. 2006; 4:34
548. Vermeulen RC, Vermeulen van Eck IW. Decreased oxygen extraction during cardiopulmonary exercise test in patients with chronic fatigue syndrome. *Journal of Translational Medicine*. 2014; 12:20
549. Vernon D, Stockport ME Group Members. Survey. 2004.
550. Verspaandonk J, Coenders M, Bleijenberg G, Lobbestael J, Knoop H. The role of the partner and relationship satisfaction on treatment outcome in patients with chronic fatigue syndrome. *Psychological Medicine*. 2015; 45(11):2345-2352
551. Vink M. Assessment of individual pace trial data: In myalgic encephalomyelitis/chronic fatigue syndrome, cognitive behavioral and graded

- exercise therapy are ineffective, do not lead to actual recovery and negative outcomes may be higher than reported. *Journal of Neurology and Neurobiology*. 2017; 3(1):1-10
552. Vink M, Vink-Niese A. Cognitive behavioural therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective. Re-analysis of a Cochrane review. *Health Psychology Open*. 2019; 6(1):1-23
553. Vink M, Vink-Niese A. Graded exercise therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective and unsafe. Re-analysis of a Cochrane review. *Health Psychology Open*. 2018; 5(2):1-12
554. Vink M, Vink-Niese A. Multidisciplinary rehabilitation treatment is not effective for myalgic encephalomyelitis/chronic fatigue syndrome: A review of the FatiGo trial. *Health Psychology Open*. 2018; 5(2):1-8
555. Vink M, Vink-Niese F. Work rehabilitation and medical retirement for myalgic encephalomyelitis/chronic fatigue syndrome patients. A review and appraisal of diagnostic strategies. *Diagnostics*. 2019; 9(4):1-33
556. Wallis A, Ball M, Butt H, Lewis DP, McKechnie S, Paull P et al. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: Neuropsychological symptoms and sex comparisons. *Journal of Translational Medicine*. 2018; 16:24
557. Wallis A, Butt H, Ball M, Lewis DP, Bruck D. Support for the microgenderome: Associations in a human clinical population. *Scientific Reports*. 2016; 6:19171
558. Wang H, Liu X, Lv B, Yang F, Hong Y. Reliable multi-label learning via conformal predictor and random forest for syndrome differentiation of chronic fatigue in traditional Chinese medicine. *PloS One*. 2014; 9(6):e99565
559. Wang H, Zhang X. Magnetic fields and reactive oxygen species. *International Journal of Molecular Sciences*. 2017; 18(10):2175
560. Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L et al. Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. *Journal of Medical Virology*. 2012; 84(12):1967-1974
561. Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S et al. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: Randomised controlled trial. *BMJ*. 2010; 340:c1777
562. Wearden AJ, Emsley R. Mediators of the effects on fatigue of pragmatic rehabilitation for chronic fatigue syndrome. *Journal of Consulting and Clinical Psychology*. 2013; 81(5):831-838
563. Wearden AJ, Riste L, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK et al. Fatigue Intervention by Nurses Evaluation--the FINE Trial. A randomised controlled trial of nurse led self-help treatment for patients in primary care with chronic fatigue syndrome: study protocol. *BMC Medicine*. 2006; 4:9
564. Webb CM, Collin SM, Deave T, Haig-Ferguson A, Spatz A, Crawley E. What stops children with a chronic illness accessing health care: A mixed methods study in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *BMC Health Services Research*. 2011; 11:308

565. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Alternative Medicine Review*. 2000; 5(2):93-108
566. Westendorp T, Verbunt JA, Remerie SC, de Blécourt AC, van Baalen B, Smeets RJ. Social functioning in adulthood: understanding long-term outcomes of adolescents with chronic pain/fatigue treated at inpatient rehabilitation programs. *European Journal of Pain*. 2016; 20(7):1121-1130
567. White PD, Goldsmith K, Johnson AL, Chalder T, Sharpe M. Recovery from chronic fatigue syndrome after treatments given in the PACE trial. *Psychological Medicine*. 2013; 43(10):2227-2235
568. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. *Lancet*. 2011; 377(9768):823-836
569. White PD, Sharpe MC, Chalder T, DeCesare JC, Walwyn R, Pace Trial Group. Protocol for the PACE trial: A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise, as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. *BMC Neurology*. 2007; 7:6
570. White PD, Thomas JM, Kangro HO, Bruce-Jones WD, Amess J, Crawford DH et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. *Lancet*. 2001; 358(9297):1946-1954
571. Whitehead L. The measurement of fatigue in chronic illness: A systematic review of unidimensional and multidimensional fatigue measures. *Journal of Pain and Symptom Management*. 2009; 37(1):107-128
572. Whitehead L, Champion P. Can general practitioners manage chronic fatigue syndrome? A controlled trial. *Journal of Chronic Fatigue Syndrome*. 2002; 10(1):55-64
573. Wiborg JF, Knoop H, Prins JB, Bleijenberg G. Does a decrease in avoidance behavior and focusing on fatigue mediate the effect of cognitive behavior therapy for chronic fatigue syndrome? *Journal of Psychosomatic Research*. 2011; 70(4):306-310
574. Wiborg JF, Knoop H, Stulemeijer M, Prins JB, Bleijenberg G. How does cognitive behaviour therapy reduce fatigue in patients with chronic fatigue syndrome? The role of physical activity. *Psychological Medicine*. 2010:1-7
575. Wiborg JF, van Bussel J, van Dijk A, Bleijenberg G, Knoop H. Randomised controlled trial of cognitive behaviour therapy delivered in groups of patients with chronic fatigue syndrome. *Psychotherapy and Psychosomatics*. 2015; 84(6):368-376
576. Wiborg JF, Wensing M, Tummers M, Knoop H, Bleijenberg G. Implementing evidence-based practice for patients with chronic fatigue syndrome. *Clinical Psychology & Psychotherapy*. 2014; 21(2):108-114
577. Wilshire C, Kindlon T, Matthees A, McGrath S. Can patients with chronic fatigue syndrome really recover after graded exercise or cognitive behavioural therapy? A critical commentary and preliminary re-analysis of the PACE trial. *Fatigue: Biomedicine, Health and Behavior*. 2017; 5(1):43-56

578. Wilshire C, Kindlon T, McGrath S. PACE trial claims of recovery are not justified by the data: A rejoinder to Sharpe, Chalder, Johnson, Goldsmith and White. *Fatigue: Biomedicine, Health and Behavior*. 2017; 5(1):62-67
579. Wilshire CE, Kindlon T. Response: Sharpe, Goldsmith and Chalder fail to restore confidence in the PACE trial findings. *BMC Psychology*. 2019; 7(1):19
580. Wilshire CE, Kindlon T, Courtney R, Matthees A, Tuller D, Geraghty K et al. Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. *BMC Psychology*. 2018; 6(1):6
581. Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM, van Riel P et al. The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. *Journal of Psychosomatic Research*. 2017; 98:40-46
582. Worm-Smeitink M, Janse A, van Dam A, Evers A, van der Vaart R, Wensing M et al. Internet-based cognitive behavioral therapy in stepped care for chronic fatigue syndrome: Randomized noninferiority trial. *Journal of Medical Internet Research*. 2019; 21(3):e11276
583. Worm-Smeitink M, Nikolaus S, Goldsmith K, Wiborg J, Ali S, Knoop H et al. Cognitive behaviour therapy for chronic fatigue syndrome: Differences in treatment outcome between a tertiary treatment centre in the United Kingdom and the Netherlands. *Journal of Psychosomatic Research*. 2016; 87:43-49
584. Zablotskii V, Lunov O, Kubinova S, Polyakova T, Sykova E, Dejneka A. Effects of high-gradient magnetic fields on living cell machinery. *Journal of Physics D: Applied Physics*. 2016; 49(49):493003
585. Zablotskii V, Polyakova T, Dejneka A. Cells in the non-uniform magnetic world: How cells respond to high-gradient magnetic fields. *Bioessays*. 2018; 40(8):1800017
586. Zhi W-J, Wang L-F, Hu X-J. Recent advances in the effects of microwave radiation on brains. *Military Medical Research*. 2017; 4:29
587. Zielinski MR, Systrom DM, Rose NR. Fatigue, sleep, and autoimmune and related disorders. *Frontiers in Immunology*. 2019; 10:1827